10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-19-005378.txt : 20190109 0001193125-19-005378.hdr.sgml : 20190109 20190109163220 ACCESSION NUMBER: 0001193125-19-005378 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20181130 FILED AS OF DATE: 20190109 DATE AS OF CHANGE: 20190109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CytoDyn Inc. CENTRAL INDEX KEY: 0001175680 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 753056237 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-49908 FILM NUMBER: 19518511 BUSINESS ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 BUSINESS PHONE: 360-980-8524 MAIL ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 FORMER COMPANY: FORMER CONFORMED NAME: CYTODYN INC DATE OF NAME CHANGE: 20031114 FORMER COMPANY: FORMER CONFORMED NAME: REXRAY CORP DATE OF NAME CHANGE: 20020617 10-Q 1 d683024d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended November 30, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1933

For the transition period from to

Commission File Number: 000-49908

CYTODYN INC.

(Exact name of registrant as specified in its charter)


Delaware		83-1887078
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer or Identification No.)

1111 Main Street, Suite 660 Vancouver, Washington		98660
(Address of principal executive offices)		(Zip Code)

(Registrant’s telephone number, including area code) (360) 980-8524

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☒

On December 31, 2018, there were 292,923,481 shares outstanding of the registrant’s $0.001 par value common stock.

TABLE OF CONTENTS


	PAGE
PART I		3
ITEM 1. FINANCIAL STATEMENTS		3
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS		28
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK		34
ITEM 4. CONTROLS AND PROCEDURES		34
PART II		35
ITEM 1. LEGAL PROCEEDINGS		35
ITEM 1A. RISK FACTORS		35
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS		35
ITEM 3. DEFAULTS UPON SENIOR SECURITIES		35
ITEM 4. MINE SAFETY DISCLOSURES		35
ITEM 5. OTHER INFORMATION		36
ITEM 6. EXHIBITS		36

PART I

Item 1. Financial Statements.

CytoDyn Inc.

Consolidated Balance Sheets


	November 30, 2018			May 31, 2018
	(unaudited)
Assets
Current assets:
Cash	$	772,361		$	1,231,445
Prepaid expenses		200,890			227,173
Prepaid service fees		2,954,624			1,862,009

Total current assets		3,927,875			3,320,627
Furniture and equipment, net		10,127			11,228
Intangibles, net		16,452,951			1,567,143

Total assets	$	20,390,953		$	4,898,998

Liabilities and Stockholders’ (Deficit) Equity
Current liabilities:
Accounts payable	$	18,852,414		$	15,841,859
Accrued liabilities and compensation		560,013			757,778
Accrued license fees		347,333			133,600
Accrued interest on convertible notes		23,001			—
Convertible note payable, net		4,200,000			—

Total current liabilities		23,982,761			16,733,237

Long-term liabilities:
Convertible note payable, net		1,396,974			—
Derivative liabilities		3,075,142			1,323,732

Total long-term liabilities		4,472,116			1,323,732

Total liabilities		28,454,877			18,056,969
Commitments and Contingencies		—			—
Stockholders’ (Deficit) equity
Series B convertible preferred stock, $0.001 par value; 400,000 shares authorized, 92,100 shares issued and outstanding at November 30, 2018 and May 31, 2018, respectively		92			92
Common stock, $0.001 par value; 600,000,000 and 375,000,000 shares authorized, 290,808,960 and 216,881,790 issued and 290,649,949 and 216,722,779 outstanding at November 30, 2018 and May 31, 2018, respectively		290,810			216,881
Additional paid-in capital		193,503,678			159,764,611
Accumulated (deficit)		(201,858,345	)		(173,139,396	)
Less: treasury stock, at par (159,011 shares at $0.001)		(159	)		(159	)

Total stockholders’ (deficit)		(8,063,924	)		(13,157,971	)

Total liabilities and stockholders’ (deficit) equity	$	20,390,953		$	4,898,998

See accompanying notes to consolidated financial statements.

CytoDyn Inc.

Consolidated Statements of Operations

(Unaudited)


	Three Months Ended November 30,						Six Months Ended November 30,
	2018			2017			2018			2017
Operating expenses:
General and administrative	$	2,663,745		$	1,608,743		$	4,594,804		$	3,178,420
Research and development		12,869,244			9,077,172			24,337,910			17,225,348
Amortization and depreciation		154,801			89,136			243,772			178,282

Total operating expenses		15,687,790			10,775,051			29,176,486			20,582,050

Operating loss		(15,687,790	)		(10,775,051	)		(29,176,486	)		(20,582,050	)
Interest income		1,021			422			2,002			1,206
Change in fair value of derivative liabilities		281,055			829,600			(466,412	)		466,934
Interest expense:
Amortization of discount on convertible notes		(52,954	)		(728,843	)		(117,534	)		(1,172,995	)
Amortization of debt issuance costs		(10,411	)		(168,429	)		(19,589	)		(282,129	)
Loss on extinguishment of convertible note		(1,519,603	)		—			(1,519,603	)		—
Inducement interest related to warrant exercise		—			—			—			(826,252	)
Interest on convertible note payable		(143,617	)		(105,384	)		(248,247	)		(180,673	)

Total interest expense		(1,726,585	)		(1,002,656	)		(1,904,973	)		(2,462,049	)

Loss before income taxes		(17,132,299	)		(10,947,685	)		(31,545,869	)		(22,575,959	)
Income tax benefit		2,826,919			—			2,826,919			—

Net loss	$	(14,305,380	)	$	(10,947,685	)	$	(28,718,950	)	$	(22,575,959	)

Basic and diluted loss per share	$	(0.06	)	$	(0.07	)	$	(0.12	)	$	(0.15	)

Basic and diluted weighted average common shares outstanding		259,088,835			157,843,773			238,731,091			154,774,327

See accompanying notes to consolidated financial statements.

CytoDyn Inc.

Consolidated Statements of Cash Flows

(Unaudited)


	Six Months Ended November 30,
	2018			2017
Cash flows from operating activities:
Net loss	$	(28,718,950	)	$	(22,575,959	)
Adjustments to reconcile net loss to net cash used by operating activities:
Amortization and depreciation		243,772			178,282
Amortization of debt issuance costs		19,589			282,129
Amortization of discount on convertible notes		117,534			1,172,995
Inducement interest related to warrant exercise		—			826,252
Interest expense associated with derivative liabilities		—			—
Change in fair value of derivative liabilities		466,412			(466,934	)
Stock-based compensation		1,510,486			529,617
Loss on extinguishment of convertible note		1,519,603			—
Deferred income tax benefit		(2,826,919	)		—
Changes in current assets and liabilities:
(Increase) decrease in prepaid expenses		(1,807,629	)		907,606
Increase in accounts payable and accrued expenses		3,283,113			6,256,192

Net cash used in operating activities		(26,192,989	)		(12,889,820	)

Cash flows from investing activities:
Furniture and equipment purchases		(2,262	)		—

Net cash used in investing activities		(2,262	)		—

Cash flows from financing activities:
Proceeds from sale of common stock and warrants		23,463,585			7,050,651
Proceeds from warrant exercises		—			1,647,500
Proceeds from convertible note payable		5,000,000			4,888,500
Payment of offering costs		(2,727,418	)		(1,175,575	)

Net cash provided by financing activities		25,736,167			12,411,076

Net change in cash		(459,084	)		(478,744	)
Cash, beginning of period		1,231,445			1,775,583

Cash, end of period	$	772,361		$	1,296,839

Non-cash investing and financing transactions:
Financing costs associated with placement agent warrants	$	—		$	70,383

Accrued interest converted into note payable	$	225,245		$	—

Debt discount associated with convertible notes payable	$	700,000		$	1,574,628

Common stock issued for acquisition of ProstaGene, LLC	$	11,558,000			—

Derivative liability associated a convertible note payable	$	1,284,998		$	—

See accompanying notes to consolidated financial statements.

CytoDyn Inc.

Consolidated Statement of Changes in Stockholders’ (Deficit)/ Equity

(Unaudited)


	Preferred Stock				Common Stock				Treasury Stock
	Shares		Amount		Shares		Amount		Shares		Amount
Balance May 31, 2017		92,100	$	92		149,468,244	$	149,468		—	$	—
First Quarter Fiscal Year Ended May 31, 2018
Proceeds from warrant exercise ($0.50/share)		—		—		3,295,000		3,295		—		—
Offering costs related to warrant tender offer		—		—		—		—		—		—
Proceeds from private equity offering ($0.50/share)		—		—		—		—		—		—
Offering costs related to private equity offering		—		—		—		—		—		—
Proceeds from registered direct offering ($0.50/share)		—		—		—		—		—		—
Offering costs related to registered direct offering		—		—		—		—		—		—
Legal fees in connection with equity offerings		—		—		—		—		—		—
Interest expense related to warrant tender offer		—		—		—		—		—		—
Interest expense related to conversion of notes payable		—		—		—		—		—		—
Stock issued for bonuses and tendered for income tax		—		—		—		—		—		—
Stock issued for board compensation		—		—		—		—		—		—
Stock-based compensation		—		—		—		—		—		—
Interest expense related to warrant extension		—		—		—		—		—		—
Debt discount related to convertible notes payable		—		—		—		—		—		—
Net loss August 31, 2017		—		—		—		—		—		—

Balance August 31, 2017		92,100	$	92		152,763,244	$	152,763		—	$	—
Second Quarter Fiscal Year Ended May 31, 2018
Proceeds from warrant exercise ($0.50/share)		—		—		—		—		—		—
Offering costs related to warrant tender offer		—		—		—		—		—		—
Proceeds from private equity offering ($0.50/share)		—		—		6,651,800		6,652		—		—
Offering costs related to private equity offering		—		—		—		—		—		—
Proceeds from registered direct offering ($0.50/share)		—		—		5,720,111		5,720		—		—
Offering costs related to registered direct offering		—		—		—		—		—		—
Legal fees in connection with equity offerings		—		—		—		—		—		—
Interest expense related to conversion of notes payable		—		—		—		—		—		—
Interest expense related to warrant tender offer		—		—		—		—		—		—
Stock issued for bonuses and tendered for income tax		—		—		—		—		—		—
Stock issued for board compensation		—		—		—		—		—		—
Stock-based compensation		—		—		—		—		—		—
Interest expense related to warrant extension		—		—		—		—		—		—
Debt discount related to convertible notes payable		—		—		—		—		—		—
Net loss November 30, 2017		—		—		—		—		—		—

Balance November 30, 2017		92,100	$	92		165,135,155	$	165,135		—	$	—

See accompanying notes to consolidated financial statements

CytoDyn Inc.

Consolidated Statement of Changes in Stockholders’ (Deficit)/ Equity

(Unaudited)


	Preferred Stock				Common Stock				Treasury Stock
	Shares		Amount		Shares		Amount		Shares		Amount
Third Quarter Fiscal Year Ended May 31, 2018
Proceeds from warrant exercise ($0.50/share)		—		—		—		—		—		—
Offering costs related to warrant tender offer		—		—		—		—		—		—
Proceeds from private equity offering ($0.50/share)		—		—		28,635,104		28,635		—		—
Offering costs related to private equity offering		—		—		—		—		—		—
Proceeds from registered direct offering ($0.50/share)		—		—		15,133,742		15,134		—		—
Offering costs related to registered direct offering		—		—		—		—		—		—
Legal fees in connection with equity offerings		—		—		—		—		—		—
Interest expense related to conversion of notes payable		—		—		—		—		—		—
Interest expense related to warrant tender offer		—		—		—		—		—		—
Stock issued for bonuses and tendered for income tax		—		—		—		—		—		—
Stock issued for board compensation		—		—		—		—		—		—
Stock-based compensation		—		—		—		—		—		—
Interest expense related to warrant extension		—		—		—		—		—		—
Debt discount related to convertible notes payable		—		—		—		—		—		—
Net loss February 28, 2018		—		—		—		—		—		—

Balance February 28, 2018		92,100	$	92		208,904,001	$	208,904		—	$	—
Fourth Quarter Fiscal Year Ended May 31, 2018
Proceeds from warrant exercise ($0.50/share)		—		—		3,027,263		3,027		—		—
Offering costs related to warrant tender offer		—		—		—		—		—		—
Proceeds from private equity offering ($0.50/share)		—		—		—		—		—		—
Offering costs related to private equity offering		—		—		—		—		—		—
Proceeds from registered direct offering ($0.50/share)		—		—		4,640,000		4,640		—		—
Offering costs related to registered direct offering		—		—		—		—		—		—
Legal fees in connection with equity offerings		—		—		—		—		—		—
Interest expense related to conversion of notes payable		—		—		—		—		—		—
Interest expense related to warrant tender offer		—		—		—		—		—		—
Stock issued for bonuses and tendered for income tax		—		—		310,526		310		159,011		(159	)
Stock issued for board compensation		—		—		—		—		—		—
Stock-based compensation		—		—		—		—		—		—
Interest expense related to warrant extension		—		—		—		—		—		—
Debt discount related to convertible notes payable		—		—		—		—		—		—
Net Loss May 31, 2018		—		—		—		—		—		—

Balance May 31, 2018		92,100	$	92		216,881,790	$	216,881		159,011	$	(159	)

See accompanying notes to consolidated financial statements

CytoDyn Inc.

Consolidated Statement of Changes in Stockholders’ (Deficit)/ Equity

(Unaudited)


	Preferred Stock				Common Stock				Treasury Stock
	Shares		Amount		Shares		Amount		Shares		Amount
Balance May 31, 2018		92,100	$	92		216,881,790	$	216,881		159,011	$	(159	)
First Quarter Fiscal Year Ended May 31, 2019
Acquisition of ProstaGene LLC		—		—		—		—		—		—
Issuance of stock payment shares		—		—		—		—		—		—
Proceeds from registered direct offering ($0.50/share)		—		—		1,970,000		1,970		—		—
Offering costs related to registered direct offering		—		—		—		—		—		—
Proceeds from private equity offering ($0.50/share)		—		—		15,028,600		15,029		—		—
Offering costs related to private equity offering		—		—		—		—		—		—
Legal fees in connection with equity offerings		—		—		—		—		—		—
Stock-based compensation		—		—		—		—		—		—
Net Loss August 31, 2018		—		—		—		—		—		—

Balance August 31, 2018		92,100	$	92		233,880,390	$	233,880		159,011	$	(159	)
Second Quarter Fiscal Year Ended May 31, 2019
Acquisition of ProstaGene LLC		—		—		18,658,000		18,658		—		—
Issuance of stock payment shares		—		—		8,342,000		8,342		—		—
Proceeds from registered direct offering ($0.50/share)		—		—		—		—		—		—
Offering costs related to registered direct offering		—		—		—		—		—		—
Proceeds from private equity offering ($0.50/share)		—		—		29,928,570		29,930		—		—
Offering costs related to private equity offering		—		—		—		—		—		—
Legal fees in connection with equity offerings		—		—		—		—		—		—
Stock-based compensation		—		—		—		—		—		—
Net Loss November 30, 2018		—		—				—		—		—

Balance November 30, 2018		92,100	$	92		290,808,960	$	290,810		159,011	$	(159	)

See accompanying notes to consolidated financial statements

CytoDyn Inc.

Consolidated Statement of Changes in Stockholders’ (Deficit)/ Equity

(Unaudited)


	Additional Paid-In Capital			Accumulated Deficit			Total			Fiscal Year To Date
Balance May 31, 2017	$	121,736,921		$	(122,989,715	)	$	(1,103,234	)	$	(1,103,234	)
First Quarter Fiscal Year Ended May 31, 2018
Proceeds from warrant exercise ($0.50/share)		1,644,205			—			1,647,500			1,647,500
Offering costs related to warrant tender offer		—			—			—			—
Proceeds from private equity offering ($0.50/share)		—			—			—			—
Offering costs related to private equity offering		—			—			—			—
Proceeds from registered direct offering ($0.50/share)		—			—			—			—
Offering costs related to registered direct offering		—			—			—			—
Legal fees in connection with equity offerings		—			—			—			—
Interest expense related to warrant tender offer		—			—			—			—
Interest expense related to conversion of notes payable		—			—			—			—
Stock issued for bonuses and tendered for income tax		—			—			—			—
Stock issued for board compensation		—			—			—			—
Stock-based compensation		254,952			—			254,952			254,952
Interest expense related to warrant extension		826,252			—			826,252			826,252
Debt discount related to convertible notes payable		1,645,010			—			1,645,010			1,645,010
Net loss August 31, 2017		—			(11,628,273	)		(11,628,273	)		(11,628,273	)

Balance August 31, 2017	$	126,107,340		$	(134,617,988	)	$	(8,357,793	)	$	(8,357,793	)

Second Quarter Fiscal Year Ended May 31, 2018
Proceeds from warrant exercise ($0.50/share)		—			—			—			1,647,500
Offering costs related to warrant tender offer		—			—			—			—
Proceeds from private equity offering ($0.50/share)		3,318,745			—			3,325,397			3,325,397
Offering costs related to private equity offering		(312,456	)		—			(312,456	)		(312,456	)
Proceeds from registered direct offering ($0.50/share)		3,719,534			—			3,725,254			3,725,254
Offering costs related to registered direct offering		(319,228	)		—			(319,228	)		(319,228	)
Legal fees in connection with equity offerings		(178,664	)		—			(178,664	)		(178,664	)
Interest expense related to conversion of notes payable		—			—			—			—
Interest expense related to warrant tender offer		—			—			—			—
Stock issued for bonuses and tendered for income tax		—			—			—			—
Stock issued for board compensation		—			—			—			—
Stock-based compensation		274,665			—			274,665			529,617
Interest expense related to warrant extension		—			—			—			826,252
Debt discount related to convertible notes payable		—			—			—			1,645,010
Net loss November 30, 2017		—			(10,947,685	)		(10,947,685	)		(22,575,958	)

Balance November 30, 2017	$	132,609,936		$	(145,565,673	)	$	(12,790,510	)	$	(12,790,510	)

See accompanying notes to consolidated financial statements

CytoDyn Inc.

Consolidated Statement of Changes in Stockholders’ (Deficit)/ Equity

(Unaudited)


	Additional Paid-In Capital			Accumulated Deficit			Total			Fiscal Year To Date
Balance November 30, 2017	$	132,609,936		$	(145,565,673	)	$	(12,790,510	)	$	(12,790,510	)

Third Quarter Fiscal Year Ended May 31, 2018
Proceeds from warrant exercise ($0.50/share)		—			—			—			1,647,500
Offering costs related to warrant tender offer		—			—			—			—
Proceeds from private equity offering ($0.50/share)		14,288,916			—			14,317,551			17,642,948
Offering costs related to private equity offering		(1,416,786	)		—			(1,416,786	)		(1,729,242	)
Proceeds from registered direct offering ($0.50/share)		7,551,031			—			7,566,165			11,291,419
Offering costs related to registered direct offering		(331,621	)		—			(331,621	)		(650,849	)
Legal fees in connection with equity offerings		(166,222	)		—			(166,222	)		(344,886	)
Interest expense related to conversion of notes payable		2,352,045			—			2,352,045			2,352,045
Interest expense related to warrant tender offer		—			—			—			—
Stock issued for bonuses and tendered for income tax		—			—			—			—
Stock issued for board compensation		260,190			—			260,190			260,190
Stock-based compensation		566,609			—			566,609			1,096,226
Interest expense related to warrant extension		—			—			—			826,252
Debt discount related to convertible notes payable		—			—			—			1,645,010
Net loss February 28, 2018		—			(17,950,100	)		(17,950,100	)		(40,526,058	)

Balance February 28, 2018	$	155,714,098		$	(163,515,773	)	$	(7,592,679	)	$	(7,592,679	)

Fourth Quarter Fiscal Year Ended May 31, 2018
Proceeds from warrant exercise ($0.50/share)		1,510,604			—			1,513,631			3,161,131
Offering costs related to warrant tender offer		(73,234	)		—			(73,234	)		(73,234	)
Proceeds from private equity offering ($0.50/share)		—			—			—			17,642,948
Offering costs related to private equity offering		—			—			—			(1,729,242	)
Proceeds from registered direct offering ($0.50/share)		2,315,360			—			2,320,000			13,611,419
Offering costs related to registered direct offering		(206,300	)		—			(206,300	)		(857,149	)
Legal fees in connection with equity offerings		(188,548	)		—			(188,548	)		(533,434	)
Interest expense related to conversion of notes payable		—			—			—			2,352,045
Interest expense related to warrant tender offer		393,686			—			393,686			393,686
Stock issued for bonuses and tendered for income tax		104,394			—			104,545			104,545
Stock issued for board compensation		—			—			—			260,190
Stock-based compensation		194,551			—			194,551			1,290,777
Interest expense related to warrant extension		—			—			—			826,252
Debt discount related to convertible notes payable		—			—			—			1,645,010
Net Loss May 31, 2018		—			(9,623,623	)		(9,623,623	)		(50,149,681	)

Balance May 31, 2018	$	159,764,611		$	(173,139,396	)	$	(13,157,971	)	$	(13,157,971	)

See accompanying notes to consolidated financial statements

CytoDyn Inc.

Consolidated Statement of Changes in Stockholders’ (Deficit)/ Equity

(Unaudited)


	Additional Paid-In Capital			Accumulated Deficit			Total			Fiscal Year To Date
Balance May 31, 2018	$	159,764,611		$	(173,139,396	)	$	(13,157,971	)	$	(13,157,971	)
First Quarter Fiscal Year Ended May 31, 2019
Acquisition of ProstaGene LLC		—			—			—			—
Issuance of stock payment shares		—			—			—			—
Proceeds from registered direct offering ($0.50/share)		983,030			—			985,000			985,000
Offering costs related to registered direct offering		(75,151	)		—			(75,151	)		(75,151	)
Proceeds from private equity offering ($0.50/share)		7,499,271			—			7,514,300			7,514,300
Offering costs related to private equity offering		(882,716	)		—			(882,716	)		(882,716	)
Legal fees in connection with equity offerings		(50,544	)		—			(50,544	)		(50,544	)
Stock-based compensation		283,346			—			283,346			283,346
Net Loss August 31, 2018		—			(14,413,569	)		(14,413,569	)		(14,413,569	)

Balance August 31, 2018	$	167,521,847		$	(187,552,965	)	$	(19,797,305	)		(19,797,305	)
Second Quarter Fiscal Year Ended May 31, 2019
Acquisition of ProstaGene LLC		11,539,342			—			11,558,000			11,558,000
Issuance of stock payment shares		—			—			8,342			8,342
Proceeds from registered direct offering ($0.50/share)		—			—			—			985,000
Offering costs related to registered direct offering		—			—			—			(75,151	)
Proceeds from private equity offering ($0.50/share)		14,934,355			—			14,964,285			22,478,585
Offering costs related to private equity offering		(1,693,354	)		—			(1,693,354	)		(2,576,070	)
Legal fees in connection with equity offerings		(25,652	)		—			(25,652	)		(76,195	)
Stock-based compensation		1,227,140			—			1,227,140			1,510,486
Net Loss November 30, 2018					(14,305,380	)		(14,305,380	)		(28,718,950	)

Balance November 30, 2018	$	193,503,678		$	(201,858,345	)	$	(8,063,924	)	$	(8,063,924	)

See accompanying notes to consolidated financial statements

CYTODYN INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF NOVEMBER 30, 2018

(UNAUDITED)

Note 1 – Organization

CytoDyn Inc. (the “Company”, “we” or “us”) was originally incorporated under the laws of Colorado on May 2, 2002 under the name RexRay Corporation (its previous name) and, effective August 27, 2015, reincorporated under the laws of Delaware. Effective November 16, 2018, we implemented a holding company reorganization, as a result of which, we became the successor issuer and reporting company to the former CytoDyn Inc. (now our wholly owned subsidiary, CytoDyn Operations Inc.). We are a clinical-stage biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (“HIV”) infection. Our lead product candidate, leronlimab (PRO 140), belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

The Company is developing a class of therapeutic monoclonal antibodies to address unmet medical needs in the areas of HIV and graft-versus-host disease (“GvHD”). In addition, we are expanding the clinical focus of leronlimab (PRO 140) to include the evaluation of certain cancer and immunological indications where CCR antagonism has shown initial promise.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect all adjustments, which consist solely of normal recurring adjustments, needed to fairly present the financial results for these periods. The consolidated financial statements and notes thereto are presented as prescribed by Form 10-Q. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted. The accompanying consolidated financial statements should be read in conjunction with the financial statements for the fiscal years ended May 31, 2018 and 2017 and notes thereto in the Company’s Annual Report on Form 10-K and Form 10-K/A for the fiscal year ended May 31, 2018, filed with the Securities and Exchange Commission on July 27, 2018 and September 28, 2018, respectively. Operating results for the three months ended November 30, 2018 are not necessarily indicative of the results that may be expected for the entire year. In the opinion of management, all adjustments have been made, which consist only of normal recurring adjustments necessary for a fair statement of (a) the results of operations for the three and six months ended November 30, 2018 and November 30, 2017, (b) the financial position at November 30, 2018 and (c) cash flows for the six month periods ended November 30, 2018 and November 30, 2017.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, CytoDyn Operations Inc., Advanced Genetic Technologies, Inc. (“AGTI”) and CytoDyn Veterinary Medicine LLC (“CVM”), of which both AGTI and CVM are dormant entities. All intercompany transactions and balances are eliminated in consolidation.

Reclassifications

Certain prior year amounts shown in the accompanying consolidated financial statements have been reclassified to conform to the 2018 presentation. These reclassifications did not have any effect on total current assets, total assets, total current liabilities, total liabilities, total stockholders’ (deficit) equity, net loss or loss per share.

Going Concern

The consolidated accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company had losses for all periods presented. The Company incurred a net loss of $28,718,950 for the six months ended November 30, 2018 and has an accumulated deficit of $201,858,345 as of November 30, 2018. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

to its clinical trials. These research and development activities are subject to significant risks and uncertainties. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity and debt securities, combined with additional funding from other traditional sources. There can be no assurance, however, that the Company will be successful in these endeavors.

Use of Estimates

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash

Cash is maintained at federally insured financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Balances in excess of federally insured limits at November 30, 2018 and May 31, 2018 approximated $0.5 million and $1.1 million, respectively.

Identified Intangible Assets

The Company follows the provisions of Financial Accounting Standards Board (“FASB”) ASC Topic 350 Intangibles-Goodwill and Other, which establishes accounting standards for the impairment of long-lived assets such as intangible assets subject to amortization. The Company reviews long-lived assets to be held and used for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. If the sum of the undiscounted expected future cash flows over the remaining useful life of a long-lived asset group is less than its carrying value, the asset is considered impaired. Impairment losses are measured as the amount by which the carrying amount of the asset group exceeds the fair value of the asset. There were no impairment charges for the six months ended November 30, 2018 and 2017. The value of the Company’s patents would be significantly impaired by any adverse developments as they relate to the clinical trials pursuant to the patents acquired as discussed in Notes 7 and 9.

Research and Development

Research and development costs are expensed as incurred. Clinical trial costs incurred through third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development collaboration arrangements or other contractual agreements, the milestone payment obligations are expensed when the milestone conditions are probable and the amount of payment is reasonably estimable.

Pre-launch Inventory

The Company may scale-up and make commercial quantities of its product candidate prior to the date it anticipates that such product will receive final FDA approval. The scale-up and commercial production of pre-launch inventories involves the risk that such products may not be approved for marketing by the FDA on a timely basis, or ever. This risk notwithstanding, the Company may scale-up and build pre-launch inventories of product that have not yet received final governmental approval when the Company believes that such action is appropriate in relation to the commercial value of the product launch opportunity. The determination to capitalize is made once the Company (or its third party development partners) has filed a Biologics License Application (“BLA”) that has been acknowledged by the FDA as containing sufficient information to allow the FDA to conduct its review in an efficient and timely manner and management is reasonably certain that all regulatory and legal requirements will be satisfied. This determination is based on the particular facts and circumstances relating to the expected FDA approval of the drug product being considered. As of November 30, 2018 and May 31, 2018, the Company did not have pre-launch inventory that qualified for capitalization pursuant to U.S. GAAP ASC 330 “Inventory.”

Fair Value of Financial Instruments

Fair Value Hierarchy

The three levels of inputs that may be used to measure fair value are as follows:

Level 1. Quoted prices in active markets for identical assets or liabilities.

Level 2. Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated with observable market data for substantially the full term of the assets or liabilities. Level 2 inputs also include non-binding market consensus prices that can be corroborated with observable market data, as well as quoted prices that were adjusted for security-specific restrictions.

Level 3. Unobservable inputs to the valuation methodology are significant to the measurement of the fair value of assets or liabilities. These Level 3 inputs also include non-binding market consensus prices or non-binding broker quotes that the Company was unable to corroborate with observable market data.

Liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of November 30, 2018 and May 31, 2018 is as follows:


	Fair Value Measurement at				Fair Value Measurement at
	November 30, 2018 (1)				May 31, 2018 (1)
	Using				Using
	Level 3		Total		Level 3		Total
Liabilities:
Derivative liability - warrants	$	1,789,066	$	1,789,066	$	1,323,732	$	1,323,732
Derivative liability - convertible note redemption provision		1,286,076		1,286,076		—		—

Total liabilities	$	3,075,142	$	3,075,142	$	1,323,732	$	1,323,732

(1)	The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of November 30, 2018 and May 31, 2018.

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurements. These instruments are not quoted on an active market. The Company uses a Binomial Lattice Model to estimate the value of the warrant derivative liability and a Monte Carlo Simulation to value the derivative liability of the redemption provision within a convertible promissory note. These valuation models were used because management believes they reflect all the assumptions that market participants would likely consider in negotiating the transfer of the instruments. The Company’s derivative liabilities are classified within Level 3 of the fair value hierarchy because certain unobservable inputs were used in the valuation models. The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended November 30, 2018 and the year ended May 31, 2018:


Investor warrants issued with registered direct equity offering	$	4,360,000
Placement agent warrants issued with registered direct equity offering		819,200
Fair value adjustments		(3,855,468	)

Balance at May 31, 2018		1,323,732
Inception date value of redemption provision		1,284,998
Fair value adjustments		466,412

Balance at November 30, 2018	$	3,075,142

Stock-Based Compensation

U.S. GAAP requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award (requisite service period) or when designated milestones have been achieved.

The Company accounts for stock-based awards established by the fair market value of the instrument using the Black-Scholes option pricing model utilizing certain weighted average assumptions including stock price volatility, expected term and risk-free interest rates, as of the grant date. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of the stock-based award. The expected volatility is based on the historical volatility of the Company’s common stock on monthly intervals. The computation of the expected option term is based on the “simplified method,” as the Company issuances are considered “plain vanilla” options. For stock-based awards with defined vesting, the Company recognizes compensation expense over the requisite service period or when designated milestones have been achieved. The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods, if actual forfeitures differ from those estimates. Based on limited historical experience of forfeitures, the Company estimated future unvested forfeitures at 0% for all periods presented. Periodically, the Company will issue restricted common stock to third parties as compensation for services rendered. Such stock awards are valued at fair market value on the effective date of the Company’s obligation.

Common Stock

On August 24, 2017, at the 2017 Annual Meeting of Stockholders, a proposal was approved to increase the total number of authorized shares of common stock from 350,000,000 to 375,000,000. On June 7, 2018, at a special meeting of stockholders, a proposal was approved to increase the total number of authorized shares of common stock of the Company from 375,000,000 to 450,000,000. Subsequent to each stockholders’ meeting, an amendment to the Company’s Certificate of Incorporation was filed with the Secretary of State of the State of Delaware to give effect to each authorized share increase.

On November 8, 2018 at the 2018 Annual Meeting of Stockholders, a proposal was approved to increase the total number of authorized shares of common stock from 450,000,000 to 600,000,000. Subsequent to the meeting, an amendment to the Company’s Certificate of Incorporation was filed with the Secretary of State of the State of Delaware to give effect to the authorized share increase.

Preferred Stock

The Company’s Board of Directors is authorized to issue up to 5,000,000 shares of preferred stock without stockholder approval. As of November 30, 2018, the Company has authorized the issuance of 400,000 shares of Series B Convertible Preferred Stock, of which 92,100 shares were outstanding. The remaining preferred shares authorized have no specified rights.

Treasury Stock

Treasury stock purchases are accounted for under the par value method, whereby the cost of the acquired stock is recorded at par value. During the year ended May 31, 2018, the Company purchased 159,011 shares of $0.001 par value treasury stock for shares tendered in satisfaction of income tax withholding, in connection with incentive compensation paid to certain officers in the form of common stock.

Debt Discount

During the six months ended November 30, 2018 and the year ended May 31, 2018, the Company incurred approximately $0.6 million and $1.5 million of debt discount related to the issuance of convertible notes, as described in Note 4. The discount is amortized over the life of the convertible promissory notes. During the six months ended November 30, 2018 and November 30, 2017, the Company recorded approximately $117,500 and $1.2 million of related amortization.

Debt Issuance Cost

During the six months ended November 30, 2018 and the year ended May 31, 2018, the Company incurred direct costs associated with the issuance of convertible notes, as described in Note 4, and recorded approximately $0.1 million and $0.4 million, respectively of debt issuance costs. In connection with the debt issuance costs, the Company recognized approximately $20,000 and $0.3 million of related amortization for the six months ended November 30, 2018 and November 30, 2017, respectively.

Offering Costs

The Company incurred direct incremental costs associated with the sale of equity securities, as described in Notes 10 and 11. The costs were approximately $3.5 million for the year ended May 31, 2018, and approximately $2.7 million and $0.6 million for the six months ended November 30, 2018 and November 30, 2017, respectively. The offering costs were recorded as a component of equity upon receipt of proceeds.

Stock for Services

The Company periodically issues warrants to consultants for various services. The Black-Scholes option pricing model, as described more fully above, is utilized to measure the fair value of the equity instruments on the date of issuance. The Company recognizes the compensation expense associated with the equity instruments over the requisite service or vesting period.

Loss per Common Share

Basic loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share would include the weighted average number of shares of common stock outstanding and potentially dilutive common stock equivalents. Because of the net losses for all periods presented, the basic and diluted weighted average shares outstanding are the same since including the additional shares would have an anti-dilutive effect on the loss per share. For this reason, common stock options and warrants to purchase 155,836,676 and 87,551,801 shares of common stock were not included in the computation of basic and diluted weighted average number of shares of common stock outstanding for the six months ended November 30, 2018 and November 30, 2017, respectively. Additionally, as of November 30, 2018, shares of Series B convertible preferred stock in the aggregate of 92,100 shares can potentially convert into 921,000 shares of common stock.

Income Taxes

Deferred taxes are provided on the asset and liability method, whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Future tax benefits for net operating loss carry forwards are recognized to the extent that realization of these benefits is considered more likely than not. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company follows the provisions of FASB Accounting Standards Codification (“ASC”) ASC 740-10 “Uncertainty in Income Taxes”. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there are no unrecognized benefits for all periods presented. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefit in interest expense and penalties in operating expenses.

The Tax Cuts and Jobs Act (the “Act”) was enacted on December 22, 2017. The Act reduces the U.S. federal corporate tax rate from 35% to 21% effective as of January 1, 2018. In accordance with Section 15 of the Internal Revenue Code, we utilized a blended rate of 28.62% for our fiscal 2018 tax year, by applying a prorated percentage of the number of days prior to and subsequent to the January 1, 2018 effective date. For the fiscal year ended May 31, 2018, we recorded provisional charges for the re-measurement of the deferred tax assets and reduced our deferred taxes before the valuation allowance by $17,497,051 to our income tax expense. The net tax expense for the year ended May 31, 2018, is zero, due to the reduction in the deferred tax valuation allowance. For the year ending May 31, 2019 a deferred tax rate of 21% is being utilized and a corresponding valuation allowance adjustment is being recorded for the generation of deferred tax assets reversing in the future. For the three months ending November 30, 2018 the Company recorded a $2,826,919 deferred income tax benefit from a reduction in the Company’s deferred tax valuation allowance resulting from recording a deferred tax liability of $2,826,919 in connection with the acquisition of assets in the ProstaGene LLC transaction (see Note 7) . The deferred tax liability represents the tax effect of the difference in the carrying value of the assets and their tax basis at acquisition. The Company has a full valuation allowance on the Company’s net deferred tax assets as of November 30, 2018 and May 31, 2018, as management does not consider it more than likely than not that the benefits from the deferred taxes will be realized.

Note 3 – Recent Accounting Pronouncements

Recent accounting pronouncements, other than below, issued by the FASB (including its EITF), the AICPA and the SEC did not or are not believed by management to have a material effect on the Company’s present or future financial statements.

In August 2018, FASB issued Accounting Standards Update (“ASU”) No. 2018-13 Fair Value Measurement (Topic 820) Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update provides guidance that remove, modify and add to the disclosure requirements related to fair value measurements. The guidance removes the requirements to disclose the amount and reasons for transfers between Level 1 and Level 2 assets, the policy for timing and transfers between levels and the valuation process for Level 3 fair value measurements. The guidance modifies disclosure requirements for investments in certain entities that calculate net asset value and clarifies the purpose of the measurement uncertainty disclosure. The guidance adds requirements to disclose changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurements and to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The guidance is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. The Company does not expect the adoption to have a material impact on its consolidated financial statements.

In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company is currently assessing the impact this Update may have on its consolidated financial statements.

In March 2018, FASB issued ASU No. 2018-05, Income Taxes (Topic 740), Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118. The amendments in this Update add various Securities and Exchange Commission (“SEC) paragraphs pursuant to the issuance of SEC Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“Act”) (“SAB 118). The SEC issued SAB 118 to address concerns about reporting entities’ ability to timely comply with the accounting requirements to recognize all of the effects of the Act in the period of enactment. SAB 118 allows disclosure that timely determination of some or all of the income tax effects from the Act are incomplete by the due date of the financial statements and if possible to provide a reasonable estimate. The Company has provided a reasonable estimate in the notes to the consolidated financial statements.

In July 2017, FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (“EPS”) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt— Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. Management is currently assessing the impact the adoption of ASU 2017-11 will have on the Company’s consolidated financial statements.

In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718), Scope of Modification Accounting. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for public business entities for reporting periods for which financial statements have not yet been issued. The adoption of ASU 2017-09 did not have a material impact on the Company’s consolidated financial statements.

In January 2017, the FASB issued ASU 2017-01, Clarifying the Definition of a Business, which narrows the definition of a business and clarifies that to be considered a business, the fair value of gross assets acquired (or disposed of) should not be concentrated in a single identifiable asset or a group of similar identifiable assets. In addition, to be considered a business, an acquisition would have to include an input and a substantive process that together will significantly contribute to the ability to create an output. Also, the amendments narrow the definition of the term “output” so that it is consistent with how outputs are defined in ASC Topic 606, Revenue from Contracts with Customers. This ASU was effective for the Company on June 1, 2018. Adoption of this new guidance must be applied on a prospective basis. The adoption of this ASU did not have a significant impact on the Company’s consolidated financial statements.

Business combinations are accounted for by applying the acquisition method in accordance with ASC 805, Business Combinations. Under the acquisition method, identifiable assets acquired and liabilities assumed are measured at their fair values as of the date of acquisition and are recognized separately from goodwill. The results of operations of the acquired entity are included in the consolidated statement of income from the date of acquisition. Customers recognize goodwill when the acquisition price exceeds the estimated fair value of the net assets acquired.

Note 4 – Convertible Instruments

Series B Convertible Preferred Stock

preferences over the common shares at $5.00 per share plus any accrued dividends. Dividends are payable to the Series B holders when declared by the board of directors at the rate of $0.25 per share per annum. Such dividends are cumulative and accrue whether or not declared and whether or not there are any profits, surplus or other funds or assets of the Company legally available. The Series B holders have no voting rights. As of November 30, 2018 and May 31, 2018, the undeclared, accrued dividends were approximately $205,000 and $199,000, respectively, or 410,000 and 387,000 shares of common stock, respectively.

Short-term Convertible Notes

During the fiscal year ended May 31, 2018, the Company issued approximately $4.89 million in aggregate principal of short-term Convertible Notes, with a maturity date of January 31, 2018, and related warrants to investors for cash. The principal amount of the short-term Convertible Notes, including any accrued but unpaid interest thereon, was convertible at the election of the holder at any time into shares of common shares at any time prior to maturity at a conversion price of $0.75 per share. The short-term Convertible Notes bore simple interest at the annual rate of 7%. Principal and accrued interest, to the extent not previously paid or converted, is due and payable on the maturity date. At the commitment date, the Company determined that the conversion feature related to these short-term Convertible Notes to be beneficial to the investors. As a result, the Company determined the intrinsic value of the beneficial conversion feature utilizing the fair value of the underlying common stock on the commitment dates and the effective conversion price after discounting the short-term Convertible Notes for the fair value of the related warrants.

In connection with the sale of the short-term Convertible Notes, detachable common stock warrants to purchase a total of 4,025,656 common shares, with an exercise price of $1.00 per share and a five-year term were issued to the investors. The Company determined the fair value of the warrants at issuance using the Black-Scholes option pricing model utilizing certain weighted average assumptions, such as expected stock price volatility, expected term of the warrants, risk-free interest rates and expected dividend yield at the grant date.


		2018
Expected dividend yield		0%
Stock price volatility		69.80%
Expected term		5 year
Risk-free interest rate		1.77-1.93%
Grant-date fair value		$0.30-$0.39

The fair value of the warrants, coupled with the beneficial conversion features, were recorded as a debt discount to the short-term Convertible Notes and a corresponding increase to additional paid-in capital was amortized over the term of the short-term Convertible Notes. The Company incurred debt discount of approximately $1.5 million related to the beneficial conversion feature and detachable warrants issued with the short-term Convertible Notes during the year ended May 31, 2018. Accordingly, the Company recognized approximately $-0- and $1.2 million of non-cash debt discount during the six months ended November 30, 2018 and November 30, 2017. In connection with the short-term Convertible Notes, the Company incurred direct issuance costs of approximately $0.4 million during the year ended May 31, 2018. The issuance costs were amortized over the term of the short-term Convertible Notes and accordingly, the Company recognized approximately $-0- and $0.3 million of debt issuance costs during the six months ended November 30, 2018 and November 30, 2017, respectively.

On January 31, 2018, in connection with a registered direct equity offering, as fully described in Note 11, the short-term Convertible Notes in an aggregate principal amount of $5,788,500, plus accrued unpaid interest of approximately $243,000 were sold for 12,062,728 shares of common stock. The short-term Convertible Note investors also received warrants to purchase 7,718,010 shares of common stock. The securities were sold at a combined purchase price of $0.50 per share of common stock and related warrants, for aggregate gross proceeds to the Company of approximately $6.0 million. The Company repaid one short-term Convertible Note, including accrued interest in the aggregate of approximately $259,000. During the six months ended November 30, 2018 and November 30, 2017, the Company recognized approximately $-0- and $75,000, of interest expense related to the short-term Convertible Notes.

Activity related to the short-term Convertible Notes was as follows:


	November 30, 2018		May 31, 2018
Face amount of short-term Convertible Notes	$	—	$	6,038,500

Unamortized discount		—		—
Registered direct equity offering		—		(5,788,500	)
Note repayment		—		(250,000	)

Carrying value of short-term Convertible Notes	$	—	$	—

Long-term Convertible Note

On June 26, 2018, the Company entered into a securities purchase agreement, pursuant to which the Company issued a convertible promissory note (the “Note”) with a two-year term to an institutional accredited investor in the initial principal amount of $5.7 million. The investor gave consideration of $5.0 million to the Company. The Note bears interest of 10% and is convertible into common stock, at $0.55 per share. The Note is convertible in total, or in part, of the outstanding balance, at any time after six months from the issue date upon five trading days’ notice, subject to certain adjustments and ownership limitations specified in the Note. The Investor may redeem any portion of the Note, at any time after six months from the issue date upon five trading days’ notice, subject to a maximum monthly redemption amount of $350,000. The securities purchase agreement requires the Company to reserve shares for future conversions or redemptions by dividing the outstanding principal balance plus accrued interest by the conversion price of $0.55 per share times 1.5.

In connection with the Note, the Company recorded debt discount of $0.6 million and debt issuance costs of $0.1 million. The discount and issuance costs will be amortized over the life of the Note, and accordingly, the Company recognized approximately $20,000 and $-0- amortization of debt issuance costs for the six months ended November 30, 2018 and November 30, 2017, respectively and approximately $118,000 and $-0- of amortization of debt discount for the six months ended November 30, 2018 and November 30, 2017, respectively.

Effective November 15, 2018, the Note was amended to allow the Investor to redeem the monthly redemption amount of $350,000 in cash or stock, at the lesser of (i) $0.55, or (ii) the lowest closing bid price of the Company’s common stock during the 20 days prior to the conversion, multiplied by a conversion factor of 85%. The variable rate redemption provision meets the definition of a derivative instrument and subsequent to the amendment, it no longer meets the criteria to be considered indexed to the Company’s own stock. As of November 15, 2018, the redemption provision requires bifurcation as a derivative liability at fair value under the guidance in ASC Topic No. 815, “Derivatives and Hedging.”

The amendment of the Note was also evaluated under ASC Topic 470-50-40, “Debt Modifications and Extinguishments.” Based on the guidance, the instruments were determined to be substantially different, and debt extinguishment accounting was applied. We recorded approximately $1.5 million as an extinguishment loss, which was the difference in the net carrying value of the Note prior to the amendment of approximately $5.4 million, and the fair value of the Note and embedded derivatives after the amendment of approximately $6.9 million. The extinguishment loss includes a write-off of unamortized debt issuance costs and the debt discount associated with the original Note. During the six months ended November 30, 2018 and November 30, 2017, the Company recognized approximately $248,000 and $-0-, of interest expense related to the Notes.

Activity related to the Note was as follows:


	November 30, 2018
	Short term			Long term			Total			May 31, 2018
Face amount of convertible promissory note	$	—		$	—		$	—		$	—
June 26, 2018 convertible promissory note		2,100,000			3,600,000			5,700,000			—
Monthly redemption		700,000			(700,000	)		—			—
Unamortized discount at August 31, 2018		(344,614	)		(281,628	)		(626,242	)		—

Carrying value of convertible notes at August 31, 2018	$	2,455,386		$	2,618,372		$	5,073,758		$	—

Carrying value of convertible notes at November 30, 2018	$	4,200,000		$	1,396,974		$	5,596,974		$	—

Note 5 – Derivative Liabilities

The investor and placement agent warrants, issued in connection with a registered direct offering in September 2016, contained a provision for net cash settlement in the event that there is a fundamental transaction (contractually defined as a merger, sale of substantially all assets, tender offer or share exchange, whereby such other Person or group acquires more than 50% of the outstanding common stock). If a fundamental transaction occurs in which the consideration issued consists principally of cash or stock in a successor entity, then the warrantholder has the option to receive cash equal to the fair value of the remaining unexercised portion of the warrant. Due to this contingent cash settlement provision, the investor and placement agent warrants require liability classification as derivatives in accordance with ASC 480 and ASC 815 and are recorded at fair value.

The following tables summarize the fair value of the warrant derivative liability and related common shares as of inception date September 15, 2016, May 31, 2018, August 31, 2018 and November 30, 2018:


	Shares Indexed		Derivative Liability
Inception date September 15, 2016		7,733,334	$	5,179,200
Balance May 31, 2018		7,733,334	$	1,323,732
Balance August 31, 2018		7,733,334	$	2,071,199
Balance November 30, 2018		7,733,334	$	1,789,066

The Company recognized approximately $466,000 of non-cash loss and approximately $467,000 of non-cash gain, due to the changes in the fair value of the liability associated with such classified warrants during the six months ended November 30, 2018 and November 30, 2017, respectively.

ASC 820 provides requirements for disclosure of liabilities that are measured at fair value on a recurring basis in periods subsequent to the initial recognition. Fair values for the warrants were determined using a Binomial Lattice (“Lattice”) valuation model.

The Company estimated the fair value of the warrant derivative liability as of inception date September 15, 2016, May 31, 2018 and November 30, 2018, using the following assumptions:


	September 15, 2016			May 31, 2018			November 30, 2018
Fair value of underlying stock	$	0.78		$	0.49		$	0.58
Risk free rate		1.20	%		2.63	%		2.83	%
Expected term (in years)		5			3.3			2.79
Stock price volatility		106	%		64	%		62	%
Expected dividend yield		—			—			—
Probability of Fundamental Transaction		50	%		50	%		95	%
Probability of holder requesting cash payment		50	%		50	%		50	%

Due to the fundamental transaction provision contained in the warrants, which could provide for early redemption of the warrants, the model also considered subjective assumptions related to the fundamental transaction provision. The fair value of the warrants will be significantly influenced by the fair value of the Company’s stock price, stock price volatility, changes in interest rates and management’s assumptions related to the fundamental transaction provisions.

As described above in Note 4, the redemption provision embedded in the Note required bifurcation and measurement at fair value as a derivative. The fair value of the convertible note redemption provision derivative liability was calculated using a Monte Carlo Simulation which uses randomly generated stock-price paths obtained through a Geometric Brownian Motion stock price simulation. Various assumptions used in the valuation model included: annual volatility of 58.8%, risk free rate of 2.78%, an exercise factor of 2x and an expected term of 1.61 years.

The fair value of the derivative liability resulting from the redemption provision was approximately $1.28 million as of its inception date, November 15, 2018 and November 30, 2018. The fair value of the redemption provision will be significantly influenced by the fair value of the Company’s stock price, stock price volatility, changes in interest rates and management’s assumptions related to the redemption factor. The Company recognized approximately $1,100 of non-cash loss, due to the changes in the fair value of the liability associated with such classified redemption provision between the inception date and November 30, 2018.

The following table summarizes the fair value of the convertible note redemption provision derivative liability as of inception date November 15, 2018 and November 30, 2018:


	Net Proceeds		Derivative Liability
Inception date, November 15, 2018	$	5,000,000	$	1,284,998
Balance November 30, 2018	$	5,000,000	$	1,286,076

The Company estimated the fair value of the redemption provision using the following assumptions on the closing date of November 15, 2015 and November 30, 2018:


	November 15, 2018			November 30, 2018
Fair value of underlying stock	$	0.57		$	0.58
Risk free rate		2.78	%		2.78	%
Expected term (in years)		1.61			1.61
Stock price volatility		58.8	%		58.8	%
Expected dividend yield		—			—
Discount factor		85	%		85	%

Note 6 – Stock Options and Warrants

The Company has one active stock-based equity plan at November 30, 2018, the CytoDyn Inc. 2012 Equity Incentive Plan, as amended (the “2012 Plan”) and one stock-based equity plan that is no longer active, but under which certain prior awards remain outstanding, the CytoDyn Inc. 2004 Stock Incentive Plan (the “2004 Plan” and, together with the 2012 Plan, the “Incentive Plans”). The 2012 Plan was approved by stockholders at the Company’s 2012 annual meeting to replace the 2004 Plan. The 2012 Plan was amended by stockholder approval in February 2015 to increase the number of shares available for issuance from 3,000,000 to 5,000,000 shares of common stock and in March 2016 to increase the number of shares available for issuance from 5,000,000 to 7,000,000 shares of common stock. At the annual meeting of stockholders held on August 24, 2017, the stockholders approved an amendment to the 2012 Plan to increase the number of shares available for issuance from 7,000,000 to 15,000,000 shares of common stock. As of November 30, 2018, the Company had 553,048 shares available for future stock-based grants under the 2012 Plan.

Stock Options

During the six months ended November 30, 2018, the Company granted annual stock option awards to directors to purchase a total of 680,822 shares of common stock. The exercise price of the stock option awards is $0.49 per share, except for one stock option award covering 80,822 shares of common stock, which has an exercise price of $0.47 per share. These stock option awards vest quarterly over one year and have a ten-year term. The grant date fair value related to these stock options was $0.31 per share, except the stock option award covering 80,822 shares of common stock, which was $0.30 per share. These awards reflect an increase in the annual non-employee director stock option award from 75,000 to 100,000 shares per year, effective for fiscal year 2019.

During the six months ended November 30, 2018, the Company granted a stock option award covering 950,000 shares of common stock with an exercise price of $0.49 per share, to its Executive Chairman. This stock option award vests ratably over 24 months, has a ten-year term and a grant date fair value of $0.41 per share.

During the six months ended November 30, 2018, the Company granted stock options, covering an aggregate of 875,000 shares of common stock, to executive management and employees with exercise prices of $0.49 per share. The stock option awards vest annually over three years, with a ten-year term and grant date fair values of $0.31 per share. Additionally, the Company granted a stock option covering an aggregate of 1,000,000 shares of common stock, to an officer with an exercise price of $0.565 per share. The stock option award vests 50% upon grant and 50% on April 8, 2019; it has a ten-year term and grant date fair value of $0.30 per share. The Company also granted stock options, covering an aggregate of 500,000 shares of common stock to directors for consulting services with an exercise price of $0.565 per share. The stock option awards vest upon grant, have a ten-year term and grant date fair value of $0.30 per share.

During the six months ended November 30, 2018, the Company granted a stock option award covering 350,000 shares of common stock with an exercise price of $0.551 per share to Dr. Richard G. Pestell, M.D., Ph.D., in connection with his employment agreement as Chief Medical Officer and the closing of the ProstaGene transaction described in Note 7. The stock option award vests annually over three years, with a ten-year term and grant date fair value of $0.30 per share.

Warrants

On June 15, 2018, in connection with a registered direct equity offering, as fully described in Note 11, the Company issued warrants covering 1,970,000 shares of common stock to investors. The investor warrants have a five-year term and an exercise price of $0.75 per share. In connection with the registered direct offering, the Company also issued warrants covering 133,600 shares of common stock to the placement agent. The placement agent warrants have a five-year term and an exercise price of $0.55 per share.

During the six months ended November 30, 2018, in connection with a private equity offering, as fully described in Note 10, the Company issued common stock warrants covering a total of 22,478,585 shares of common stock to investors. The investor warrants have a five-year term and an exercise price of $0.75 per share. In connection with this offering, the Company also issued common stock warrants covering 4,245,117 shares of common stock to the placement agent. The placement agent warrants have a five-year term, an exercise price of $0.50 per share and a cashless exercise provision.

During the six months ended November 30, 2018, the Company issued compensable warrants covering an aggregate of 300,000 shares of common stock to consultants. The warrants have a five-year term, an exercise price of $0.56 per share and a grant date fair value of $0.30 per share.

During the year ended May 31, 2018, the Company determined to extend the expiration dates of certain warrants from May 31, 2017 to June 30, 2017 covering 3,295,000 shares of common stock. The warrants were originally issued in connection with 2012 convertible promissory notes and had an amended exercise price of $1.00 per share. The extension to June 30, 2017 was contingent upon immediate exercise of the warrants at a reduced exercise price of $0.50 per share. The Company received proceeds of approximately $1.6 million and, pursuant to U.S. GAAP, the Company recognized non-cash inducement interest expense of approximately $0.8 million, which represented the incremental increase in the fair value of the extended warrants.

Compensation expense related to stock options, compensatory warrants and common stock reserved for advisory services, for the three and six months ended November 30, 2018 and November 30, 2017 was approximately $1.2 million and $275,000 and $1.5 million and $530,000, respectively. The grant date fair value of options and compensatory warrants vested during the three and six month periods ended November 30, 2018 and November 30, 2017 was approximately $485,000 and $127,000 and $1.2 million and $574,000, respectively. As of November 30, 2018, there was approximately $5.7 million of unrecognized compensation expense related to share-based payments for unvested options, which is expected to be recognized over a weighted average period of 2.69 years.

The following table represents stock option and warrant activity as of and for the six months ended November 30, 2018:


	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Options and warrants outstanding - May 31, 2018		132,385,269		$	0.80		3.78	$	3,673

Granted		33,483,124			0.69		—		—
Exercised		—			—		—		—
Forfeited/expired/cancelled		(10,031,717	)		0.75		—		—

Options and warrants outstanding - November 30, 2018		155,836,676			0.78		3.97		769,360

Outstanding exercisable - November 30, 2018		150,960,607		$	0.78		3.80	$	565,356

Note 7 – Acquisition of Patents and Intangibles

As discussed in Note 9 below, the Company consummated an asset purchase on October 16, 2012, and paid $3,500,000 for certain assets, including intellectual property, certain related licenses and sublicenses, FDA filings and various forms of the leronlimab (PRO 140) drug substance. The Company followed the guidance in Financial Accounting Standards Topic 805 to determine if the Company acquired a business. Based on the prescribed accounting, the Company acquired assets and not a business. As of November 30, 2018, the Company has recorded and is amortizing $3,500,000 of intangible assets in the form of patents. The Company estimates the acquired patents have an estimated life of ten years. Subsequent to the acquisition date, the Company has continued to expand, amend and file new patents central to its current clinical trial strategies, which, in turn, have extended the protection period for certain methods of using leronlimab (PRO 140) and formulations comprising leronlimab (PRO 140) out through at least 2031 and 2038, respectively, in various countries.

On November 16, 2018, the Company completed the acquisition of substantially all of the assets of ProstaGene, LLC (“ProstaGene”), a biotechnology start-up company, which included patents related to clinical research, a proprietary CCR5 technology for early cancer diagnosis, and a noncompetition agreement with ProstaGene’s founder and Chief Executive Officer, Richard G. Pestell, M.D., Ph.D. The acquisition of ProstaGene’s assets expands the Company’s clinical development of leronlimab (PRO 140) into cancer indications and commercialization of certain cancer diagnostic tests.

The aggregate purchase price paid for the ProstaGene acquisition was $11,558,000 based on the issuance of 20,278,000 shares of common stock of CytoDyn at $0.57 per share, including 1,620,000 shares earned, but not yet issued, by the investment bank for advisory services. In connection with the purchase, the Company entered into a Stock Restriction Agreement (“Agreement”), restricting the transfer of 8,342,000 shares of common stock payable to Dr. Pestell for a three-year period from the closing date of the transaction. In the event Dr. Pestell’s employment with the Company is terminated, as defined in the employment agreement, the Company will have an option to repurchase such Restricted Shares from Dr. Pestell at a purchase price of $0.001 per shares. The Restricted Shares will vest and be released from the Agreement in three equal annual installments commencing one year after the closing date of the acquisition of ProstaGene.

A summary of the net purchase price and allocation to the acquired assets is as follows:


	ProstaGene, LLC
CytoDyn Inc. Equity	$	11,558,000
Acquisition Expenses		741,297
Release of Deferred Tax Asset		2,826,919

Total Cost of Acquisition	$	15,126,216

Intangible assets	$	15,126,216
Other		—

Allocation of Acquisition Costs	$	15,126,216

Assets acquired from ProstaGene include (1) patents issued in the United States and Australia related to “Prostate Cancer Cell Lines, Gene Signatures and Uses Thereof” and “Use of Modulators of CCR5 in the Treatment of Cancer and Cancer Metastasis,” (2) an algorithm used to identify a 14-gene signature to predict the likelihood and severity of cancer diagnoses, and (3) a noncompetition agreement in connection with an employment agreement with Dr. Pestell as Chief Medical Officer of the Company. The fair value of the assets acquired approximates the consideration paid. The Company did not assume any liabilities. The Company accounted for the ProstaGene acquisition as an asset acquisition under ASC 805-10-55 “Business Combinations” because the assets retained from ProstaGene do not include an assembled workforce, and the gross value of the assets acquired meets the screen test in ASC 805-10-55-5A related to substantially all of the fair value being concentrated in a single asset or group of assets (i.e., the proprietary technology and patents) and, thus, is not considered a business. Thus, management concluded that the acquisition did not include both an input and substantive processes that together significantly contribute to the ability to create outputs.

The fair value of the technology acquired is identified using the Income Approach. The fair value of the patents acquired is identified using the Cost to Reproduce Method. The fair value of noncompetition agreement acquired is identified using the Residual Value Method. Goodwill is not recorded as the transaction represents an asset acquisition in accordance with ASU 2017-01. Acquisition costs for asset acquisitions are capitalized and included in the total cost of the transaction. In addition, pursuant to ASC 805, the net tax effect of the deferred tax liability arising from the book to tax basis differences is recorded as a cost of the acquisition.

The following presents intangible assets activity:


	November 30, 2018			May 31, 2018
Gross carrying amounts	$	3,500,000		$	3,500,000
Intangible asset acquisition:
ProstaGene, LLC		15,126,216			—
Accumulated amortization		(2,209,254	)		(1,968,846	)

Total amortizable intangible assets, net		16,416,962			1,531,154
Patents currently not amortized		35,989			35,989

Carrying value of intangibles, net	$	16,452,951		$	1,567,143

Amortization expense related to intangible assets patents was approximately $152,900 and $240,400 and $87,500 and $175,000 for the three and six months ended November 30, 2018 and 2017, respectively. The estimated aggregate future amortization expense related to the Company’s intangible assets with finite lives is estimated, on average, to be approximately $1.6 million per year for the next five years.

Note 8 – License Agreements

The Company has a license agreement with a third-party licensor covering the licensor’s “system know-how” technology with respect to the Company’s use of proprietary cell lines to manufacture new leronlimab (PRO 140) material. The Company accrues an annual license fee of £300,000 (approximately US$400,000 utilizing current exchange rates), which is payable annually in December, except for the December 2017 and 2018 payments, which were extended to March 15, 2018 and March 15, 2019, respectively. Future annual license fees and royalty rate will vary depending on whether the Company manufactures leronlimab (PRO 140), utilizes the third-party licensor as a contract manufacturer, or utilizes an independent party as a contract manufacturer. The licensor does not charge an annual license fee when it serves as the manufacturer. In addition, the Company will incur royalties of up to 0.75% to 2% of net sales, depending upon who serves as the manufacturer, when the Company commences their first commercial sale, which will continue as long as the license agreement is maintained.

Note 9 – Commitments and Contingencies

Under the Progenics Purchase Agreement, the Company acquired rights to the HIV viral-entry inhibitor drug candidate leronlimab (PRO 140), a humanized anti-CCR5 monoclonal antibody, as well as certain other related assets, including the existing inventory of bulk leronlimab (PRO 140) drug product, intellectual property, certain related licenses and sublicenses, and FDA regulatory filings. In connection with purchase, the Company has two remaining milestone payments, (i) $0.5 million upon filing a BLA with the FDA or non-U.S. equivalent regulatory body and (ii) $5.0 million, which will become due at the time of the first U.S. new drug application approval by the FDA or other non-U.S. approval for the sale of leronlimab (PRO 140). In addition, the Company will incur royalty payments of up to 5% on net sales during the period beginning on the date of the first commercial sale of leronlimab (PRO 140) until the later of (a) the expiration of the last to expire patent included in the acquired assets, and (b) 10 years, in each case determined on a country-by country basis. During the year ended May 31, 2016 the Company paid a milestone obligation of $1.5 million owed to Progenics as a result of the first dosing in a U.S. Phase 3 trial. To the extent that the remaining milestone payment and royalties are not timely made, under the terms of the Progenics Purchase Agreement, Progenics has certain repurchase rights relating to the assets sold to the Company thereunder. As of the date of this filing, it is management’s conclusion that the probability of achieving the subsequent future scientific research milestone is not reasonably determinable, thus the future milestone payments payable to Progenics and its sub-licensors are deemed contingent consideration and, therefore, are not currently accruable.

Payments to the third-party licensor and to Progenics are in addition to payments due under a Development and License Agreement, dated April 30, 1999 (the “PDL License”), between Protein Design Labs (now AbbVie Inc.) (“PDL”) and Progenics, which was assigned to the Company in the Progenics Purchase Agreement, pursuant to which the Company has an exclusive worldwide license to develop, make, have made, import, use, sell, offer to sell or have sold products that incorporate the humanized form of the leronlimab (PRO 140) antibody developed by PDL under the agreement the Company has paid various milestone obligations, with one remaining milestone payment of $0.5 million, which will become due upon FDA approval or approval by another non-U.S. equivalent regulatory body. In addition, the Company will incur royalties of up to 3.5% of net sales for the longer of 10 years and the date of expiration of the last to expire licensed patent. Additionally, the PDL License provides for an annual maintenance fee of $150,000 or until annual royalties paid exceed that amount. To the extent the remaining milestone payment and royalties are not timely made, under the terms of the PDL License, AbbVie Inc. has certain termination rights relating to the Company’s license of leronlimab (PRO 140) thereunder. As of the date of this filing, it is management’s conclusion that the probability of achieving the subsequent future scientific research milestones is not reasonably determinable, thus the future milestone payments payable to PDL, Progenics and its sub-licensors are deemed contingent consideration and, therefore, are not currently accruable.

The Company has entered into project work orders, as amended, for each of its clinical research organization (“CRO”) and related laboratory vendors. Under the terms of these agreements, the Company incurs execution fees for direct services costs, which are recorded as a current asset. In the event the Company were to terminate any trial, it may incur certain financial penalties which would become payable to the CRO. Conditioned upon the form of termination of any one trial, the financial penalties may range up to $0.2 million. In the remote circumstance that the Company would terminate all clinical trials, the collective financial penalties may range from an approximate low of $0.5 million to an approximate high of $1.1 million. During the year ended May 31, 2017, the Company entered into agreements with contract manufacturing companies. Under the terms of the agreements, the Company incurred approximately $2.1 million of execution fees for process validation and manufacturing activities, which have been utilized. In the event the Company were to terminate any of the agreements, it may incur certain financial penalties which would become payable to the manufacturers. Conditioned on the timing of termination, the financial penalties may range up to an approximate high of $0.3 million. From time to time, the Company is involved in routine litigation that arises in the ordinary course of business. There are no pending significant legal proceedings to which the Company is a party for which management believes the ultimate outcome would have a material adverse effect on the Company’s financial position.

Note 10 – Private Securities Offerings

During the six months ended November 30, 2018, the Company conducted a private equity offering, in which accredited investors purchased unregistered common stock at $0.50 per share with warrant coverage rate of 50%. Pursuant to the offering, the Company sold a total of 44,957,170 shares of common stock, $0.001 par value, for aggregate gross proceeds of approximately $22.5 million and issued to the investors five-year warrants covering 22,478,585 shares of common stock with an exercise price of $0.75 per share. The Company received net proceeds from the offering of approximately $19.9 million. In addition, the placement agent received warrants covering 4,245,117 shares of common stock (or 10% of total shares sold to investors) with a per share exercise price of $0.50, a five-year term and include a cashless exercise provision. The Company also paid a one-time non-accountable expense fee of $25,000 to the placement agent for its services in connection with the offering.

Note 11 – Registered Direct Equity Offerings

On January 31, 2018, the Company entered into subscription agreements with certain investors who owned convertible promissory notes of the Company (the “Notes”) for the sale by the Company of 12,062,728 shares of common stock in a registered direct offering (the “January 31 Offering”). The investors in the January 31 Offering also received warrants to purchase 7,718,010 shares of common stock. The securities were sold at a combined purchase price of $0.50 per share of common stock and related warrants, for aggregate gross proceeds to the Company of approximately $6.0 million. The Notes matured on January 31, 2018, upon which date the Company became obligated to pay the principal amount of approximately $6.0 million on the Notes, plus accrued but unpaid interest of approximately $0.3 million, for aggregate payment obligations at maturity of approximately $6.3 million. The common stock and warrants were issued in full satisfaction of approximately $6.0 million of such payment obligations, with one holder of an aggregate principal amount and accrued unpaid interest of approximately $0.3 million electing to be repaid in cash instead of participating in the January 31, 2018 Offering. As a result, all of the proceeds from the January 31 Offering were used to satisfy the Company’s payment obligations pursuant to the Notes. The warrants will be exercisable for a period of five years commencing on their issuance date, at an exercise price of $0.75 per share of common stock, subject to certain ownership limitations and adjustments as provided under the terms of the warrants. The number of shares of common stock underlying the warrant issued to each investor was calculated as the difference between (x) the number of shares of common stock issued to each investor in the January 31, 2018 Offering in respect of the payment obligations relating solely to principal amounts on the Notes and (y) the number of shares of common stock underlying certain warrants originally issued to such investor in the original Notes offering. The effect was to bring each investor from 50% warrant coverage in the original offering of Notes, assuming conversion of the principal amount thereof at an original conversion price of $0.75 per share, to 100% warrant coverage after the January 31 Offering, assuming reinvestment of the principal amount on the Notes at $0.50 per share. The warrants in the January 31 Offering, had an original exercise price of $1.00 per share, therefore, due to the reduction of exercise price to $0.75 per share, the Company recognized a non-cash inducement interest expense of approximately $2.4 million due to the modification. In connection with this January 31 Offering, the Company paid a commission of $164,425 to the placement agent.

On June 15, 2018, the Company entered into subscription agreements with certain investors for the sale of 1,970,000 shares of common stock at a purchase price of $0.50 per shares in a registered direct offering, pursuant to a registration statement on Form S-3. The investors in the offering also received warrants to purchase 1,970,000 shares of common stock with an exercise price of $0.75 per share and a five-year term. The Company received net proceeds from the offering of approximately $0.9 million. In addition, the placement agent received warrants covering 133,600 shares of common stock (or 8% of total shares sold to investors) with a per share exercise price of $0.55, a five-year term and include a cashless exercise provision.

Note 12 – Employee Benefit Plan

The Company has an employee savings plan (the “Plan”) pursuant to Section 401(k) of the Internal Revenue Code (the “Code”), covering all of its employees. The Company makes a qualified non-elective contribution of 3%, which consequently vests immediately. In addition, participants in the Plan may contribute a percentage of their compensation, but not in excess of the maximum allowed under the Code. During the three and six months ended November 30, 2018 and 2017, the Company incurred an expense of approximately $15,200 and $31,000 and $10,800 and $21,500, respectively, for qualified non-elective contributions.

Note 13 – Related Party Transactions

On July 26, 2017, Jordan G. Naydenov, a director with the Company, participated in the private placement of convertible promissory notes, as fully described in Note 4. Mr. Naydenov purchased a convertible promissory note, bearing interest of 7%, for $100,000 in aggregate principal and received a warrant covering 66,666 shares of common stock at an exercise price of $1.00. The terms and conditions of Mr. Naydenov’s investment were identical to those offered to all other investors in the offering and his investment was approved by the Audit Committee of the Board of Directors.

On July 28, 2017, Alpha Venture Capital Partners, LP (“AVCP”), participated in the private placement of convertible promissory notes, as fully described in Note 4. Carl C. Dockery, the principal of AVCP, is a director of the Company. AVCP purchased a convertible promissory note, bearing interest of 7%, for $50,000 in aggregate principal and received a warrant covering 33,333 shares of common stock at an exercise price of $1.00. The terms and conditions of the AVCP investment were identical to those offered to all other investors in the offering and his investment was approved by the Audit Committee of the Board of Directors.

On November 8, 2017, in connection with a private equity offering, a limited liability company in which Anthony D. Caracciolo, Executive Chairman of the Company, holds a partial ownership interest purchased $100,000 of common stock and warrants on terms identical to those applicable to the other investors in the private equity offering.

On January 31, 2018 each of Mr. Caracciolo, Mr. Naydenov and AVCP participated with other investors in the offering of common stock and warrants in satisfaction of the payment obligations relating to the convertible promissory notes, as fully described in Note 11 above.

The Audit Committee of the Board of Directors, comprised of independent directors, reviews and approves all related party transactions. The above terms and amounts are not necessarily indicative of the terms and amounts that would have been incurred had comparable transactions been entered into with independent parties.

On July 12, 2018, the Company announced certain leadership changes in connection with the strategic expansion and entry into certain cancer and immunologic indications. In connection with such leadership changes and effective July 11, 2018, Denis R. Burger, Ph.D. and A. Bruce Montgomery, M.D., resigned as members of the Company’s board of directors. Dr. Burger also resigned as Chief Science Officer of the Company, which was not an executive officer position. On July 10, 2018, In connection with the resignations of Dr. Burger and Dr. Montgomery, the Company’s board of directors determined to accelerate the vesting of all outstanding and unvested stock options held by Dr. Burger and Dr. Montgomery. Upon the effectiveness of their resignations, stock options covering 500,000 shares 100,000 shares, held by Dr. Burger and Dr. Montgomery, respectively became fully vested. The stock options retained their exercise period through their respective expiration dates and the terms of the stock options remained otherwise unchanged.

On November 16, 2018, the Company closed its acquisition of ProstaGene, as described in Note 7. In connection with the closing of the acquisition, the Company hired Dr. Pestell as its Chief Medical Officer. As previously disclosed by the Company, Dr. Pestell is the holder of approximately 77.2% of the outstanding equity interests in ProstaGene and consequently holds an indirect interest in approximately (i) 8,611,427 of 13,258,000 shares of the Company’s common stock, currently pending distribution by ProstaGene to its members, and (ii) 4,171,013 of 5,400,000 shares of common stock, currently held in escrow for the benefit of ProstaGene and its members, which are subject to forfeiture to satisfy certain indemnity obligations of ProstaGene and will be released ratably every six months over the eighteen-month period following the closing date. In addition, as specified in a Stock Restriction Agreement with the Company entered into on the closing date, 8,342,000 additional shares of common stock previously distributed to Dr. Pestell in the ProstaGene acquisition are currently subject to transfer restrictions and forfeiture obligations, subject to certain continuing employment obligations of Dr. Pestell, which will vest ratably each year over the three-years period following the closing date.

As specified in a Confidential Information, Inventions and Noncompetition Agreement between the Company and Dr. Pestell, which was entered into on the closing date of the ProstaGene acquisition, the Company may participate in the development and license of certain intellectual property created by Dr. Pestell, in connection with Dr. Pestell’s ongoing research obligations to outside academic institutions. The Company also has the right to work with Dr. Pestell to manage any potential conflict between the Company’s clinical development activities and such ongoing research obligations.

Note 14 – Subsequent Events

Between December 7, 2018 and December 11, 2018, the Company conducted a private equity offering, in which accredited investors purchased common stock at $0.50 per share with warrant coverage ratio of 50%. Pursuant to the offering, the Company sold a total of 2,018,000 shares of common stock, $0.001 par value, for aggregate gross proceeds of approximately $1.0 million and issued to the investors five-year warrants covering 1,009,000 shares of common stock with an exercise price of $0.75 per share. In connection with the equity offering, the Company paid an aggregate cash fee of approximately $0.1 million to the placement agent and issued warrants covering an aggregate of 201,800 shares of common stock to the placement agent as additional compensation. The placement agent warrants have a five-year term and an exercise price of $0.50 per share and a cashless exercise provision.

On December 10, 2018, Anthony D. Caracciolo resigned as the Chairman of the Board, but remains a director and Scott A. Kelly, M.D., was named Chairman of the Board. On December 19, 2018, the Compensation Committee of the Board approved an amendment to certain compensation arrangements for Anthony D. Caracciolo, pursuant to which his employment with the Company would be extended through April 16, 2019, at a salary reduced from $16,667 to $5,000 per month, with continuing benefits. In addition, the Compensation Committee approved an extension to 10-years of the expiration terms of certain previously awarded stock options covering an aggregate of 150,000 shares of the Company’s common stock, provided that such stock options are out-of-the-money upon the date of such extension. These arrangements were conditioned upon Mr. Caracciolo’s agreement to resign from the Board upon identification by the Company of an appropriately qualified candidate to fill the vacancy. Mr. Caracciolo has agreed to the foregoing terms. These arrangements were not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

On December 22, 2018 the board of directors appointed Nitya G. Ray, Ph.D., as Chief Technology Officer – Head of Process Sciences, Manufacturing and Supply Chain. In connection with Dr. Ray’s appointment, the Company and Dr. Ray entered into an Employment Agreement that provides for (i) an annual base salary of $335,000, (ii) a target annual bonus equal to 50% of base salary, (iii) an initial signing bonus of $100,000 to be paid in two equal installments of $50,000 over the course of six months from the date of signing and (iv) other customary benefits described in the form of employment agreement. In connection with the appointment of Dr. Ray, the Company also issued Dr. Ray a stock option award under the Company’s equity incentive plan, covering 400,000 shares of the Company’s common stock, vesting in three equal annual installments from the grant date.

On December 27, 2018, the Company received a redemption notice from the holder of the Company’s convertible note issued on June 26, 2018, requesting the redemption of $100,000 of the outstanding balance thereof. In satisfaction of the redemption notice, the Company issued 255,532 shares of common stock to the note holder in accordance with the terms of the convertible note. Following the redemption, the outstanding balance of the convertible note, including accrued but unpaid interest, was approximately $5.9 million.

Beginning December 28, 2018 through January 8, 2019, the Company issued $3.1 million (of which $0.5 million was purchased by Michael A. Klump, a director, on terms identical to all other investors) in aggregate principal amount of unsecured convertible promissory notes (the “Notes”) and related warrants (the “Warrants”) to purchase common stock of the Company (the “Common Stock”), to accredited investors (the “Private Placements”) pursuant to subscription agreements entered into with each investor (collectively, the “Subscription Agreements”), in exchange for cash in an equal amount. The proceeds of the Private Placements are anticipated to be used for general working capital and to fund clinical trials.

The principal amount of the Notes plus unpaid accrued interest at an annual rate of 10.0% is convertible at the election of the holders into shares of Common Stock at any time prior to maturity, at an initial conversion price of $0.50 per share, with an aggregate of 6,200,000 shares of the Company’s Common Stock initially underlying the Notes. As part of the investment in the Notes, the Company also issued Warrants exercisable for 50% of the shares into which the Notes are convertible, with Warrants for an aggregate of 3,100,000 shares of Common Stock issued in the Private Placements. The Warrants are exercisable at a price of $0.30 per share. The Warrants are currently exercisable in full and will expire five years from the date of issuance. The Subscription Agreements contain certain “piggyback” registration rights relating to resales of shares of Common Stock underlying the Notes and the Warrants.

As a result of the issuance of the Notes, pursuant to the terms of the Placement Agent Agreement, dated July 26, 2018, entered into in connection with a recently completed private securities offering, the placement agent in that offering earned a “tail fee” comprising warrants exercisable for 620,000 shares of Common Stock (the “Placement Agent Warrants”) and a cash fee of $372,000. The Placement Agent Warrants are exercisable at a price of $0.50 per share and will expire five years from the date of issuance. The Placement Agent Warrants provide for cashless exercise.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This filing, contains forward-looking statements. The words “anticipate,” “believe,” “expect,” “intend,” “predict,” “plan,” “seek,” “estimate,” “project,” “continue,” “could,” “may,” and similar terms and expressions are intended to identify forward-looking statements. These statements include, among others, information regarding future operations, future capital expenditures and future net cash flows. Such statements reflect current views with respect to future events and financial performance and involve risks and uncertainties, including, without limitation, regulatory initiatives and compliance with governmental regulations, the sufficiency of the Company’s cash position and the ability to raise additional capital, clinical priorities, the results of clinical trials for the Company’s drug candidate, and various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated. Consequently, all of the forward-looking statements made in this filing are qualified by these cautionary statements and there can be no assurance of the actual results or developments.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the other sections of this Quarterly Report, including our financial statements and related notes appearing elsewhere herein. To the extent not otherwise defined herein, capitalized terms shall have the same meanings as in such financial statements and related notes. This discussion and analysis contains forward-looking statements including information about possible or assumed results of our financial condition, operations, plans, objectives and performance that involve risk, uncertainties and assumptions. The actual results may differ materially from those anticipated and set forth in such forward-looking statements.

Results of Operations

Clinical Trials Update

Phase 2b Extension Study for HIV, as Monotherapy

Currently, there are a total of six patients in this ongoing extension study and each has surpassed four years of suppressed viral load with leronlimab (PRO 140) as a single agent therapy. These patients are continuing in extension studies of this monotherapy trial by self-administering, subcutaneous weekly injection of leronlimab (PRO 140).

Phase 2b/3 Pivotal Trial for HIV, as Combination Therapy

This is a pivotal 25-week trial for leronlimab (PRO 140) as a combination therapy to a highly active antiretroviral therapy (“HAART”) drug regimens. This trial was a double blind, placebo controlled trial. In late February 2018, we reported that we had enrolled 52 patients and the trial’s primary endpoint was achieved with a p-value of 0.0032. The primary endpoint for efficacy was defined as 0.5log reduction in viral load after one week of therapy with leronlimab (PRO 140) in combination with the patient’s failing HAART regimen. Following the achievement of primary endpoint, the trial is continuing to enroll under an open label for safety analysis. Forty-seven out of fifty-two patients have successfully completed this trial and most of the patients have transitioned into an FDA-cleared rollover study, as described below, in order to provide continued access to leronlimab (PRO 140) therapy, at the request of their treating physician. Management projects that the total costs of this trial, including the open label portion, may range from $12 million to $14 million. The successful results of this trial will serve as the basis for our BLA filing, which is expected to be completed in the first half of 2019.

Rollover Study for HIV, as Combination Therapy

This study is designed for patients who successfully complete the Phase 2b/3 Combination Therapy trial and for whom the treating physicians request a continuation of leronlimab (PRO 140) therapy in order to maintain suppressed viral load. If this study enrolls 40 patients from the Phase 2b/3 trial and all patients remain in the rollover study for one year, management estimates the cost of this study to be approximately $3 million to $4 million.

Phase 2b/3 Investigative Trial for HIV, as Long-term Monotherapy

This is a trial of over 370 patients that assesses using leronlimab (PRO 140) subcutaneously as a long-acting single-agent maintenance therapy for 48 weeks in patients with suppressed viral load with CCR5-tropic HIV-1 infection. The primary endpoint is the proportion of participants with a suppressed viral load to those who experienced virologic failure. The secondary endpoint is the length of time to virologic failure. Enrollment of the first several patients was announced in December 2016. We are currently evaluating two higher-dose arms, one with 525 mg dose (a 50% increase from the original dosage of 350 mg), as well as a 700 mg dose. We believe that a higher dose of 700 mg will result in a much higher response rate, which is supported by preliminary data and

most likely be the dose used for leronlimab (PRO 140) in the future. The estimates for the total cost of this trial currently range from $22 million to $25 million, with an expected $8 million to $9 million remaining in connection with maintaining patients to provide safety data for the BLA filing. We expect enrollment to be completed in 2019. Subject to the continuation of a high responder rate from preliminary data from the 700 mg dose arm, this trial may be discontinued if and when we successfully file a protocol for a pivotal Phase 3 trial for monotherapy and receives clearance from the FDA to initiate such a trial.

Phase 2 Trial for Graft-versus-Host Disease

This Phase 2 multi-center100-day study with 60 patients is designed to evaluate the feasibility of the use of leronlimab (PRO 140) as an add-on therapy to standard graft-versus-host disease (“GvHD”) prophylaxis treatment for prevention of acute GvHD in adult patients with acute myeloid leukemia (“AML”) or myelodysplastic syndrome (“MDS”) undergoing allogeneic hematopoietic stem cell transplantation (“HST”). Enrollment of the first patient was announced in May of 2017. On October 5, 2017, the Company announced that the FDA had granted orphan drug designation to leronlimab (PRO 140) for the prevention of GvHD. In March 2018, we announced that the Independent Data Monitoring Committee (“IDMC”) for leronlimab (PRO 140) Phase 2 trial in GvHD had completed a planned interim analysis of trial data on the first 10 patients enrolled. Following this review of data from the first 10 patients in the Phase 2 trial, the Company filed amendments to the protocol with the FDA. The amendments included switching the pretreatment conditioning regimen from aggressive myeloablative (“MA”) conditioning to a reduced intensity conditioning (“RIC”), and switching from a blinded one-for-one randomized placebo-controlled design to an open-label design under which all enrollees receive leronlimab (PRO 140). The amendments also provide for a 100% increase in the dose of leronlimab (PRO 140), to 700 mg, to more closely mimic preclinical dosing. The next review of data by the IDMC will occur following enrollment of 10 patients under the amended protocol after each patient has been dosed for 30 days. Management estimates the cost of this trial to be approximately $3.5 to $4 million. Due to the necessary prioritization of limited capital, enrollment under the amended protocol has been delayed.

Cancer and Immunological Applications for Leronlimab (PRO 140)

We are continuing to explore opportunities for clinical applications for leronlimab (PRO 140) involving the CCR5 receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases and cancer.

The target of leronlimab (PRO 140) is the important G protein coupled receptor CCR5. CCR5 is more than the pathway to HIV replication; it is also a crucial component of inflammatory responses and is a key mediator in many cancer metastasis. We believe this opens the potential for multiple pipeline opportunities for leronlimab (PRO 140). CCR5 is a protein located on the surface of white blood cells and cancer epithelial cells that serves as a receptor for attractants called chemokines. Chemokines are the key orchestrators of leukocyte trafficking by attracting immune cells to the sites of inflammation.

At the site of an inflammatory reaction, chemokines are released. These chemokines are specific for CCR5 and cause the migration of T-cells to these sites promoting further inflammation. We believe the mechanism of action of leronlimab (PRO 140) has the potential to block the movement of T-cells to inflammatory sites, which could be instrumental in diminishing or eliminating inflammatory responses. CCR5 is also expressed on the surface of epithelial cells in certain cancers. Some disease processes that we believe could benefit from CCR5 blockade include many types of common cancers, GvHD (a reaction occurring in some patients after bone marrow transplantation), autoimmunity and chronic inflammation, such as rheumatoid arthritis and psoriasis. Recent published data by Richard G. Pestell, M.D., Ph.D., our Chief Medical Officer, has shown that the cancer cells within the tumor consist of two types of cells-one with CCR5 and others without them. The published data clearly indicated that cancer cells that can metastasizeexpress CCR5. Metastases are the cause of death in the vast majority of cancer patients. Moreover, Dr. Pestell’s prior publication indicates that CCR5 antagonists can turn off certain calcium signaling and reduce the migration of CCR5 positive cancer cells. Inhibition of CCR5 signaling blocks the guided migration and reduces the metastasis. Leronlimab (PRO 140) has demonstrated (in an in-vitro study) that it also turns off calcium signaling and blocks breast cancer cellular invasion. Furthermore, published studies showed current chemotherapy induces CCR5, and CCR5 antagonists enhance the effectiveness of current chemotherapies, potentially allowing a reduction in chemotherapy, which may provide an improved quality of life for patients.

Due to its mechanism of action, we believe leronlimab (PRO 140) has significant advantages in terms of safety and reduced side effects over other CCR5 antagonists. Prior studies have demonstrated that leronlimab (PRO 140) does not cause direct activation of T-cells. We have already reported encouraging human safety data for our clinical trials with leronlimab (PRO 140) in HIV-infected patients.

As a result of the foregoing, we are expanding the clinical focus with leronlimab (PRO 140) to include the evaluation in certain cancer and immunological indications where CCR5 antagonism has shown initial promise. We recently filed an investigational new drug application (“IND”) with the FDA and received approval in late November 2018 to begin a clinical trial with leronlimab (PRO 140) for metastatic triple-negative breast cancer. We also previously initiated our first clinical trial with leronlimab (PRO 140) in an immunological indication – a Phase 2 clinical trial with leronlimab (PRO 140) for GvHD in patients with AML or MDS who are undergoing bone marrow stem cell transplantation. As noted above, enrollment under the amended protocol for the GvHD trial has been delayed subject to increased capital resources. In addition, we also intend to explore potential strategic partnerships with certain pharmaceutical companies, including for the development of follow-on technologies involving the use of leronlimab (PRO 140) alongside their existing products.

The Company will require a significant amount of additional capital to complete the foregoing clinical trials for HIV and make its BLA submission, as well as to advance its trials for GvHD and certain cancer indications. See “Liquidity and Capital Resources” below.

ProstaGene Transaction

On November 16, 2018, we completed an acquisition with ProstaGene, LLC, a Delaware limited liability company (“ProstaGene”). The ProstaGene transaction was consummated pursuant to the Transaction Agreement (the “Transaction Agreement”), dated as of August 27, which provided for the purchase of substantially all of the assets and rights, and the assumption of certain liabilities and obligations, associated with ProstaGene. In order to achieve certain tax efficiencies for the selling members of ProstaGene, as an initial step in the transaction, we effected a holding company reorganization under Section 251(g) of the Delaware General Corporation Law. The terms of the ProstaGene transaction were previously reported in our Current Reports on Form 8-K filed with the Securities and Exchange Commission on November 19, 2018 and August 28, 2018. As described in Note 7 to the accompanying financial statements, the aggregate purchase price paid in the ProstaGene transaction was approximately $11.6 million, which was recorded as intangibles, including a certain proprietary technology in an algorithm, noncompetition agreements and patents. Such intangibles have estimated amortizable lives from three years to 13 years.

We are currently evaluating strategic opportunities with respect to the assets acquired in the ProstaGene transaction, including potential licensing or other opportunities to monetize intellectual property assets relating to prostate cancer diagnostics. As an integral part of the acquisition of ProstaGene, we acquired a proprietary technology that demonstrated in a retrospective clinical trial assessing patients for more than 10 years that its prostate cancer prognostic test (“PCa Test”) provides substantial additive discriminate value for predicting outcomes of patients diagnosed with prostate cancer compared to the intermediate Gleason score, the current standard for prostate cancer diagnosis. The clinical objective is to more precisely guide therapeutic options for men thereby avoiding unnecessary surgery (prostatectomy) and radiation and/or chemotherapy with its attendant side effects.

Results of Operations for the three months ended November 30, 2018 and 2017 are as follows:

For the three months ended November 30, 2018 and November 30, 2017, the Company had no activities that produced revenues from operations.

For the three months ended November 30, 2018, the Company incurred a net loss of approximately $14.3 million, as compared to a net loss of approximately $10.9 million for the similar period in 2017. The increase in net loss of approximately $3.4 million related primarily to increases in research and development expenses of approximately $3.8 million and increases in general and administrative expenses of approximately $1.1 million and a decrease in the non-cash benefit from change in derivative liabilities of approximately $0.6 million, a non-comparable non-cash loss on extinguishment of debt of approximately $1.5 million, offset by a reduction in interest expenses of approximately $0.8 million and a deferred tax benefit of approximately $2.8 million, which arose from the recognition of a deferred income tax benefit from a reduction in the Company’s deferred tax valuation allowance resulting from recording a deferred tax liability of $2,826,919 in connection with the acquisition of assets in the ProstaGene transaction. The deferred tax liability represents the tax effect of the difference in the carrying value of the assets and their tax basis at acquisition. The loss per share for the quarters ended November 30, 2018 and November 30, 2017 was $(0.06) and $(0.07), respectively, with the reduction in loss per share (despite an increase in aggregate net loss) caused by a significant increase in the number of shares outstanding from the prior period.

For the three months ended November 30, 2018 and November 30, 2017, operating expenses totaled approximately $15.7 million and $10.8 million, respectively, consisting of research and development, general and administrative expenses, and amortization and depreciation. The increase in operating expenses of approximately $4.9 million, or 45.6%, was attributable to increases in research and development expenses of approximately $3.8 million and increased general and administrative expenses of approximately $1.1 million. General and administrative expenses, which totaled approximately $2.7 million for the three months ended November 30, 2018, were comprised of salaries and benefits, non-cash stock-based compensation expense, professional fees, insurance and various other expenses. The increase in general and administrative expenses of approximately $1.1 million, or 66%, for the three months ended November 30, 2018 was due to an increase in non-cash stock-based compensation expenses of approximately $1.0 million, in connection stock issued for advisory services and employee awards, coupled with increased insurance and investor relations expenses, offset by a reduction in expenses for professional services.

Research and development (“R&D”) expenses, which totaled approximately $12.7 million for the three months ended November 30, 2018, increased approximately $3.8 million, or 42%, over the comparable 2017 quarter principally due to higher manufacturing-related expenses in connection with the preparation of our BLA filing. For the quarter ended November 30, 2018, R&D expenditures continue to be primarily devoted to: (1) increased CMC (chemistry, manufacturing and controls) activities to address regulatory compliance requirements of a future BLA filing and to advance the preparations for manufacturing new quantities of leronlimab (PRO 140), (2) our pivotal Phase 2b/3 combination therapy trial and our investigative Phase 2b/3 monotherapy trial, and (3) continuing activities necessary to complete the BLA filing with the FDA.

We expect R&D expenses in future periods to level off modestly to reflect completion of manufacturing activities in preparation for an anticipated BLA filing in the first half of 2019, followed by a potential strategic advancement in clinical priorities for a pivotal monotherapy trial and cancer indications, all of which are subject to the availability of sufficient additional capital. Any acceleration in clinical activities would increase R&D expenses.

For the three months ended November 30, 2018, the Company recognized a non-cash benefit associated with the decrease in fair value of derivative liabilities of approximately $0.3 million, as compared to a non-cash benefit of approximately $0.8 in the similar 2017 quarter. The warrants that contain a provision which gives rise to a derivative liability originated in September 2016. For each reporting period, we determine the fair value of the derivative liabilities and record a corresponding non-cash benefit or non-cash charge, as a consequence of a decrease or increase, respectively, in the calculated derivative liabilities.

Interest expense for the three months ended November 30, 2018 totaled approximately $1.7 million, as compared to approximately $1.0 million for the similar quarter in 2017. The components of interest expense include a loss on extinguishment of a long-term convertible note, accrued interest on a convertible note, along with the amortization of debt discount and debt issuance costs. On November 15, 2018, as previously reported, the Company amended the convertible note to include an additional feature which allows the holder to receive the redemption amount (a) in cash or (b) by converting the redemption amount into shares of common stock. The amendment caused the embedded redemption provision to require bifurcation as a liability at fair value under ASC 815 (Topic 815). In addition, management also considered the accounting for the amendment under the accounting guidance in ASC 470, Debt (Topic 470), and determined that the amendment was substantive and extinguishment accounting applied. Accordingly, the carrying value of the original debt on the modification date is derecognized and the new debt is recorded at fair value. The difference was recorded as an extinguishment loss of approximately $1.5 million.

The future trends in all expenses will be driven, in large part, by the future outcomes of clinical trials and their correlative effect on research and development expenses, as well as general and administrative expenses, in addition to manufacturing of new additional quantities of commercial leronlimab (PRO 140), along with the necessary regulatory processes to confirm its qualification for future sale, if approved. The Company requires a significant amount of additional capital and its ability to continue to fund operations will continue to depend on its ability to raise such capital. See in particular, “Liquidity and Capital Resources” below and Item 1A Risk Factors in our Annual Report on Form 10-K for the year ended May 31, 2018 and in our Form 10-Q for the quarterly period ended August 31, 2018 in the section titled “Risk Factors” in Part II, Item 1A.

Results of Operations for the six months ended November 30, 2018 and 2017 are as follows:

For the six months ended November 30, 2018 and November 30, 2017, the Company had no activities that produced revenues from operations.

For the six months ended November 30, 2018, the Company incurred a net loss of approximately $28.7 million, as compared to a net loss of approximately $22.6 million for the similar period in 2017. The increase in net loss of approximately $6.1 million related primarily to increases in research and development expenses of approximately $7.1 million, increases in general and administrative expenses of approximately $1.4 million, non-cash expense from change in derivative liabilities of approximately $0.9 million, offset by a deferred tax benefit approximately $2.8 million, and a reduction in interest expenses of approximately $0.6 million. The credit for taxes on income arose from the recognition of a deferred income tax benefit from a reduction in the Company’s deferred tax valuation allowance resulting from recording a deferred tax liability of $2,826,919 in connection with the acquisition of assets in the ProstaGene LLC transaction. The deferred tax liability represents the tax effect of the difference in the carrying value of the assets and their tax basis at acquisition. The loss per share for the six months ended November 30, 2018 and November 30, 2017 was $(0.12) and $(0.15), respectively, with the reduction in loss per share (despite an increase in aggregate net loss) caused by a significant increase in the number of shares outstanding from the prior period.

For the six months ended November 30, 2018 and November 30, 2017, operating expenses totaled approximately $29.2 million and $20.6 million, respectively, consisting of research and development, general and administrative expenses, and amortization and depreciation. The increase in operating expenses of approximately $8.6 million, or 42%, was attributable to increases in research and development expenses of approximately $7.1 million and an increase in general and administrative expenses of approximately $1.4 million.

General and administrative expenses, which totaled approximately $4.6 million for the six months ended November 30, 2018, were comprised of salaries and benefits, non-cash stock-based compensation expense, professional fees, insurance and various other expenses. The increase in general and administrative expenses of approximately $1.4 million, or 45%, for the six months ended November 30, 2018 over the comparable period a year ago was primarily due to an increase in non-cash stock-based compensation expenses of approximately $1.0 million in connection with common stock issued for advisory services and an employee awards.

Research and development (“R&D”) expenses, which totaled approximately $24.3 million for the six months ended November 30, 2018, increased approximately $7.1 million, or 41%, over the comparable 2017 period principally due to higher manufacturing-and clinical trial elated expenses. For the six-month period ended November 30, 2018, R&D expenditures continue to be primarily devoted to: (1) increased CMC (chemistry, manufacturing and controls) activities to address regulatory compliance requirements of a future BLA filing and to advance the preparations for manufacturing new quantities of leronlimab (PRO 140), (2) our pivotal Phase 2b/3 combination therapy trial and our investigative Phase 2b/3 monotherapy trial, and (3) continuing activities necessary to complete the BLA filing with the FDA.

We expect R&D expenses in future periods to level off modestly to reflect completion of manufacturing activities preparation for an anticipated BLA filing in the first half of 2019 followed by a potential strategic advancement in clinical priorities for a pivotal monotherapy trial and cancer indications, all of which are subject to the availability of sufficient additional capital. Any acceleration in clinical activities would increase R&D expenses.

For the six months ended November 30, 2018, the Company recognized a non-cash charge associated with the increase in fair value of derivative liabilities of approximately $0.5 million, as compared to a non-cash benefit of approximately $0.5 in the similar 2017 period. The warrants that contain a provision which gives rise to a derivative liability originated in September 2016. For each reporting period, we determine the fair value of the derivative liabilities and record a corresponding non-cash benefit or non-cash charge, as a consequence of a decrease or increase, respectively, in the calculated derivative liabilities.

Interest expense for the six months ended November 30, 2018 totaled approximately $1.9 million, as compared to approximately $2.5 million for the similar period in 2017. The components of interest expense include a loss on extinguishment of a long-term convertible note, accrued interest on a convertible note, along with the amortization of debt discount and debt issuance costs. On November 15, 2018, as previously reported, the Company amended the convertible note to include an additional feature which allows the holder to receive the redemption amount (a) in cash or (b) by converting the redemption amount into shares of common stock. The amendment caused the embedded redemption provision to require bifurcation as a liability at fair value under ASC 815 (Accounting Standards Codification Derivatives and Hedging (Topic 815). In addition, management also considered the accounting for the amendment under the accounting guidance in ASC 470, Debt (Topic 470), and determined that the amendment was substantive and extinguishment accounting applied. Accordingly, the carrying value of the original debt on the modification date is derecognized and the new debt is recorded at fair value. The difference was recorded as an extinguishment loss of approximately $1.5 million.

Liquidity and Capital Resources

The Company’s cash position at November 30, 2018 decreased approximately $0.4 million to approximately $0.8 million, as compared to a balance of approximately $1.2 million as of May 31, 2018. The net decrease in cash for the six months ended November 30, 2018 was attributable to net cash used in operating activities of approximately $26.2 million, offset in part by net cash provided by financing activities of approximately $25.7 million.

As of November 30, 2018, the Company had significant negative working capital of approximately $20.1 million compared to negative working capital of approximately $13.4 million at May 31, 2018, an increase in negative working capital of approximately $6.7 million attributable primarily to cash used in operations.

Cash Flows

Net cash used in operating activities totaled approximately $26.2 million during the six months ended November 30, 2018, which reflects an increase of approximately $13.3 million of net cash used in operating activities over the six months ended November 30, 2017. The increase in net cash used in operating activities was due to an increase in net loss of approximately $6.1 million, coupled with an increase in working capital components totaling approximately $5.7 million, a non-cash loss on extinguishment of debt of approximately $1.5 million and increased stock based compensation of approximately $1.0 million, which was mitigated in part by non-cash deferred income tax benefit of approximately $2.8 million, a reduction in amortization of approximately $2.1 million and a non-cash credit of approximately $1 million due to the change in derivative liabilities.

Net cash used in investing activities was immaterial during the six months ended November 30, 2018, and there was no activity during the six months ended November 30, 2017.

Net cash provided by financing activities of approximately $25.7 million during the six months ended November 30, 2018, increased approximately $13.3 million over the $12.4 million of net cash provided by financing activities during the six months ended November 30, 2017. The increase in net cash provided from financing activities was attributable to net proceeds from the sale of common stock and warrants of approximately $23.5 million, an increase of approximately $16.4 million in net proceeds from the sale of similar securities, offset by an increase of approximately $1.6 million in offering costs. During the 2017 six-month period the Company realized non-comparable proceeds of approximately $1.6 million from the exercise of warrants.

Capital Requirements

We have not generated revenue to date, and will not generate product revenue in the foreseeable future, although revenues are anticipated to be realized following approval of the Company’s BLA. We expect to continue to incur significant operating losses as expenses continue as we proceed with clinical trials with respect to leronlimab (PRO 140) and continue to advance it through the product development and regulatory process. The future trends of all expenses will be driven, in large part, by the future outcomes of the clinical trials and their correlative effect on general and administrative expenses, in addition to the manufacturing of new commercial leronlimab (PRO 140), along with the increasing activities to prepare and file a BLA for leronlimab (PRO 140) as a combination therapy. We will require a significant amount of additional capital in the future for our clinical trials and to advance our manufacturing activities of leronlimab (PRO 140) necessary for completion of our BLA filing.

In connection with this undertaking, we have entered into an arrangement with a third party contract manufacturing organization (the “CMO”) to provide process transfer, validation and manufacturing services for leronlimab (PRO 140). Management believes the CMO will best serve our strategic objectives for the anticipated BLA filing and, if approved, the long-term commercial manufacturing capabilities for leronlimab (PRO 140). Management will continue to assess manufacturing capacity requirements as new market information becomes available regarding anticipated demand, subject to FDA approval. In the event that we terminate the agreement with our CMO, we may incur certain financial penalties which would become payable to the CMO. Conditioned on the timing of termination, the financial penalties may range up to an approximate high of $0.3 million. These CMO undertakings are anticipated to require approximately $9 million of additional capital over the next several fiscal quarters, including the estimated costs to fill, label, and package product into the final commercial package for commercial sale.

We have entered into project work orders for each of our clinical trials with our CRO and related laboratory vendors. Under the terms of these agreements, we have prepaid certain execution fees for direct services costs. In connection with our clinical trials, we have entered into separate project work orders for each trial with our CRO. In the event that we terminate any trial, we may incur certain financial penalties which would become payable to the CRO. Conditioned upon the form of termination of any one trial, the financial penalties may range up to $0.2 million. In the remote circumstance that we terminate all clinical trials, the collective financial penalties may range from an approximate low of $0.5 million to an approximate high of $1.1 million.

Under the Progenics Purchase Agreement, we are required to pay Progenics the following ongoing milestone payments and royalties: (i) $5.0 million at the time of the first U.S. new drug application approval by the FDA or other non-U.S. approval for the sale of leronlimab (PRO 140); and (ii) royalty payments of up to five percent (5%) on net sales during the period beginning on the date of the first commercial sale of leronlimab (PRO 140) until the later of (a) the expiration of the last to expire patent included in the acquired assets, and (b) 10 years, in each case determined on a country-by country basis. In addition, under a Development and License Agreement, dated April 30, 1999 (the “PDL License”), between Protein Design Labs (now AbbVie Inc.) and Progenics, which was previously assigned to us, we are required to pay AbbVie Inc. additional milestone payments and royalties as follows: (i) $0.5 million upon filing a BLA with the FDA or non-U.S. equivalent regulatory body; (ii) $0.5 million upon FDA approval or approval by another non-U.S. equivalent regulatory body; and (iii) royalties of up to 3.5% of net sales for the longer of 10 years and the date of expiration of the last to expire licensed patent. Additionally, the PDL License provides for an annual maintenance fee of $150,000 until royalties paid exceed that amount.

As of the date of this filing, it is management’s conclusion that the probability of achieving the subsequent future clinical development and regulatory milestones is not reasonably determinable, thus the future milestone payments payable to Progenics and its sub-licensors are deemed contingent consideration and, therefore, are not currently accruable.

Going Concern

As reported in the accompanying consolidated financial statements, for the six months ended November 30, 2018 and November 30, 2017, we incurred net losses of approximately $28.7 million and $22.6 million, respectively. We have no activities that produced revenue in the periods presented and have sustained operating losses since inception.

We currently require and will continue to require a significant amount of additional capital to fund operations, pay our accounts payables, and our ability to continue as a going concern is dependent upon our ability to raise such additional capital, commercialize our product and achieve profitability. If we are not able to raise such additional capital on a timely basis or on favorable terms, we may need to scale back our operations or slow down or cease certain clinical trials or CMO activities, which could materially delay the timeframe to BLA submission. Our failure to raise additional capital could also affect our relationships with key vendors, disrupting our ability to timely execute our business plan. In extreme cases, we could be forced to file for bankruptcy protection, discontinue our operations or liquidate our assets.

Since inception, we have financed our activities principally from the sale of public and private equity securities and proceeds from convertible notes payable and related party notes payable. We intend to finance our future operating activities and our working capital needs largely from the sale of equity and debt securities, combined with additional funding from other traditional financing sources. As of the date of this filing, we have approximately 124 million shares of common stock authorized and available for issuance under our certificate of incorporation, as amended, and approximately $166 million available for future registered offerings of securities under our universal shelf registration statement on Form S-3, which was declared effective on March 9, 2018 (assuming the full exercise of outstanding warrants, at the currently applicable exercise prices, that were previously issued in registered transactions thereunder).

The sale of equity and convertible debt securities to raise additional capital may result in dilution to stockholders and those securities may have rights senior to those of common shares. If we raise additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these activities or other debt could contain covenants that would restrict our operations. Any other third-party funding arrangements could require us to relinquish valuable rights. We may require additional capital beyond currently anticipated needs. Additional capital, if available, may not be available on reasonable or non-dilutive terms. Please refer to the matters discussed under the heading “Risk Factors” above.

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred losses for all periods presented and have a substantial accumulated deficit. As of November 30, 2018, these factors, among several others, raise substantial doubt about our ability to continue as a going concern.

The consolidated financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should we be unable to continue as a going concern. Our continuation as a going concern is dependent upon our ability to obtain a significant amount of additional operating capital, complete development of our product candidate, obtain FDA approval, outsource manufacturing of our product, and ultimately to attain profitability. We intend to seek additional funding through equity or debt offerings, licensing agreements or strategic alliances to implement our business plan. There are no assurances, however, that we will be successful in these endeavors.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Under the supervision and with the participation of management, including the Chief Executive Officer and the Chief Financial Officer of the Company, the Company has evaluated the effectiveness of its disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of November 30, 2018. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of November 30, 2018.

Internal Control Over Financial Reporting

Changes in Control Over Financial Reporting

No changes occurred during the quarter ended November 30, 2018, that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

There have been no material changes in the risk factors applicable to us from those identified in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on July 27, 2018, as amended on September 28, 2018, as supplemented by the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 9, 2018.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

(a) Exhibits:



2.1		Transaction Agreement by and among CytoDyn Inc., Point NewCo, Inc., Point Merger Sub, Inc., ProstaGene, LLC, and Dr. Richard Pestell, dated August 27, 2018 (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K, as amended, filed August 28, 2018).

3.1		Amended and Restated Certificate of Incorporation of CytoDyn Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K12G3 filed November 19, 2018).

3.2		Amended and Restated Bylaws of CytoDyn Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K12G3 filed November 19, 2018).

4.1		Form of Warrant Agreement (September 2018 Offering) (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed September 4, 2018).

4.2		Amended and Restated Convertible Promissory Note (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K12G3 filed November 19, 2018).

10.1		Form of Subscription Agreement (September 2018 Offering) (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed September 4, 2018).

10.2		Convertible Promissory Note Amendment and Restatement, dated November 15, 2018 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K12G3 filed November 19, 2018).

10.3		Escrow Agreement, dated as of November 16, 2018, by and among ProstaGene, LLC, CytoDyn Inc., and Computershare Trust Company, N.A. (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K12G3 filed November 19, 2018).

10.4		Stock Restriction Agreement, dated as of November 16, 2018, by and among CytoDyn Inc., ProstaGene, LLC and Dr. Richard G. Pestell (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K12G3 filed November 19, 2018).

10.5		Confidential Information, Inventions and Noncompetition Agreement, dated as of November 16, 2018, by and among CytoDyn Inc., CytoDyn Operations Inc. and Dr. Richard G. Pestell (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K12G3 filed November 19, 2018).

10.6		Employment Agreement, dated as of November 16, 2018, by and among CytoDyn, Inc., CytoDyn Operations Inc. and Dr. Richard G. Pestell (incorporated by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K12G3 filed November 19, 2018).

31.1*		Rule 13a-14(a) Certification by CEO of Registrant.

31.2*		Rule 13a-14(a) Certification by CFO of the Registrant.

32.1*		Certification of CEO of the Registrant pursuant to 18 U.S.C. Section 1350.

32.2*		Certification of CFO of the Registrant pursuant to 18 U.S.C. Section 1350.

101.INS *		XBRL Instance Document.

101.SCH *		XBRL Taxonomy Extension Schema Document.

101.CAL *		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF *		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB *		XBRL Taxonomy Extension Label Linkbase Document.

101.PRE *		XBRL Taxonomy Extension Presentation Linkbase Document.

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


						CYTODYN INC. (Registrant)

Dated: January 9, 2019						/s/ Nader Z. Pourhassan
						Nader Z. Pourhassan
						President and Chief Executive Officer

Dated: January 9, 2019						/s/ Michael D. Mulholland
						Michael D. Mulholland
						Chief Financial Officer, Treasurer and Corporate Secretary

EX-31.1 2 d683024dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer

I, Nader Z. Pourhassan, certify that:

I have reviewed this Quarterly Report on Form 10-Q of CytoDyn Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and

disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the registrant’s most-recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

EX-31.2 3 d683024dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer

I, Michael D. Mulholland, certify that:

I have reviewed this Quarterly Report on Form 10-Q of CytoDyn Inc.;

any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

EX-32.1 4 d683024dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

Certification of Chief Executive Officer

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the Quarterly Report of CytoDyn Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended November 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Form 10-Q”), I, Nader Z. Pourhassan, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on my knowledge:

(1)

The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2)

The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

EX-32.2 5 d683024dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

Certification of Chief Financial Officer

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the Quarterly Report of CytoDyn Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended November 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Form 10-Q”), I, Michael D. Mulholland, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on my knowledge:

(1)

The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2)

The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

EX-101.INS 6 cydy-20181130.xml XBRL INSTANCE DOCUMENT

100000000

1.00

66666

1.00

33333

350000000

375000000

7000000

15000000

0.30

3100000

P5Y

0.100

0.50

500000 3100000

600000000

450000000

1280000

1284998

0.85

0.588

0.0278

741297

15126216

5400000

4171013

13258000

8611427

0.772

8342000

0.50

201800

P5Y

0.50

0.001

P5Y

0.75

1009000

150000

5900000

292923481

3000000

5000000

7000000

0.50

-8357793

126107340

0.5

152763244

152763

92100

-134617988

-8357793

1296839

0.50

-12790510

600000

132609936

0.50

165135155

165135

92100

-145565673

-12790510

1.00

0.75

7718010

6300000

6000000

0.50

P5Y

5788500 300000

0.50

-7592679

155714098

0.50

208904001

208904

92100

-163515773

-7592679

300000 400000

450000000

0.75

1970000

0.50

P5Y

0.75

1970000

P5Y

0.55

133600

P5Y

0.10

5700000

100000

500000

5700000

626242

5073758

0.50

-19797305

2071199

7733334

3600000

281628

2618372

2100000

344614

2455386

167521847

0.50

233880390

233880

92100

-187552965

159011

-159

-19797305

18852414

20390953

3927875

193503678

772361

500000

600000000

290649949

0.001

290808960

290810

1396974

4200000

3075142

1280000

560013

2826919

2209254

1600000

3075142

1600000

3500000

16416962

16452951

3500000

35989

28454877

20390953

23001

23982761

3075142

4472116

5596974

200890

10127

-201858345

0.50

159

-8063924

159011

2954624 347333 769360 0 565356 150960607 155836676 0.78 0.78

15126216

0.57

20278000

1620000

8342000

553048

1.00

4025656

600000

0.6980 0

410000

600000

6900000

5400000

100000

1789066

7733334

0.50

1396974

4200000

1286076

3075142

1789066

1286076

2700000

0.85

0.588

0.62 0

0.0278

200000 300000 1100000 500000 0.05 0.035

5700000

5000000

0.0200 0.0075

5.00

92100

0.001

400000

92100

193503678

0.50

290808960

290810

92100

-201858345

0.001

159011

-159

1789066

0.75

22478585

0.001

P5Y

0.50

4245117

P5Y

0.75

22478585

1286076

0.56

300000

P5Y

0.30

-8063924

300000 400000

0.001

400000

5.00

5179200

7733334

1.06 0

1775583

-1103234

121736921

149468244

149468

92100

-122989715

-1103234

15841859

4898998

3320627

159764611

1231445

1100000

375000000

216722779

0.001

216881790

216881

1323732

757778

1968846

1323732

3500000

1531154

1567143

35989

18056969

4898998

16733237

1323732

227173

11228

-173139396

0.50

159

-13157971

159011

1862009 133600 3673 0 132385269 0.80 0.001

1500000

400000

387000

0.07

0.75

5788500

6038500

4890000

1323732

7733334

1323732

3500000

0.64 0

0.50

3295000

1.00

92100

0.001

400000

92100

159764611

0.50

216881790

216881

92100

-173139396

0.001

159011

-159

1323732

-13157971

P10Y

3500000

0.07

100000

0.07

50000

0.75 0.50

6200000

372000 P5Y 620000 100000 0.55 350000 Effective November 15, 2018, the Note was amended to allow the Investor to redeem the monthly redemption amount of $350,000 in cash or stock, at the lesser of (i) $0.55, or (ii) the lowest closing bid price of the Company’s common stock during the 20 days prior to the conversion, multiplied by a conversion factor of 85%. 0.85 P20D

5000000

0.57 P1Y7M9D 0

15126216

11558000

15126216

2826919 P3Y

16667

5000

P10Y 2019-04-16

335000

P3Y

400000

2 0.50 100000 50000 P6M

100000

255532

0.50

2400000

2018-01-31

259000

12062728

6000000 243000 0.50 0.50

164425

1.00

900000

1970000

0.08 5000000 5 0.55 P2Y 350000 The Investor may redeem any portion of the Note, at any time after six months from the issue date upon five trading days' notice, subject to a maximum monthly redemption amount of $350,000. 1.5 0.78 P5Y 0.0120 0.50 0.50

282129

1172995

87551801

-478744

1574628

282129

178282

466934

-0.15

6256192

3178420

1206

-22575959

2462049

-907606

180673

12411076

20582050

-12889820

-22575959

4888500

-20582050

1175575

1647500

17225348

529617

154774327

0 826252 70383 7050651

1200000

300000

75000

175000

530000

574000

21500

<div> Note 3 – Recent Accounting Pronouncements Recent accounting pronouncements, other than below, issued by the FASB (including its EITF), the AICPA and the SEC did not or are not believed by management to have a material effect on the Company’s present or future financial statements. In August 2018, FASB issued Accounting Standards Update (“ASU”) No. 2018-13 Fair Value Measurement (Topic 820) Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update provides guidance that remove, modify and add to the disclosure requirements related to fair value measurements. The guidance removes the requirements to disclose the amount and reasons for transfers between Level 1 and Level 2 assets, the policy for timing and transfers between levels and the valuation process for Level 3 fair value measurements. The guidance modifies disclosure requirements for investments in certain entities that calculate net asset value and clarifies the purpose of the measurement uncertainty disclosure. The guidance adds requirements to disclose changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurements and to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The guidance is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. The Company does not expect the adoption to have a material impact on its consolidated financial statements. In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company is currently assessing the impact this Update may have on its consolidated financial statements. In March 2018, FASB issued ASU No. 2018-05, Income Taxes (Topic 740), Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118. The amendments in this Update add various Securities and Exchange Commission (“SEC) paragraphs pursuant to the issuance of SEC Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“Act”) (“SAB 118). The SEC issued SAB 118 to address concerns about reporting entities’ ability to timely comply with the accounting requirements to recognize all of the effects of the Act in the period of enactment. SAB 118 allows disclosure that timely determination of some or all of the income tax effects from the Act are incomplete by the due date of the financial statements and if possible to provide a reasonable estimate. The Company has provided a reasonable estimate in the notes to the consolidated financial statements.   In July 2017, FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (“EPS”) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—  Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. Management is currently assessing the impact the adoption of ASU 2017-11 will have on the Company’s consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718), Scope of Modification Accounting. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for public business entities for reporting periods for which financial statements have not yet been issued. The adoption of ASU 2017-09 did not have a material impact on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Clarifying the Definition of a Business, which narrows the definition of a business and clarifies that to be considered a business, the fair value of gross assets acquired (or disposed of) should not be concentrated in a single identifiable asset or a group of similar identifiable assets. In addition, to be considered a business, an acquisition would have to include an input and a substantive process that together will significantly contribute to the ability to create an output. Also, the amendments narrow the definition of the term “output” so that it is consistent with how outputs are defined in ASC Topic 606, Revenue from Contracts with Customers. This ASU was effective for the Company on June 1, 2018. Adoption of this new guidance must be applied on a prospective basis. The adoption of this ASU did not have a significant impact on the Company’s consolidated financial statements. Business combinations are accounted for by applying the acquisition method in accordance with ASC 805, Business Combinations. Under the acquisition method, identifiable assets acquired and liabilities assumed are measured at their fair values as of the date of acquisition and are recognized separately from goodwill. The results of operations of the acquired entity are included in the consolidated statement of income from the date of acquisition. Customers recognize goodwill when the acquisition price exceeds the estimated fair value of the net assets acquired. </div>

19589

false

117534

155836676

<div> Basis of Presentation The accompanying consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect all adjustments, which consist solely of normal recurring adjustments, needed to fairly present the financial results for these periods. The consolidated financial statements and notes thereto are presented as prescribed by Form 10-Q. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted. The accompanying consolidated financial statements should be read in conjunction with the financial statements for the fiscal years ended May 31, 2018 and 2017 and notes thereto in the Company’s Annual Report on Form 10-K and Form 10-K/A for the fiscal year ended May 31, 2018, filed with the Securities and Exchange Commission on July 27, 2018 and September 28, 2018, respectively. Operating results for the three months ended November 30, 2018 are not necessarily indicative of the results that may be expected for the entire year. In the opinion of management, all adjustments have been made, which consist only of normal recurring adjustments necessary for a fair statement of (a) the results of operations for the three and six months ended November 30, 2018 and November 30, 2017, (b) the financial position at November 30, 2018 and (c) cash flows for the six month periods ended November 30, 2018 and November 30, 2017. </div>

<div> Note 7 – Acquisition of Patents and Intangibles As discussed in Note 9 below, the Company consummated an asset purchase on October 16, 2012, and paid $3,500,000 for certain assets, including intellectual property, certain related licenses and sublicenses, FDA filings and various forms of the leronlimab (PRO 140) drug substance. The Company followed the guidance in Financial Accounting Standards Topic 805 to determine if the Company acquired a business. Based on the prescribed accounting, the Company acquired assets and not a business. As of November 30, 2018, the Company has recorded and is amortizing $3,500,000 of intangible assets in the form of patents. The Company estimates the acquired patents have an estimated life of ten years. Subsequent to the acquisition date, the Company has continued to expand, amend and file new patents central to its current clinical trial strategies, which, in turn, have extended the protection period for certain methods of using leronlimab (PRO 140) and formulations comprising leronlimab (PRO 140) out through at least 2031 and 2038, respectively, in various countries. On November 16, 2018, the Company completed the acquisition of substantially all of the assets of ProstaGene, LLC (“ProstaGene”), a biotechnology start-up company, which included patents related to clinical research, a proprietary CCR5 technology for early cancer diagnosis, and a noncompetition agreement with ProstaGene’s founder and Chief Executive Officer, Richard G. Pestell, M.D., Ph.D. The acquisition of ProstaGene’s assets expands the Company’s clinical development of leronlimab (PRO 140) into cancer indications and commercialization of certain cancer diagnostic tests. The aggregate purchase price paid for the ProstaGene acquisition was $11,558,000 based on the issuance of 20,278,000 shares of common stock of CytoDyn at $0.57 per share, including 1,620,000 shares earned, but not yet issued, by the investment bank for advisory services. In connection with the purchase, the Company entered into a Stock Restriction Agreement (“Agreement”), restricting the transfer of 8,342,000 shares of common stock payable to Dr. Pestell for a three-year period from the closing date of the transaction. In the event Dr. Pestell’s employment with the Company is terminated, as defined in the employment agreement, the Company will have an option to repurchase such Restricted Shares from Dr. Pestell at a purchase price of $0.001 per shares. The Restricted Shares will vest and be released from the Agreement in three equal annual installments commencing one year after the closing date of the acquisition of ProstaGene. A summary of the net purchase price and allocation to the acquired assets is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">ProstaGene, LLC</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> CytoDyn Inc. Equity </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,558,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Acquisition Expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">741,297</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Release of Deferred Tax Asset </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,826,919</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Cost of Acquisition </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,126,216</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Intangible assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,126,216</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Allocation of Acquisition Costs </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,126,216</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Assets acquired from ProstaGene include (1) patents issued in the United States and Australia related to “Prostate Cancer Cell Lines, Gene Signatures and Uses Thereof” and “Use of Modulators of CCR5 in the Treatment of Cancer and Cancer Metastasis,” (2) an algorithm used to identify a 14-gene signature to predict the likelihood and severity of cancer diagnoses, and (3) a noncompetition agreement in connection with an employment agreement with Dr. Pestell as Chief Medical Officer of the Company. The fair value of the assets acquired approximates the consideration paid. The Company did not assume any liabilities. The Company accounted for the ProstaGene acquisition as an asset acquisition under ASC 805-10-55 “Business Combinations” because the assets retained from ProstaGene do not include an assembled workforce, and the gross value of the assets acquired meets the screen test in ASC 805-10-55-5A related to substantially all of the fair value being concentrated in a single asset or group of assets (i.e., the proprietary technology and patents) and, thus, is not considered a business. Thus, management concluded that the acquisition did not include both an input and substantive processes that together significantly contribute to the ability to create outputs. The fair value of the technology acquired is identified using the Income Approach. The fair value of the patents acquired is identified using the Cost to Reproduce Method. The fair value of noncompetition agreement acquired is identified using the Residual Value Method. Goodwill is not recorded as the transaction represents an asset acquisition in accordance with ASU 2017-01. Acquisition costs for asset acquisitions are capitalized and included in the total cost of the transaction. In addition, pursuant to ASC 805, the net tax effect of the deferred tax liability arising from the book to tax basis differences is recorded as a cost of the acquisition.   The following presents intangible assets activity:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">November 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">May 31, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Gross carrying amounts </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,500,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,500,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Intangible asset acquisition: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> ProstaGene, LLC </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,126,216</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accumulated amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,209,254</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,968,846</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total amortizable intangible assets, net </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,416,962</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,531,154</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Patents currently not amortized </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,989</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,989</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Carrying value of intangibles, net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,452,951</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,567,143</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Amortization expense related to intangible assets patents was approximately $152,900 and $240,400 and $87,500 and $175,000 for the three and six months ended November 30, 2018 and 2017, respectively. The estimated aggregate future amortization expense related to the Company’s intangible assets with finite lives is estimated, on average, to be approximately $1.6 million per year for the next five years. </div>

<div> Note 12 – Employee Benefit Plan The Company has an employee savings plan (the “Plan”) pursuant to Section 401(k) of the Internal Revenue Code (the “Code”), covering all of its employees. The Company makes a qualified non-elective contribution of 3%, which consequently vests immediately. In addition, participants in the Plan may contribute a percentage of their compensation, but not in excess of the maximum allowed under the Code. During the three and six months ended November 30, 2018 and 2017, the Company incurred an expense of approximately $15,200 and $31,000 and $10,800 and $21,500, respectively, for qualified non-elective contributions. </div>

<div> Cash Cash is maintained at federally insured financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Balances in excess of federally insured limits at November 30, 2018 and May 31, 2018 approximated $0.5 million and $1.1 million, respectively. </div>

<div> Note 8 – License Agreements The Company has a license agreement with a third-party licensor covering the licensor’s “system know-how” technology with respect to the Company’s use of proprietary cell lines to manufacture new leronlimab (PRO 140) material. The Company accrues an annual license fee of £300,000 (approximately US$400,000 utilizing current exchange rates), which is payable annually in December, except for the December 2017 and 2018 payments, which were extended to March 15, 2018 and March 15, 2019, respectively. Future annual license fees and royalty rate will vary depending on whether the Company manufactures leronlimab (PRO 140), utilizes the third-party licensor as a contract manufacturer, or utilizes an independent party as a contract manufacturer. The licensor does not charge an annual license fee when it serves as the manufacturer. In addition, the Company will incur royalties of up to 0.75% to 2% of net sales, depending upon who serves as the manufacturer, when the Company commences their first commercial sale, which will continue as long as the license agreement is maintained. </div>

<div> Note 9 – Commitments and Contingencies Under the Progenics Purchase Agreement, the Company acquired rights to the HIV viral-entry inhibitor drug candidate leronlimab (PRO 140), a humanized anti-CCR5 monoclonal antibody, as well as certain other related assets, including the existing inventory of bulk leronlimab (PRO 140) drug product, intellectual property, certain related licenses and sublicenses, and FDA regulatory filings. In connection with purchase, the Company has two remaining milestone payments, (i) $0.5 million upon filing a BLA with the FDA or non-U.S. equivalent regulatory body and (ii) $5.0 million, which will become due at the time of the first U.S. new drug application approval by the FDA or other non-U.S. approval for the sale of leronlimab (PRO 140). In addition, the Company will incur royalty payments of up to 5% on net sales during the period beginning on the date of the first commercial sale of leronlimab (PRO 140) until the later of (a) the expiration of the last to expire patent included in the acquired assets, and (b) 10 years, in each case determined on a country-by country basis. During the year ended May 31, 2016 the Company paid a milestone obligation of $1.5 million owed to Progenics as a result of the first dosing in a U.S. Phase 3 trial. To the extent that the remaining milestone payment and royalties are not timely made, under the terms of the Progenics Purchase Agreement, Progenics has certain repurchase rights relating to the assets sold to the Company thereunder. As of the date of this filing, it is management’s conclusion that the probability of achieving the subsequent future scientific research milestone is not reasonably determinable, thus the future milestone payments payable to Progenics and its sub-licensors are deemed contingent consideration and, therefore, are not currently accruable. Payments to the third-party licensor and to Progenics are in addition to payments due under a Development and License Agreement, dated April 30, 1999 (the “PDL License”), between Protein Design Labs (now AbbVie Inc.) (“PDL”) and Progenics, which was assigned to the Company in the Progenics Purchase Agreement, pursuant to which the Company has an exclusive worldwide license to develop, make, have made, import, use, sell, offer to sell or have sold products that incorporate the humanized form of the leronlimab (PRO 140) antibody developed by PDL under the agreement the Company has paid various milestone obligations, with one remaining milestone payment of $0.5 million, which will become due upon FDA approval or approval by another non-U.S. equivalent regulatory body. In addition, the Company will incur royalties of up to 3.5% of net sales for the longer of 10 years and the date of expiration of the last to expire licensed patent. Additionally, the PDL License provides for an annual maintenance fee of $150,000 or until annual royalties paid exceed that amount. To the extent the remaining milestone payment and royalties are not timely made, under the terms of the PDL License, AbbVie Inc. has certain termination rights relating to the Company’s license of leronlimab (PRO 140) thereunder. As of the date of this filing, it is management’s conclusion that the probability of achieving the subsequent future scientific research milestones is not reasonably determinable, thus the future milestone payments payable to PDL, Progenics and its sub-licensors are deemed contingent consideration and, therefore, are not currently accruable.   The Company has entered into project work orders, as amended, for each of its clinical research organization (“CRO”) and related laboratory vendors. Under the terms of these agreements, the Company incurs execution fees for direct services costs, which are recorded as a current asset. In the event the Company were to terminate any trial, it may incur certain financial penalties which would become payable to the CRO. Conditioned upon the form of termination of any one trial, the financial penalties may range up to $0.2 million. In the remote circumstance that the Company would terminate all clinical trials, the collective financial penalties may range from an approximate low of $0.5 million to an approximate high of $1.1 million. During the year ended May 31, 2017, the Company entered into agreements with contract manufacturing companies. Under the terms of the agreements, the Company incurred approximately $2.1 million of execution fees for process validation and manufacturing activities, which have been utilized. In the event the Company were to terminate any of the agreements, it may incur certain financial penalties which would become payable to the manufacturers. Conditioned on the timing of termination, the financial penalties may range up to an approximate high of $0.3 million. From time to time, the Company is involved in routine litigation that arises in the ordinary course of business. There are no pending significant legal proceedings to which the Company is a party for which management believes the ultimate outcome would have a material adverse effect on the Company’s financial position. </div>

-459084

<div> Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, CytoDyn Operations Inc., Advanced Genetic Technologies, Inc. (“AGTI”) and CytoDyn Veterinary Medicine LLC (“CVM”), of which both AGTI and CVM are dormant entities. All intercompany transactions and balances are eliminated in consolidation. </div>

700000

<div> Offering Costs The Company incurred direct incremental costs associated with the sale of equity securities, as described in Notes 10 and 11. The costs were approximately $3.5 million for the year ended May 31, 2018, and approximately $2.7 million and $0.6 million for the six months ended November 30, 2018 and November 30, 2017, respectively. The offering costs were recorded as a component of equity upon receipt of proceeds. </div>

19589

--05-31

<div> Note 4 – Convertible Instruments Series B Convertible Preferred Stock During fiscal 2010, the Company issued 400,000 shares of Series B, $0.001 par value Convertible Preferred Stock (“Series B”) at $5.00 per share for cash proceeds totaling $2,009,000, of which 92,100 shares remain outstanding at November 30, 2018. Each share of the Series B is convertible into ten shares of the Company’s $0.001 par value common stock, including any accrued dividends, with an effective fixed conversion price of $0.50 per share. The holders of the Series B can only convert their shares to common shares provided the Company has sufficient authorized common shares at the time of conversion. Accordingly, the conversion option was contingent upon the Company increasing its authorized common shares, which occurred in April 2010, when the Company’s stockholders approved an increase in the authorized shares of common stock to 100,000,000. At the commitment date, which occurred upon such stockholder approval, the conversion option related to the Series B was beneficial. The intrinsic value of the conversion option at the commitment date resulted in a constructive dividend to the Series B holders of approximately $6,000,000. The constructive dividend increased and decreased additional paid-in capital by identical amounts. The Series B has liquidation preferences over the common shares at $5.00 per share plus any accrued dividends. Dividends are payable to the Series B holders when declared by the board of directors at the rate of $0.25 per share per annum. Such dividends are cumulative and accrue whether or not declared and whether or not there are any profits, surplus or other funds or assets of the Company legally available. The Series B holders have no voting rights. As of November 30, 2018 and May 31, 2018, the undeclared, accrued dividends were approximately $205,000 and $199,000, respectively, or 410,000 and 387,000 shares of common stock, respectively. Short-term Convertible Notes During the fiscal year ended May 31, 2018, the Company issued approximately $4.89 million in aggregate principal of short-term Convertible Notes, with a maturity date of January 31, 2018, and related warrants to investors for cash. The principal amount of the short-term Convertible Notes, including any accrued but unpaid interest thereon, was convertible at the election of the holder at any time into shares of common shares at any time prior to maturity at a conversion price of $0.75 per share. The short-term Convertible Notes bore simple interest at the annual rate of 7%. Principal and accrued interest, to the extent not previously paid or converted, is due and payable on the maturity date. At the commitment date, the Company determined that the conversion feature related to these short-term Convertible Notes to be beneficial to the investors. As a result, the Company determined the intrinsic value of the beneficial conversion feature utilizing the fair value of the underlying common stock on the commitment dates and the effective conversion price after discounting the short-term Convertible Notes for the fair value of the related warrants. In connection with the sale of the short-term Convertible Notes, detachable common stock warrants to purchase a total of 4,025,656 common shares, with an exercise price of $1.00 per share and a five-year term were issued to the investors. The Company determined the fair value of the warrants at issuance using the Black-Scholes option pricing model utilizing certain weighted average assumptions, such as expected stock price volatility, expected term of the warrants, risk-free interest rates and expected dividend yield at the grant date.   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="85%"></td> <td valign="bottom" width="6%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">2018</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom" align="center">0%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Stock price volatility </td> <td valign="bottom">  </td> <td valign="bottom" align="center">69.80%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected term </td> <td valign="bottom">  </td> <td valign="bottom" align="center">5 year</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.77-1.93%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Grant-date fair value </td> <td valign="bottom">  </td> <td valign="bottom" align="center">$0.30-$0.39</td> </tr> </table> The fair value of the warrants, coupled with the beneficial conversion features, were recorded as a debt discount to the short-term Convertible Notes and a corresponding increase to additional paid-in capital was amortized over the term of the short-term Convertible Notes. The Company incurred debt discount of approximately $1.5 million related to the beneficial conversion feature and detachable warrants issued with the short-term Convertible Notes during the year ended May 31, 2018. Accordingly, the Company recognized approximately $-0- and $1.2 million of non-cash debt discount during the six months ended November 30, 2018 and November 30, 2017. In connection with the short-term Convertible Notes, the Company incurred direct issuance costs of approximately $0.4 million during the year ended May 31, 2018. The issuance costs were amortized over the term of the short-term Convertible Notes and accordingly, the Company recognized approximately $-0- and $0.3 million of debt issuance costs during the six months ended November 30, 2018 and November 30, 2017, respectively. On January 31, 2018, in connection with a registered direct equity offering, as fully described in Note 11, the short-term Convertible Notes in an aggregate principal amount of $5,788,500, plus accrued unpaid interest of approximately $243,000 were sold for 12,062,728 shares of common stock. The short-term Convertible Note investors also received warrants to purchase 7,718,010 shares of common stock. The securities were sold at a combined purchase price of $0.50 per share of common stock and related warrants, for aggregate gross proceeds to the Company of approximately $6.0 million. The Company repaid one short-term Convertible Note, including accrued interest in the aggregate of approximately $259,000. During the six months ended November 30, 2018 and November 30, 2017, the Company recognized approximately $-0- and $75,000, of interest expense related to the short-term Convertible Notes.   Activity related to the short-term Convertible Notes was as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">November 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">May 31, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Face amount of short-term Convertible Notes </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,038,500</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Unamortized discount </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Registered direct equity offering </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,788,500</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Note repayment </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(250,000</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Carrying value of short-term Convertible Notes </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Long-term Convertible Note On June 26, 2018, the Company entered into a securities purchase agreement, pursuant to which the Company issued a convertible promissory note (the “Note”) with a two-year term to an institutional accredited investor in the initial principal amount of $5.7 million. The investor gave consideration of $5.0 million to the Company. The Note bears interest of 10% and is convertible into common stock, at $0.55 per share. The Note is convertible in total, or in part, of the outstanding balance, at any time after six months from the issue date upon five trading days’ notice, subject to certain adjustments and ownership limitations specified in the Note. The Investor may redeem any portion of the Note, at any time after six months from the issue date upon five trading days’ notice, subject to a maximum monthly redemption amount of $350,000. The securities purchase agreement requires the Company to reserve shares for future conversions or redemptions by dividing the outstanding principal balance plus accrued interest by the conversion price of $0.55 per share times 1.5. In connection with the Note, the Company recorded debt discount of $0.6 million and debt issuance costs of $0.1 million. The discount and issuance costs will be amortized over the life of the Note, and accordingly, the Company recognized approximately $20,000 and $-0- amortization of debt issuance costs for the six months ended November 30, 2018 and November 30, 2017, respectively and approximately $118,000 and $-0- of amortization of debt discount for the six months ended November 30, 2018 and November 30, 2017, respectively. Effective November 15, 2018, the Note was amended to allow the Investor to redeem the monthly redemption amount of $350,000 in cash or stock, at the lesser of (i) $0.55, or (ii) the lowest closing bid price of the Company’s common stock during the 20 days prior to the conversion, multiplied by a conversion factor of 85%. The variable rate redemption provision meets the definition of a derivative instrument and subsequent to the amendment, it no longer meets the criteria to be considered indexed to the Company’s own stock. As of November 15, 2018, the redemption provision requires bifurcation as a derivative liability at fair value under the guidance in ASC Topic No. 815, “Derivatives and Hedging.” The amendment of the Note was also evaluated under ASC Topic 470-50-40, “Debt Modifications and Extinguishments.” Based on the guidance, the instruments were determined to be substantially different, and debt extinguishment accounting was applied. We recorded approximately $1.5 million as an extinguishment loss, which was the difference in the net carrying value of the Note prior to the amendment of approximately $5.4 million, and the fair value of the Note and embedded derivatives after the amendment of approximately $6.9 million. The extinguishment loss includes a write-off of unamortized debt issuance costs and the debt discount associated with the original Note. During the six months ended November 30, 2018 and November 30, 2017, the Company recognized approximately $248,000 and $-0-, of interest expense related to the Notes. Activity related to the Note was as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="57%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">November 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Short term</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Long term</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">May 31, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Face amount of convertible promissory note </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right">  —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> June 26, 2018 convertible promissory note </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,100,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,600,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,700,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Monthly redemption </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">700,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(700,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Unamortized discount at August 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(344,614</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(281,628</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(626,242</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Carrying value of convertible notes at August 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,455,386</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,618,372</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,073,758</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Carrying value of convertible notes at November 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,200,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,396,974</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,596,974</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-2826919

243772

<div> Note 5 – Derivative Liabilities The investor and placement agent warrants, issued in connection with a registered direct offering in September 2016, contained a provision for net cash settlement in the event that there is a fundamental transaction (contractually defined as a merger, sale of substantially all assets, tender offer or share exchange, whereby such other Person or group acquires more than 50% of the outstanding common stock). If a fundamental transaction occurs in which the consideration issued consists principally of cash or stock in a successor entity, then the warrantholder has the option to receive cash equal to the fair value of the remaining unexercised portion of the warrant. Due to this contingent cash settlement provision, the investor and placement agent warrants require liability classification as derivatives in accordance with ASC 480 and ASC 815 and are recorded at fair value. The following tables summarize the fair value of the warrant derivative liability and related common shares as of inception date September 15, 2016, May 31, 2018, August 31, 2018 and November 30, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares Indexed</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Derivative Liability</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Inception date September 15, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,733,334</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,179,200</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance May 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,733,334</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323,732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance August 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,733,334</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,071,199</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance November 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,733,334</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,789,066</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> The Company recognized approximately $466,000 of non-cash loss and approximately $467,000 of non-cash gain, due to the changes in the fair value of the liability associated with such classified warrants during the six months ended November 30, 2018 and November 30, 2017, respectively. ASC 820 provides requirements for disclosure of liabilities that are measured at fair value on a recurring basis in periods subsequent to the initial recognition. Fair values for the warrants were determined using a Binomial Lattice (“Lattice”) valuation model. The Company estimated the fair value of the warrant derivative liability as of inception date September 15, 2016, May 31, 2018 and November 30, 2018, using the following assumptions:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 15, 2016</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">May 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">November 30, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Fair value of underlying stock </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.78</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.58</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Risk free rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.20</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.63</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.83</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected term (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.3</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.79</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Stock price volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">106</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">64</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">62</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Probability of Fundamental Transaction </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">95</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Probability of holder requesting cash payment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> Due to the fundamental transaction provision contained in the warrants, which could provide for early redemption of the warrants, the model also considered subjective assumptions related to the fundamental transaction provision. The fair value of the warrants will be significantly influenced by the fair value of the Company’s stock price, stock price volatility, changes in interest rates and management’s assumptions related to the fundamental transaction provisions. As described above in Note 4, the redemption provision embedded in the Note required bifurcation and measurement at fair value as a derivative. The fair value of the convertible note redemption provision derivative liability was calculated using a Monte Carlo Simulation which uses randomly generated stock-price paths obtained through a Geometric Brownian Motion stock price simulation. Various assumptions used in the valuation model included: annual volatility of 58.8%, risk free rate of 2.78%, an exercise factor of 2x and an expected term of 1.61 years. The fair value of the derivative liability resulting from the redemption provision was approximately $1.28 million as of its inception date, November 15, 2018 and November 30, 2018. The fair value of the redemption provision will be significantly influenced by the fair value of the Company’s stock price, stock price volatility, changes in interest rates and management’s assumptions related to the redemption factor. The Company recognized approximately $1,100 of non-cash loss, due to the changes in the fair value of the liability associated with such classified redemption provision between the inception date and November 30, 2018.   The following table summarizes the fair value of the convertible note redemption provision derivative liability as of inception date November 15, 2018 and November 30, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net Proceeds</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Derivative Liability</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Inception date, November 15, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,000,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,284,998</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance November 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,000,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,286,076</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> The Company estimated the fair value of the redemption provision using the following assumptions on the closing date of November 15, 2015 and November 30, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">November 15, 2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">November 30, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Fair value of underlying stock </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.57</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.58</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Risk free rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.78</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.78</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected term (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.61</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.61</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Stock price volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58.8</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58.8</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Discount factor </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">85</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">85</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>

Q2 2019 10-Q CYTODYN INC. true

<div> The Company estimated the fair value of the warrant derivative liability as of inception date September 15, 2016, May 31, 2018 and November 30, 2018, using the following assumptions:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 15, 2016</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">May 31, 2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">November 30, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Fair value of underlying stock </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.78</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.49</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.58</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Risk free rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.20</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.63</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.83</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected term (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.3</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.79</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Stock price volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">106</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">64</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">62</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Probability of Fundamental Transaction </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">95</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Probability of holder requesting cash payment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>

-466412

<div> Loss per Common Share Basic loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share would include the weighted average number of shares of common stock outstanding and potentially dilutive common stock equivalents. Because of the net losses for all periods presented, the basic and diluted weighted average shares outstanding are the same since including the additional shares would have an anti-dilutive effect on the loss per share. For this reason, common stock options and warrants to purchase 155,836,676 and 87,551,801 shares of common stock were not included in the computation of basic and diluted weighted average number of shares of common stock outstanding for the six months ended November 30, 2018 and November 30, 2017, respectively. Additionally, as of November 30, 2018, shares of Series B convertible preferred stock in the aggregate of 92,100 shares can potentially convert into 921,000 shares of common stock. </div>

0001175680 2018-11-30 false Accelerated Filer

<div> The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended November 30, 2018 and the year ended May 31, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Investor warrants issued with registered direct equity offering </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,360,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Placement agent warrants issued with registered direct equity offering </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">819,200</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Fair value adjustments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,855,468</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at May 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,323,732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Inception date value of redemption provision </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,284,998</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Fair value adjustments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">466,412</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at November 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,075,142</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Fair Value of Financial Instruments Fair Value Hierarchy The three levels of inputs that may be used to measure fair value are as follows: Level 1. Quoted prices in active markets for identical assets or liabilities. Level 2. Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated with observable market data for substantially the full term of the assets or liabilities. Level 2 inputs also include non-binding market consensus prices that can be corroborated with observable market data, as well as quoted prices that were adjusted for security-specific restrictions.   Level 3. Unobservable inputs to the valuation methodology are significant to the measurement of the fair value of assets or liabilities. These Level 3 inputs also include non-binding market consensus prices or non-binding broker quotes that the Company was unable to corroborate with observable market data. Liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of November 30, 2018 and May 31, 2018 is as follows:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Fair Value Measurement at</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Fair Value Measurement at</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">November 30, 2018 (1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">May 31, 2018 (1)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Using</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Using</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Derivative liability - warrants </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,789,066</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,789,066</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323,732</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323,732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Derivative liability - convertible note redemption provision </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,286,076</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,286,076</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,075,142</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,075,142</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323,732</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323,732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left"> The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of November 30, 2018 and May 31, 2018. </td> </tr> </table> A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurements. These instruments are not quoted on an active market. The Company uses a Binomial Lattice Model to estimate the value of the warrant derivative liability and a Monte Carlo Simulation to value the derivative liability of the redemption provision within a convertible promissory note. These valuation models were used because management believes they reflect all the assumptions that market participants would likely consider in negotiating the transfer of the instruments. The Company’s derivative liabilities are classified within Level 3 of the fair value hierarchy because certain unobservable inputs were used in the valuation models. The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended November 30, 2018 and the year ended May 31, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Investor warrants issued with registered direct equity offering </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,360,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Placement agent warrants issued with registered direct equity offering </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">819,200</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Fair value adjustments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,855,468</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at May 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,323,732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Inception date value of redemption provision </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,284,998</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Fair value adjustments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">466,412</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at November 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,075,142</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-466412

-1519603

<div> Identified Intangible Assets The Company follows the provisions of Financial Accounting Standards Board (“FASB”) ASC Topic 350 Intangibles-Goodwill and Other, which establishes accounting standards for the impairment of long-lived assets such as intangible assets subject to amortization. The Company reviews long-lived assets to be held and used for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. If the sum of the undiscounted expected future cash flows over the remaining useful life of a long-lived asset group is less than its carrying value, the asset is considered impaired. Impairment losses are measured as the amount by which the carrying amount of the asset group exceeds the fair value of the asset. There were no impairment charges for the six months ended November 30, 2018 and 2017. The value of the Company’s patents would be significantly impaired by any adverse developments as they relate to the clinical trials pursuant to the patents acquired as discussed in Notes 7 and 9. </div>

-0.12

<div> Income Taxes Deferred taxes are provided on the asset and liability method, whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Future tax benefits for net operating loss carry forwards are recognized to the extent that realization of these benefits is considered more likely than not. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company follows the provisions of FASB Accounting Standards Codification (“ASC”) ASC 740-10 “Uncertainty in Income Taxes”. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there are no unrecognized benefits for all periods presented. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefit in interest expense and penalties in operating expenses. The Tax Cuts and Jobs Act (the “Act”) was enacted on December 22, 2017. The Act reduces the U.S. federal corporate tax rate from 35% to 21% effective as of January 1, 2018. In accordance with Section 15 of the Internal Revenue Code, we utilized a blended rate of 28.62% for our fiscal 2018 tax year, by applying a prorated percentage of the number of days prior to and subsequent to the January 1, 2018 effective date. For the fiscal year ended May 31, 2018, we recorded provisional charges for the re-measurement of the deferred tax assets and reduced our deferred taxes before the valuation allowance by $17,497,051 to our income tax expense. The net tax expense for the year ended May 31, 2018, is zero, due to the reduction in the deferred tax valuation allowance. For the year ending May 31, 2019 a deferred tax rate of 21% is being utilized and a corresponding valuation allowance adjustment is being recorded for the generation of deferred tax assets reversing in the future. For the three months ending November 30, 2018 the Company recorded a $2,826,919 deferred income tax benefit from a reduction in the Company’s deferred tax valuation allowance resulting from recording a deferred tax liability of $2,826,919 in connection with the acquisition of assets in the ProstaGene LLC transaction (see Note 7) . The deferred tax liability represents the tax effect of the difference in the carrying value of the assets and their tax basis at acquisition. The Company has a full valuation allowance on the Company’s net deferred tax assets as of November 30, 2018 and May 31, 2018, as management does not consider it more than likely than not that the benefits from the deferred taxes will be realized. </div>

3283113

4594804

2002

-31545869

2826919

1904973

1807629

248247

-2262

<div> Note 1 – Organization CytoDyn Inc. (the “Company”, “we” or “us”) was originally incorporated under the laws of Colorado on May 2, 2002 under the name RexRay Corporation (its previous name) and, effective August 27, 2015, reincorporated under the laws of Delaware. Effective November 16, 2018, we implemented a holding company reorganization, as a result of which, we became the successor issuer and reporting company to the former CytoDyn Inc. (now our wholly owned subsidiary, CytoDyn Operations Inc.). We are a clinical-stage biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (“HIV”) infection. Our lead product candidate, leronlimab (PRO 140), belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company is developing a class of therapeutic monoclonal antibodies to address unmet medical needs in the areas of HIV and graft-versus-host disease (“GvHD”). In addition, we are expanding the clinical focus of leronlimab (PRO 140) to include the evaluation of certain cancer and immunological indications where CCR antagonism has shown initial promise. </div>

25736167

29176486

-26192989

-28718950

5000000

2262

-29176486

2727418

<div> Reclassifications Certain prior year amounts shown in the accompanying consolidated financial statements have been reclassified to conform to the 2018 presentation. These reclassifications did not have any effect on total current assets, total assets, total current liabilities, total liabilities, total stockholders’ (deficit) equity, net loss or loss per share. </div>

<div> Note 13 – Related Party Transactions On July 26, 2017, Jordan G. Naydenov, a director with the Company, participated in the private placement of convertible promissory notes, as fully described in Note 4. Mr. Naydenov purchased a convertible promissory note, bearing interest of 7%, for $100,000 in aggregate principal and received a warrant covering 66,666 shares of common stock at an exercise price of $1.00. The terms and conditions of Mr. Naydenov’s investment were identical to those offered to all other investors in the offering and his investment was approved by the Audit Committee of the Board of Directors. On July 28, 2017, Alpha Venture Capital Partners, LP (“AVCP”), participated in the private placement of convertible promissory notes, as fully described in Note 4. Carl C. Dockery, the principal of AVCP, is a director of the Company. AVCP purchased a convertible promissory note, bearing interest of 7%, for $50,000 in aggregate principal and received a warrant covering 33,333 shares of common stock at an exercise price of $1.00. The terms and conditions of the AVCP investment were identical to those offered to all other investors in the offering and his investment was approved by the Audit Committee of the Board of Directors. On November 8, 2017, in connection with a private equity offering, a limited liability company in which Anthony D. Caracciolo, Executive Chairman of the Company, holds a partial ownership interest purchased $100,000 of common stock and warrants on terms identical to those applicable to the other investors in the private equity offering. On January 31, 2018 each of Mr. Caracciolo, Mr. Naydenov and AVCP participated with other investors in the offering of common stock and warrants in satisfaction of the payment obligations relating to the convertible promissory notes, as fully described in Note 11 above. The Audit Committee of the Board of Directors, comprised of independent directors, reviews and approves all related party transactions. The above terms and amounts are not necessarily indicative of the terms and amounts that would have been incurred had comparable transactions been entered into with independent parties. On July 12, 2018, the Company announced certain leadership changes in connection with the strategic expansion and entry into certain cancer and immunologic indications. In connection with such leadership changes and effective July 11, 2018, Denis R. Burger, Ph.D. and A. Bruce Montgomery, M.D., resigned as members of the Company’s board of directors. Dr. Burger also resigned as Chief Science Officer of the Company, which was not an executive officer position. On July 10, 2018, In connection with the resignations of Dr. Burger and Dr. Montgomery, the Company’s board of directors determined to accelerate the vesting of all outstanding and unvested stock options held by Dr. Burger and Dr. Montgomery. Upon the effectiveness of their resignations, stock options covering 500,000 shares 100,000 shares, held by Dr. Burger and Dr. Montgomery, respectively became fully vested. The stock options retained their exercise period through their respective expiration dates and the terms of the stock options remained otherwise unchanged. On November 16, 2018, the Company closed its acquisition of ProstaGene, as described in Note 7. In connection with the closing of the acquisition, the Company hired Dr. Pestell as its Chief Medical Officer. As previously disclosed by the Company, Dr. Pestell is the holder of approximately 77.2% of the outstanding equity interests in ProstaGene and consequently holds an indirect interest in approximately (i) 8,611,427 of 13,258,000 shares of the Company’s common stock, currently pending distribution by ProstaGene to its members, and (ii) 4,171,013 of 5,400,000 shares of common stock, currently held in escrow for the benefit of ProstaGene and its members, which are subject to forfeiture to satisfy certain indemnity obligations of ProstaGene and will be released ratably every six months over the eighteen-month period following the closing date. In addition, as specified in a Stock Restriction Agreement with the Company entered into on the closing date, 8,342,000 additional shares of common stock previously distributed to Dr. Pestell in the ProstaGene acquisition are currently subject to transfer restrictions and forfeiture obligations, subject to certain continuing employment obligations of Dr. Pestell, which will vest ratably each year over the three-years period following the closing date. As specified in a Confidential Information, Inventions and Noncompetition Agreement between the Company and Dr. Pestell, which was entered into on the closing date of the ProstaGene acquisition, the Company may participate in the development and license of certain intellectual property created by Dr. Pestell, in connection with Dr. Pestell’s ongoing research obligations to outside academic institutions. The Company also has the right to work with Dr. Pestell to manage any potential conflict between the Company’s clinical development activities and such ongoing research obligations. </div>

24337910

<div> Research and Development Research and development costs are expensed as incurred. Clinical trial costs incurred through third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development collaboration arrangements or other contractual agreements, the milestone payment obligations are expensed when the milestone conditions are probable and the amount of payment is reasonably estimable. </div>

<div> Stock-Based Compensation U.S. GAAP requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award (requisite service period) or when designated milestones have been achieved. The Company accounts for stock-based awards established by the fair market value of the instrument using the Black-Scholes option pricing model utilizing certain weighted average assumptions including stock price volatility, expected term and risk-free interest rates, as of the grant date. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of the stock-based award. The expected volatility is based on the historical volatility of the Company’s common stock on monthly intervals. The computation of the expected option term is based on the “simplified method,” as the Company issuances are considered “plain vanilla” options. For stock-based awards with defined vesting, the Company recognizes compensation expense over the requisite service period or when designated milestones have been achieved. The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods, if actual forfeitures differ from those estimates. Based on limited historical experience of forfeitures, the Company estimated future unvested forfeitures at 0% for all periods presented. Periodically, the Company will issue restricted common stock to third parties as compensation for services rendered. Such stock awards are valued at fair market value on the effective date of the Company’s obligation. </div>

<div> Activity related to the Note was as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="57%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">November 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Short term</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Long term</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">May 31, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Face amount of convertible promissory note </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right">  —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> June 26, 2018 convertible promissory note </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,100,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,600,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,700,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Monthly redemption </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">700,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(700,000</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Unamortized discount at August 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(344,614</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(281,628</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(626,242</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Carrying value of convertible notes at August 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,455,386</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,618,372</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,073,758</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Carrying value of convertible notes at November 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,200,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,396,974</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,596,974</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of November 30, 2018 and May 31, 2018 is as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center"> <tr> <td width="56%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Fair Value Measurement at</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Fair Value Measurement at</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">November 30, 2018 (1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">May 31, 2018 (1)</td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Using</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Using</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td colspan="2" valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">Total</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Derivative liability - warrants </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,789,066</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,789,066</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323,732</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323,732</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Derivative liability - convertible note redemption provision </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,286,076</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,286,076</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,075,142</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,075,142</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323,732</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323,732</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="4%" valign="top" align="left">(1)</td> <td align="left" valign="top"> The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of November 30, 2018 and May 31, 2018. </td> </tr> </table> </div>

<div> The following presents intangible assets activity:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">November 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">May 31, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Gross carrying amounts </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,500,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,500,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Intangible asset acquisition: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> ProstaGene, LLC </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,126,216</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Accumulated amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,209,254</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,968,846</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Total amortizable intangible assets, net </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,416,962</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,531,154</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Patents currently not amortized </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,989</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">35,989</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Carrying value of intangibles, net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,452,951</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,567,143</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

1510486

<div> Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect all adjustments, which consist solely of normal recurring adjustments, needed to fairly present the financial results for these periods. The consolidated financial statements and notes thereto are presented as prescribed by Form 10-Q. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted. The accompanying consolidated financial statements should be read in conjunction with the financial statements for the fiscal years ended May 31, 2018 and 2017 and notes thereto in the Company’s Annual Report on Form 10-K and Form 10-K/A for the fiscal year ended May 31, 2018, filed with the Securities and Exchange Commission on July 27, 2018 and September 28, 2018, respectively. Operating results for the three months ended November 30, 2018 are not necessarily indicative of the results that may be expected for the entire year. In the opinion of management, all adjustments have been made, which consist only of normal recurring adjustments necessary for a fair statement of (a) the results of operations for the three and six months ended November 30, 2018 and November 30, 2017, (b) the financial position at November 30, 2018 and (c) cash flows for the six month periods ended November 30, 2018 and November 30, 2017. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, CytoDyn Operations Inc., Advanced Genetic Technologies, Inc. (“AGTI”) and CytoDyn Veterinary Medicine LLC (“CVM”), of which both AGTI and CVM are dormant entities. All intercompany transactions and balances are eliminated in consolidation. Reclassifications Certain prior year amounts shown in the accompanying consolidated financial statements have been reclassified to conform to the 2018 presentation. These reclassifications did not have any effect on total current assets, total assets, total current liabilities, total liabilities, total stockholders’ (deficit) equity, net loss or loss per share. Going Concern The consolidated accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company had losses for all periods presented. The Company incurred a net loss of $28,718,950 for the six months ended November 30, 2018 and has an accumulated deficit of $201,858,345 as of November 30, 2018. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to obtain additional operating capital, complete development of its product candidates, obtain U.S. Food & Drug Administration (“FDA”) approval, outsource manufacturing of the product candidates, and ultimately achieve initial revenues and attain profitability. The Company is currently engaging in significant research and development activities related to these product candidates, and expects to incur significant research and development expenses in the future primarily related to its clinical trials. These research and development activities are subject to significant risks and uncertainties. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity and debt securities, combined with additional funding from other traditional sources. There can be no assurance, however, that the Company will be successful in these endeavors. Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash Cash is maintained at federally insured financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Balances in excess of federally insured limits at November 30, 2018 and May 31, 2018 approximated $0.5 million and $1.1 million, respectively. Identified Intangible Assets The Company follows the provisions of Financial Accounting Standards Board (“FASB”) ASC Topic 350 Intangibles-Goodwill and Other, which establishes accounting standards for the impairment of long-lived assets such as intangible assets subject to amortization. The Company reviews long-lived assets to be held and used for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. If the sum of the undiscounted expected future cash flows over the remaining useful life of a long-lived asset group is less than its carrying value, the asset is considered impaired. Impairment losses are measured as the amount by which the carrying amount of the asset group exceeds the fair value of the asset. There were no impairment charges for the six months ended November 30, 2018 and 2017. The value of the Company’s patents would be significantly impaired by any adverse developments as they relate to the clinical trials pursuant to the patents acquired as discussed in Notes 7 and 9. Research and Development Research and development costs are expensed as incurred. Clinical trial costs incurred through third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development collaboration arrangements or other contractual agreements, the milestone payment obligations are expensed when the milestone conditions are probable and the amount of payment is reasonably estimable. Pre-launch Inventory The Company may scale-up and make commercial quantities of its product candidate prior to the date it anticipates that such product will receive final FDA approval. The scale-up and commercial production of pre-launch inventories involves the risk that such products may not be approved for marketing by the FDA on a timely basis, or ever. This risk notwithstanding, the Company may scale-up and build pre-launch inventories of product that have not yet received final governmental approval when the Company believes that such action is appropriate in relation to the commercial value of the product launch opportunity. The determination to capitalize is made once the Company (or its third party development partners) has filed a Biologics License Application (“BLA”) that has been acknowledged by the FDA as containing sufficient information to allow the FDA to conduct its review in an efficient and timely manner and management is reasonably certain that all regulatory and legal requirements will be satisfied. This determination is based on the particular facts and circumstances relating to the expected FDA approval of the drug product being considered. As of November 30, 2018 and May 31, 2018, the Company did not have pre-launch inventory that qualified for capitalization pursuant to U.S. GAAP ASC 330 “Inventory.” Fair Value of Financial Instruments Fair Value Hierarchy The three levels of inputs that may be used to measure fair value are as follows: Level 1. Quoted prices in active markets for identical assets or liabilities. Level 2. Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated with observable market data for substantially the full term of the assets or liabilities. Level 2 inputs also include non-binding market consensus prices that can be corroborated with observable market data, as well as quoted prices that were adjusted for security-specific restrictions.   Level 3. Unobservable inputs to the valuation methodology are significant to the measurement of the fair value of assets or liabilities. These Level 3 inputs also include non-binding market consensus prices or non-binding broker quotes that the Company was unable to corroborate with observable market data. Liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of November 30, 2018 and May 31, 2018 is as follows:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="56%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Fair Value Measurement at</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Fair Value Measurement at</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">November 30, 2018 (1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">May 31, 2018 (1)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Using</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">Using</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Derivative liability - warrants </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,789,066</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,789,066</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323,732</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323,732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Derivative liability - convertible note redemption provision </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,286,076</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,286,076</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total liabilities </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,075,142</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,075,142</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323,732</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323,732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left"> The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of November 30, 2018 and May 31, 2018. </td> </tr> </table> A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurements. These instruments are not quoted on an active market. The Company uses a Binomial Lattice Model to estimate the value of the warrant derivative liability and a Monte Carlo Simulation to value the derivative liability of the redemption provision within a convertible promissory note. These valuation models were used because management believes they reflect all the assumptions that market participants would likely consider in negotiating the transfer of the instruments. The Company’s derivative liabilities are classified within Level 3 of the fair value hierarchy because certain unobservable inputs were used in the valuation models. The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended November 30, 2018 and the year ended May 31, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Investor warrants issued with registered direct equity offering </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,360,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Placement agent warrants issued with registered direct equity offering </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">819,200</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Fair value adjustments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,855,468</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance at May 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,323,732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Inception date value of redemption provision </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,284,998</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Fair value adjustments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">466,412</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance at November 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,075,142</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Stock-Based Compensation U.S. GAAP requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award (requisite service period) or when designated milestones have been achieved. The Company accounts for stock-based awards established by the fair market value of the instrument using the Black-Scholes option pricing model utilizing certain weighted average assumptions including stock price volatility, expected term and risk-free interest rates, as of the grant date. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of the stock-based award. The expected volatility is based on the historical volatility of the Company’s common stock on monthly intervals. The computation of the expected option term is based on the “simplified method,” as the Company issuances are considered “plain vanilla” options. For stock-based awards with defined vesting, the Company recognizes compensation expense over the requisite service period or when designated milestones have been achieved. The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods, if actual forfeitures differ from those estimates. Based on limited historical experience of forfeitures, the Company estimated future unvested forfeitures at 0% for all periods presented. Periodically, the Company will issue restricted common stock to third parties as compensation for services rendered. Such stock awards are valued at fair market value on the effective date of the Company’s obligation.   Common Stock On August 24, 2017, at the 2017 Annual Meeting of Stockholders, a proposal was approved to increase the total number of authorized shares of common stock from 350,000,000 to 375,000,000. On June 7, 2018, at a special meeting of stockholders, a proposal was approved to increase the total number of authorized shares of common stock of the Company from 375,000,000 to 450,000,000. Subsequent to each stockholders’ meeting, an amendment to the Company’s Certificate of Incorporation was filed with the Secretary of State of the State of Delaware to give effect to each authorized share increase. On November 8, 2018 at the 2018 Annual Meeting of Stockholders, a proposal was approved to increase the total number of authorized shares of common stock from 450,000,000 to 600,000,000. Subsequent to the meeting, an amendment to the Company’s Certificate of Incorporation was filed with the Secretary of State of the State of Delaware to give effect to the authorized share increase. Preferred Stock The Company’s Board of Directors is authorized to issue up to 5,000,000 shares of preferred stock without stockholder approval. As of November 30, 2018, the Company has authorized the issuance of 400,000 shares of Series B Convertible Preferred Stock, of which 92,100 shares were outstanding. The remaining preferred shares authorized have no specified rights. Treasury Stock Treasury stock purchases are accounted for under the par value method, whereby the cost of the acquired stock is recorded at par value. During the year ended May 31, 2018, the Company purchased 159,011 shares of $0.001 par value treasury stock for shares tendered in satisfaction of income tax withholding, in connection with incentive compensation paid to certain officers in the form of common stock. Debt Discount During the six months ended November 30, 2018 and the year ended May 31, 2018, the Company incurred approximately $0.6 million and $1.5 million of debt discount related to the issuance of convertible notes, as described in Note 4. The discount is amortized over the life of the convertible promissory notes. During the six months ended November 30, 2018 and November 30, 2017, the Company recorded approximately $117,500 and $1.2 million of related amortization. Debt Issuance Cost During the six months ended November 30, 2018 and the year ended May 31, 2018, the Company incurred direct costs associated with the issuance of convertible notes, as described in Note 4, and recorded approximately $0.1 million and $0.4 million, respectively of debt issuance costs. In connection with the debt issuance costs, the Company recognized approximately $20,000 and $0.3 million of related amortization for the six months ended November 30, 2018 and November 30, 2017, respectively. Offering Costs The Company incurred direct incremental costs associated with the sale of equity securities, as described in Notes 10 and 11. The costs were approximately $3.5 million for the year ended May 31, 2018, and approximately $2.7 million and $0.6 million for the six months ended November 30, 2018 and November 30, 2017, respectively. The offering costs were recorded as a component of equity upon receipt of proceeds. Stock for Services The Company periodically issues warrants to consultants for various services. The Black-Scholes option pricing model, as described more fully above, is utilized to measure the fair value of the equity instruments on the date of issuance. The Company recognizes the compensation expense associated with the equity instruments over the requisite service or vesting period. Loss per Common Share Basic loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share would include the weighted average number of shares of common stock outstanding and potentially dilutive common stock equivalents. Because of the net losses for all periods presented, the basic and diluted weighted average shares outstanding are the same since including the additional shares would have an anti-dilutive effect on the loss per share. For this reason, common stock options and warrants to purchase 155,836,676 and 87,551,801 shares of common stock were not included in the computation of basic and diluted weighted average number of shares of common stock outstanding for the six months ended November 30, 2018 and November 30, 2017, respectively. Additionally, as of November 30, 2018, shares of Series B convertible preferred stock in the aggregate of 92,100 shares can potentially convert into 921,000 shares of common stock.   Income Taxes Deferred taxes are provided on the asset and liability method, whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Future tax benefits for net operating loss carry forwards are recognized to the extent that realization of these benefits is considered more likely than not. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company follows the provisions of FASB Accounting Standards Codification (“ASC”) ASC 740-10 “Uncertainty in Income Taxes”. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there are no unrecognized benefits for all periods presented. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefit in interest expense and penalties in operating expenses. The Tax Cuts and Jobs Act (the “Act”) was enacted on December 22, 2017. The Act reduces the U.S. federal corporate tax rate from 35% to 21% effective as of January 1, 2018. In accordance with Section 15 of the Internal Revenue Code, we utilized a blended rate of 28.62% for our fiscal 2018 tax year, by applying a prorated percentage of the number of days prior to and subsequent to the January 1, 2018 effective date. For the fiscal year ended May 31, 2018, we recorded provisional charges for the re-measurement of the deferred tax assets and reduced our deferred taxes before the valuation allowance by $17,497,051 to our income tax expense. The net tax expense for the year ended May 31, 2018, is zero, due to the reduction in the deferred tax valuation allowance. For the year ending May 31, 2019 a deferred tax rate of 21% is being utilized and a corresponding valuation allowance adjustment is being recorded for the generation of deferred tax assets reversing in the future. For the three months ending November 30, 2018 the Company recorded a $2,826,919 deferred income tax benefit from a reduction in the Company’s deferred tax valuation allowance resulting from recording a deferred tax liability of $2,826,919 in connection with the acquisition of assets in the ProstaGene LLC transaction (see Note 7) . The deferred tax liability represents the tax effect of the difference in the carrying value of the assets and their tax basis at acquisition. The Company has a full valuation allowance on the Company’s net deferred tax assets as of November 30, 2018 and May 31, 2018, as management does not consider it more than likely than not that the benefits from the deferred taxes will be realized. </div>

<div> Common Stock On August 24, 2017, at the 2017 Annual Meeting of Stockholders, a proposal was approved to increase the total number of authorized shares of common stock from 350,000,000 to 375,000,000. On June 7, 2018, at a special meeting of stockholders, a proposal was approved to increase the total number of authorized shares of common stock of the Company from 375,000,000 to 450,000,000. Subsequent to each stockholders’ meeting, an amendment to the Company’s Certificate of Incorporation was filed with the Secretary of State of the State of Delaware to give effect to each authorized share increase. On November 8, 2018 at the 2018 Annual Meeting of Stockholders, a proposal was approved to increase the total number of authorized shares of common stock from 450,000,000 to 600,000,000. Subsequent to the meeting, an amendment to the Company’s Certificate of Incorporation was filed with the Secretary of State of the State of Delaware to give effect to the authorized share increase. </div>

<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Note 14 – Subsequent Events <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Between December 7, 2018 and December 11, 2018, the Company conducted a private equity offering, in which accredited investors purchased common stock at $0.50 per share with warrant coverage ratio of 50%. Pursuant to the offering, the Company sold a total of 2,018,000 shares of common stock, $0.001 par value, for aggregate gross proceeds of approximately $1.0 million and issued to the investors five-year warrants covering 1,009,000 shares of common stock with an exercise price of $0.75 per share. In connection with the equity offering, the Company paid an aggregate cash fee of approximately $0.1 million to the placement agent and issued warrants covering an aggregate of 201,800 shares of common stock to the placement agent as additional compensation. The placement agent warrants have a five-year term and an exercise price of $0.50 per share and a cashless exercise provision. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On December 10, 2018, Anthony D. Caracciolo resigned as the Chairman of the Board, but remains a director and Scott A. Kelly, M.D., was named Chairman of the Board. On December 19, 2018, the Compensation Committee of the Board approved an amendment to certain compensation arrangements for Anthony D. Caracciolo, pursuant to which his employment with the Company would be extended through April 16, 2019, at a salary reduced from $16,667 to $5,000 per month, with continuing benefits. In addition, the Compensation Committee approved an extension to 10-years of the expiration terms of certain previously awarded stock options covering an aggregate of 150,000 shares of the Company’s common stock, provided that such stock options are out-of-the-money upon the date of such extension. These arrangements were conditioned upon Mr. Caracciolo’s agreement to resign from the Board upon identification by the Company of an appropriately qualified candidate to fill the vacancy. Mr. Caracciolo has agreed to the foregoing terms. These arrangements were not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On December 22, 2018 the board of directors appointed Nitya G. Ray, Ph.D., as Chief Technology Officer – Head of Process Sciences, Manufacturing and Supply Chain. In connection with Dr. Ray’s appointment, the Company and Dr. Ray entered into an Employment Agreement that provides for (i) an annual base salary of $335,000, (ii) a target annual bonus equal to 50% of base salary, (iii) an initial signing bonus of $100,000 to be paid in two equal installments of $50,000 over the course of six months from the date of signing and (iv) other customary benefits described in the form of employment agreement. In connection with the appointment of Dr. Ray, the Company also issued Dr. Ray a stock option award under the Company’s equity incentive plan, covering 400,000 shares of the Company’s common stock, vesting in three equal annual installments from the grant date. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> On December 27, 2018, the Company received a redemption notice from the holder of the Company’s convertible note issued on June 26, 2018, requesting the redemption of $100,000 of the outstanding balance thereof. In satisfaction of the redemption notice, the Company issued 255,532 shares of common stock to the note holder in accordance with the terms of the convertible note. Following the redemption, the outstanding balance of the convertible note, including accrued but unpaid interest, was approximately $5.9 million. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Beginning December 28, 2018 through January 8, 2019, the Company issued $3.1 million (of which $0.5 million was purchased by Michael A. Klump, a director, on terms identical to all other investors) in aggregate principal amount of unsecured convertible promissory notes (the “Notes”) and related warrants (the “Warrants”) to purchase common stock of the Company (the “Common Stock”), to accredited investors (the “Private Placements”) pursuant to subscription agreements entered into with each investor (collectively, the “Subscription Agreements”), in exchange for cash in an equal amount. The proceeds of the Private Placements are anticipated to be used for general working capital and to fund clinical trials. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The principal amount of the Notes plus unpaid accrued interest at an annual rate of 10.0% is convertible at the election of the holders into shares of Common Stock at any time prior to maturity, at an initial conversion price of $0.50 per share, with an aggregate of 6,200,000 shares of the Company’s Common Stock initially underlying the Notes. As part of the investment in the Notes, the Company also issued Warrants exercisable for 50% of the shares into which the Notes are convertible, with Warrants for an aggregate of 3,100,000 shares of Common Stock issued in the Private Placements. The Warrants are exercisable at a price of $0.30 per share. The Warrants are currently exercisable in full and will expire five years from the date of issuance. The Subscription Agreements contain certain “piggyback” registration rights relating to resales of shares of Common Stock underlying the Notes and the Warrants. <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> As a result of the issuance of the Notes, pursuant to the terms of the Placement Agent Agreement, dated July 26, 2018, entered into in connection with a recently completed private securities offering, the placement agent in that offering earned a “tail fee” comprising warrants exercisable for 620,000 shares of Common Stock (the “Placement Agent Warrants”) and a cash fee of $372,000. The Placement Agent Warrants are exercisable at a price of $0.50 per share and will expire five years from the date of issuance. The Placement Agent Warrants provide for cashless exercise. </div>

<div> The following table represents stock option and warrant activity as of and for the six months ended November 30, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="54%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Remaining Contractual Life in Years</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options and warrants outstanding - May 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">132,385,269</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.80</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.78</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,673</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,483,124</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.69</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Forfeited/expired/cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10,031,717</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.75</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options and warrants outstanding - November 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">155,836,676</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.78</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.97</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769,360</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Outstanding exercisable - November 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150,960,607</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.78</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.80</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">565,356</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

238731091

CYDY

<div> Note 6 – Stock Options and Warrants The Company has one active stock-based equity plan at November 30, 2018, the CytoDyn Inc. 2012 Equity Incentive Plan, as amended (the “2012 Plan”) and one stock-based equity plan that is no longer active, but under which certain prior awards remain outstanding, the CytoDyn Inc. 2004 Stock Incentive Plan (the “2004 Plan” and, together with the 2012 Plan, the “Incentive Plans”). The 2012 Plan was approved by stockholders at the Company’s 2012 annual meeting to replace the 2004 Plan. The 2012 Plan was amended by stockholder approval in February 2015 to increase the number of shares available for issuance from 3,000,000 to 5,000,000 shares of common stock and in March 2016 to increase the number of shares available for issuance from 5,000,000 to 7,000,000 shares of common stock. At the annual meeting of stockholders held on August 24, 2017, the stockholders approved an amendment to the 2012 Plan to increase the number of shares available for issuance from 7,000,000 to 15,000,000 shares of common stock. As of November 30, 2018, the Company had 553,048 shares available for future stock-based grants under the 2012 Plan. Stock Options During the six months ended November 30, 2018, the Company granted annual stock option awards to directors to purchase a total of 680,822 shares of common stock. The exercise price of the stock option awards is $0.49 per share, except for one stock option award covering 80,822 shares of common stock, which has an exercise price of $0.47 per share. These stock option awards vest quarterly over one year and have a ten-year term. The grant date fair value related to these stock options was $0.31 per share, except the stock option award covering 80,822 shares of common stock, which was $0.30 per share. These awards reflect an increase in the annual non-employee director stock option award from 75,000 to 100,000 shares per year, effective for fiscal year 2019. During the six months ended November 30, 2018, the Company granted a stock option award covering 950,000 shares of common stock with an exercise price of $0.49 per share, to its Executive Chairman. This stock option award vests ratably over 24 months, has a ten-year term and a grant date fair value of $0.41 per share. During the six months ended November 30, 2018, the Company granted stock options, covering an aggregate of 875,000 shares of common stock, to executive management and employees with exercise prices of $0.49 per share. The stock option awards vest annually over three years, with a ten-year term and grant date fair values of $0.31 per share. Additionally, the Company granted a stock option covering an aggregate of 1,000,000 shares of common stock, to an officer with an exercise price of $0.565 per share. The stock option award vests 50% upon grant and 50% on April 8, 2019; it has a ten-year term and grant date fair value of $0.30 per share. The Company also granted stock options, covering an aggregate of 500,000 shares of common stock to directors for consulting services with an exercise price of $0.565 per share. The stock option awards vest upon grant, have a ten-year term and grant date fair value of $0.30 per share. During the six months ended November 30, 2018, the Company granted a stock option award covering 350,000 shares of common stock with an exercise price of $0.551 per share to Dr. Richard G. Pestell, M.D., Ph.D., in connection with his employment agreement as Chief Medical Officer and the closing of the ProstaGene transaction described in Note 7. The stock option award vests annually over three years, with a ten-year term and grant date fair value of $0.30 per share.   Warrants On June 15, 2018, in connection with a registered direct equity offering, as fully described in Note 11, the Company issued warrants covering 1,970,000 shares of common stock to investors. The investor warrants have a five-year term and an exercise price of $0.75 per share. In connection with the registered direct offering, the Company also issued warrants covering 133,600 shares of common stock to the placement agent. The placement agent warrants have a five-year term and an exercise price of $0.55 per share. During the six months ended November 30, 2018, in connection with a private equity offering, as fully described in Note 10, the Company issued common stock warrants covering a total of 22,478,585 shares of common stock to investors. The investor warrants have a five-year term and an exercise price of $0.75 per share. In connection with this offering, the Company also issued common stock warrants covering 4,245,117 shares of common stock to the placement agent. The placement agent warrants have a five-year term, an exercise price of $0.50 per share and a cashless exercise provision. During the six months ended November 30, 2018, the Company issued compensable warrants covering an aggregate of 300,000 shares of common stock to consultants. The warrants have a five-year term, an exercise price of $0.56 per share and a grant date fair value of $0.30 per share. During the year ended May 31, 2018, the Company determined to extend the expiration dates of certain warrants from May 31, 2017 to June 30, 2017 covering 3,295,000 shares of common stock. The warrants were originally issued in connection with 2012 convertible promissory notes and had an amended exercise price of $1.00 per share. The extension to June 30, 2017 was contingent upon immediate exercise of the warrants at a reduced exercise price of $0.50 per share. The Company received proceeds of approximately $1.6 million and, pursuant to U.S. GAAP, the Company recognized non-cash inducement interest expense of approximately $0.8 million, which represented the incremental increase in the fair value of the extended warrants. Compensation expense related to stock options, compensatory warrants and common stock reserved for advisory services, for the three and six months ended November 30, 2018 and November 30, 2017 was approximately $1.2 million and $275,000 and $1.5 million and $530,000, respectively. The grant date fair value of options and compensatory warrants vested during the three and six month periods ended November 30, 2018 and November 30, 2017 was approximately $485,000 and $127,000 and $1.2 million and $574,000, respectively. As of November 30, 2018, there was approximately $5.7 million of unrecognized compensation expense related to share-based payments for unvested options, which is expected to be recognized over a weighted average period of 2.69 years. The following table represents stock option and warrant activity as of and for the six months ended November 30, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="54%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted Average Remaining Contractual Life in Years</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options and warrants outstanding - May 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">132,385,269</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.80</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.78</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,673</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,483,124</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.69</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Forfeited/expired/cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(10,031,717</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.75</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Options and warrants outstanding - November 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">155,836,676</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.78</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.97</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769,360</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Outstanding exercisable - November 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150,960,607</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.78</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.80</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">565,356</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

<div> Preferred Stock The Company’s Board of Directors is authorized to issue up to 5,000,000 shares of preferred stock without stockholder approval. As of November 30, 2018, the Company has authorized the issuance of 400,000 shares of Series B Convertible Preferred Stock, of which 92,100 shares were outstanding. The remaining preferred shares authorized have no specified rights. </div>

<div> Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </div>

0 23463585 100000 10031717 33483124 0 P3Y9M18D P3Y11M19D P10Y <div> Pre-launch Inventory The Company may scale-up and make commercial quantities of its product candidate prior to the date it anticipates that such product will receive final FDA approval. The scale-up and commercial production of pre-launch inventories involves the risk that such products may not be approved for marketing by the FDA on a timely basis, or ever. This risk notwithstanding, the Company may scale-up and build pre-launch inventories of product that have not yet received final governmental approval when the Company believes that such action is appropriate in relation to the commercial value of the product launch opportunity. The determination to capitalize is made once the Company (or its third party development partners) has filed a Biologics License Application (“BLA”) that has been acknowledged by the FDA as containing sufficient information to allow the FDA to conduct its review in an efficient and timely manner and management is reasonably certain that all regulatory and legal requirements will be satisfied. This determination is based on the particular facts and circumstances relating to the expected FDA approval of the drug product being considered. As of November 30, 2018 and May 31, 2018, the Company did not have pre-launch inventory that qualified for capitalization pursuant to U.S. GAAP ASC 330 “Inventory.” </div> <div> Treasury Stock Treasury stock purchases are accounted for under the par value method, whereby the cost of the acquired stock is recorded at par value. During the year ended May 31, 2018, the Company purchased 159,011 shares of $0.001 par value treasury stock for shares tendered in satisfaction of income tax withholding, in connection with incentive compensation paid to certain officers in the form of common stock. </div> <div> Note 11 – Registered Direct Equity Offerings On January 31, 2018, the Company entered into subscription agreements with certain investors who owned convertible promissory notes of the Company (the “Notes”) for the sale by the Company of 12,062,728 shares of common stock in a registered direct offering (the “January 31 Offering”). The investors in the January 31 Offering also received warrants to purchase 7,718,010 shares of common stock. The securities were sold at a combined purchase price of $0.50 per share of common stock and related warrants, for aggregate gross proceeds to the Company of approximately $6.0 million. The Notes matured on January 31, 2018, upon which date the Company became obligated to pay the principal amount of approximately $6.0 million on the Notes, plus accrued but unpaid interest of approximately $0.3 million, for aggregate payment obligations at maturity of approximately $6.3 million. The common stock and warrants were issued in full satisfaction of approximately $6.0 million of such payment obligations, with one holder of an aggregate principal amount and accrued unpaid interest of approximately $0.3 million electing to be repaid in cash instead of participating in the January 31, 2018 Offering. As a result, all of the proceeds from the January 31 Offering were used to satisfy the Company’s payment obligations pursuant to the Notes. The warrants will be exercisable for a period of five years commencing on their issuance date, at an exercise price of $0.75 per share of common stock, subject to certain ownership limitations and adjustments as provided under the terms of the warrants. The number of shares of common stock underlying the warrant issued to each investor was calculated as the difference between (x) the number of shares of common stock issued to each investor in the January 31, 2018 Offering in respect of the payment obligations relating solely to principal amounts on the Notes and (y) the number of shares of common stock underlying certain warrants originally issued to such investor in the original Notes offering. The effect was to bring each investor from 50% warrant coverage in the original offering of Notes, assuming conversion of the principal amount thereof at an original conversion price of $0.75 per share, to 100% warrant coverage after the January 31 Offering, assuming reinvestment of the principal amount on the Notes at $0.50 per share. The warrants in the January 31 Offering, had an original exercise price of $1.00 per share, therefore, due to the reduction of exercise price to $0.75 per share, the Company recognized a non-cash inducement interest expense of approximately $2.4 million due to the modification. In connection with this January 31 Offering, the Company paid a commission of $164,425 to the placement agent. On June 15, 2018, the Company entered into subscription agreements with certain investors for the sale of 1,970,000 shares of common stock at a purchase price of $0.50 per shares in a registered direct offering, pursuant to a registration statement on Form S-3. The investors in the offering also received warrants to purchase 1,970,000 shares of common stock with an exercise price of $0.75 per share and a five-year term. The Company received net proceeds from the offering of approximately $0.9 million. In addition, the placement agent received warrants covering 133,600 shares of common stock (or 8% of total shares sold to investors) with a per share exercise price of $0.55, a five-year term and include a cashless exercise provision. </div> <div> Stock for Services The Company periodically issues warrants to consultants for various services. The Black-Scholes option pricing model, as described more fully above, is utilized to measure the fair value of the equity instruments on the date of issuance. The Company recognizes the compensation expense associated with the equity instruments over the requisite service or vesting period. </div> <div> Note 10 – Private Securities Offerings During the six months ended November 30, 2018, the Company conducted a private equity offering, in which accredited investors purchased unregistered common stock at $0.50 per share with warrant coverage rate of 50%. Pursuant to the offering, the Company sold a total of 44,957,170 shares of common stock, $0.001 par value, for aggregate gross proceeds of approximately $22.5 million and issued to the investors five-year warrants covering 22,478,585 shares of common stock with an exercise price of $0.75 per share. The Company received net proceeds from the offering of approximately $19.9 million. In addition, the placement agent received warrants covering 4,245,117 shares of common stock (or 10% of total shares sold to investors) with a per share exercise price of $0.50, a five-year term and include a cashless exercise provision. The Company also paid a one-time non-accountable expense fee of $25,000 to the placement agent for its services in connection with the offering. </div> <div> Debt Discount During the six months ended November 30, 2018 and the year ended May 31, 2018, the Company incurred approximately $0.6 million and $1.5 million of debt discount related to the issuance of convertible notes, as described in Note 4. The discount is amortized over the life of the convertible promissory notes. During the six months ended November 30, 2018 and November 30, 2017, the Company recorded approximately $117,500 and $1.2 million of related amortization. </div> <div> Going Concern The consolidated accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company had losses for all periods presented. The Company incurred a net loss of $28,718,950 for the six months ended November 30, 2018 and has an accumulated deficit of $201,858,345 as of November 30, 2018. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to obtain additional operating capital, complete development of its product candidates, obtain U.S. Food & Drug Administration (“FDA”) approval, outsource manufacturing of the product candidates, and ultimately achieve initial revenues and attain profitability. The Company is currently engaging in significant research and development activities related to these product candidates, and expects to incur significant research and development expenses in the future primarily related to its clinical trials. These research and development activities are subject to significant risks and uncertainties. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity and debt securities, combined with additional funding from other traditional sources. There can be no assurance, however, that the Company will be successful in these endeavors. </div> <div> Debt Issuance Cost During the six months ended November 30, 2018 and the year ended May 31, 2018, the Company incurred direct costs associated with the issuance of convertible notes, as described in Note 4, and recorded approximately $0.1 million and $0.4 million, respectively of debt issuance costs. In connection with the debt issuance costs, the Company recognized approximately $20,000 and $0.3 million of related amortization for the six months ended November 30, 2018 and November 30, 2017, respectively. </div> <div> A summary of the net purchase price and allocation to the acquired assets is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">ProstaGene, LLC</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> CytoDyn Inc. Equity </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,558,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Acquisition Expenses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">741,297</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Release of Deferred Tax Asset </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,826,919</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Total Cost of Acquisition </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,126,216</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Intangible assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,126,216</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Allocation of Acquisition Costs </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,126,216</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> 0 0.69 0.75 0.00 0.50 225245 1284998

11558000

11558000 0.001 P3Y

0.30

0.565

P10Y

500000

0.30

0.565

P10Y

0.50

1000000

0.30

0.551

P3Y

P10Y

350000

0.41

0.49

P24M

P10Y

950000

0.31

0.49

P3Y

P10Y

875000

100000

75000

P1Y

P10Y

0.49

680822

0.47

80822

0.31

0.30

80822

<div> The Company determined the fair value of the warrants at issuance using the Black-Scholes option pricing model utilizing certain weighted average assumptions, such as expected stock price volatility, expected term of the warrants, risk-free interest rates and expected dividend yield at the grant date.   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="85%"></td> <td valign="bottom" width="6%"></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">2018</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom" align="center">0%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Stock price volatility </td> <td valign="bottom">  </td> <td valign="bottom" align="center">69.80%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected term </td> <td valign="bottom">  </td> <td valign="bottom" align="center">5 year</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1.77-1.93%</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Grant-date fair value </td> <td valign="bottom">  </td> <td valign="bottom" align="center">$0.30-$0.39</td> </tr> </table> </div>

117500

0.39 0.30 P5Y 0.0193 0.0177 205000

118000

20000

1500000

248000

20000

<div> Activity related to the short-term Convertible Notes was as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">November 30, 2018</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">May 31, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Face amount of short-term Convertible Notes </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,038,500</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Unamortized discount </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Registered direct equity offering </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,788,500</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Note repayment </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(250,000</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Carrying value of short-term Convertible Notes </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following tables summarize the fair value of the warrant derivative liability and related common shares as of inception date September 15, 2016, May 31, 2018, August 31, 2018 and November 30, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares Indexed</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Derivative Liability</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Inception date September 15, 2016 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,733,334</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,179,200</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance May 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,733,334</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,323,732</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Balance August 31, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,733,334</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,071,199</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance November 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,733,334</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,789,066</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

<div> The Company estimated the fair value of the redemption provision using the following assumptions on the closing date of November 15, 2015 and November 30, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">November 15, 2018</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">November 30, 2018</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Fair value of underlying stock </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.57</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.58</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Risk free rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.78</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.78</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected term (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.61</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.61</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Stock price volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58.8</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">58.8</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom"> </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Discount factor </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">85</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">85</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>

5000000

<div> The following table summarizes the fair value of the convertible note redemption provision derivative liability as of inception date November 15, 2018 and November 30, 2018:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net Proceeds</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Derivative Liability</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> Inception date, November 15, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,000,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,284,998</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> Balance November 30, 2018 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,000,000</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,286,076</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> </table> </div>

240400

0.58 2 0.58 P2Y9M14D P1Y7M9D 0 0.0283 0.95 0.50 500000 5000000 150000 P10Y 500000

P2Y8M8D

275000

127000

921000

0.25

6000000

22500000

19900000

44957170

0.50 P5Y 0.10 25000

31000

0.03

2100000

1284998

P5Y

100000

1000000

2018000

0.50

0.21

0.2862

0.35

2009000

3855468

159011

800000 17497051 400000 P3Y9M10D 0 199000

2018-01-31

250000

0.49 P3Y3M18D 0.0263 0.50 0.50

1600000

2017-06-30

819200

4360000

0.21

1500000

566609

-17950100

14317551 7566165 0.50 0.50 260190 1416786 331621 166222 2352045

566609

14288916 7551031 260190 1416786 331621 166222 2352045 28635 15134 28635104 15133742 0.50 0 0

-17950100

826252

1096226

-40526058

17642948 1647500 11291419 1645010 260190 1729242 650849 344886 2352045

728843

274665

168429

89136

829600

-0.07

1608743

422

-10947685

1002656

105384

10775051

-10947685

-10775051

9077172

157843773

3325397 3725254 0.50 0.50 312456 319228 178664

87500

1500000

1200000

274665

3318745 3719534 312456 319228 178664 6652 5720 6651800 5720111 0.50 0 0

-10947685

10800

826252

529617

-22575958

3325397 1647500 3725254 1645010 312456 319228 178664

52954

1227140

10411

2826919

154801

281055

-1519603

-0.06

2663745

1021

-17132299

2826919

1726585

143617

15687790

-14305380

-15687790

12869244

8342

259088835

14964285 -1693354 0.50 25652

11558000

11539342

18658

18658000

11558000

152900

1200000

485000

1227140

14934355 -1693354 25652

8342000

8342

29930 29928570 0 0

-14305380

15200

1510486

-28718950

8342

22478585 985000 -2576070 76195 75151

826252

254952

-11628273

1647500 1645010 0.50 0.50

826252

254952

1644205 1645010 3295 3295000 0.5 0.5 0 0

-11628273

826252

254952

-11628273

1647500 1645010

283346

-14413569

7514300 985000 -882716 0.50 50544 75151 0 700000 -700000

283346

7499271 983030 -882716 50544 75151 15029 1970 15028600 1970000 0.50 0 0

-14413569

283346

-14413569

7514300 985000 -882716 50544 75151

194551

-9623623

104545

1513631 2320000 0.50 0.50 206300 188548 73234 393686

194551

104394

1510604 2315360 206300 188548 73234 393686

310

310526

3027 4640 3027263 4640000 0.50 0.50 0 0

-9623623

-159

159011

826252

1290777

-50149681

104545

17642948 3161131 13611419 1645010 260190 1729242 857149 533434 73234 2352045 393686 0001175680 cydy:FiscalYearToDateMember 2018-03-01 2018-05-31 0001175680 us-gaap:TreasuryStockMember 2018-03-01 2018-05-31 0001175680 us-gaap:RetainedEarningsMember 2018-03-01 2018-05-31 0001175680 us-gaap:PreferredStockMember 2018-03-01 2018-05-31 0001175680 us-gaap:CommonStockMember 2018-03-01 2018-05-31 0001175680 us-gaap:AdditionalPaidInCapitalMember 2018-03-01 2018-05-31 0001175680 2018-03-01 2018-05-31 0001175680 cydy:FiscalYearToDateMember 2018-06-01 2018-08-31 0001175680 us-gaap:TreasuryStockMember 2018-06-01 2018-08-31 0001175680 us-gaap:RetainedEarningsMember 2018-06-01 2018-08-31 0001175680 us-gaap:PreferredStockMember 2018-06-01 2018-08-31 0001175680 us-gaap:CommonStockMember 2018-06-01 2018-08-31 0001175680 us-gaap:AdditionalPaidInCapitalMember 2018-06-01 2018-08-31 0001175680 us-gaap:ShortTermDebtMember 2018-06-01 2018-08-31 0001175680 us-gaap:LongTermDebtMember 2018-06-01 2018-08-31 0001175680 2018-06-01 2018-08-31 0001175680 cydy:FiscalYearToDateMember 2017-06-01 2017-08-31 0001175680 us-gaap:TreasuryStockMember 2017-06-01 2017-08-31 0001175680 us-gaap:RetainedEarningsMember 2017-06-01 2017-08-31 0001175680 us-gaap:PreferredStockMember 2017-06-01 2017-08-31 0001175680 us-gaap:CommonStockMember 2017-06-01 2017-08-31 0001175680 us-gaap:AdditionalPaidInCapitalMember 2017-06-01 2017-08-31 0001175680 2017-06-01 2017-08-31 0001175680 cydy:FiscalYearToDateMember 2018-09-01 2018-11-30 0001175680 cydy:EmployeeSavingsPlanMember 2018-09-01 2018-11-30 0001175680 us-gaap:TreasuryStockMember 2018-09-01 2018-11-30 0001175680 us-gaap:RetainedEarningsMember 2018-09-01 2018-11-30 0001175680 us-gaap:PreferredStockMember 2018-09-01 2018-11-30 0001175680 us-gaap:CommonStockMember 2018-09-01 2018-11-30 0001175680 us-gaap:AdditionalPaidInCapitalMember 2018-09-01 2018-11-30 0001175680 cydy:TwoThousandTwelveStockIncentivePlanMember 2018-09-01 2018-11-30 0001175680 us-gaap:PatentsMember 2018-09-01 2018-11-30 0001175680 cydy:ProstageneLlcMember cydy:FiscalYearToDateMember 2018-09-01 2018-11-30 0001175680 cydy:ProstageneLlcMember us-gaap:CommonStockMember 2018-09-01 2018-11-30 0001175680 cydy:ProstageneLlcMember us-gaap:AdditionalPaidInCapitalMember 2018-09-01 2018-11-30 0001175680 cydy:ProstageneLlcMember 2018-09-01 2018-11-30 0001175680 2018-09-01 2018-11-30 0001175680 cydy:FiscalYearToDateMember 2017-09-01 2017-11-30 0001175680 cydy:EmployeeSavingsPlanMember 2017-09-01 2017-11-30 0001175680 us-gaap:TreasuryStockMember 2017-09-01 2017-11-30 0001175680 us-gaap:RetainedEarningsMember 2017-09-01 2017-11-30 0001175680 us-gaap:PreferredStockMember 2017-09-01 2017-11-30 0001175680 us-gaap:CommonStockMember 2017-09-01 2017-11-30 0001175680 us-gaap:AdditionalPaidInCapitalMember 2017-09-01 2017-11-30 0001175680 cydy:TwoThousandTwelveStockIncentivePlanMember 2017-09-01 2017-11-30 0001175680 us-gaap:PatentsMember 2017-09-01 2017-11-30 0001175680 2017-09-01 2017-11-30 0001175680 cydy:FiscalYearToDateMember 2017-12-01 2018-02-28 0001175680 us-gaap:TreasuryStockMember 2017-12-01 2018-02-28 0001175680 us-gaap:RetainedEarningsMember 2017-12-01 2018-02-28 0001175680 us-gaap:PreferredStockMember 2017-12-01 2018-02-28 0001175680 us-gaap:CommonStockMember 2017-12-01 2018-02-28 0001175680 us-gaap:AdditionalPaidInCapitalMember 2017-12-01 2018-02-28 0001175680 2017-12-01 2018-02-28 0001175680 2015-06-01 2016-05-31 0001175680 cydy:ProstageneLlcMember us-gaap:ScenarioForecastMember 2018-06-01 2019-05-31 0001175680 cydy:InvestorWarrantsIssuedWithRegisteredDirectEquityOfferingMember 2017-06-01 2018-05-31 0001175680 cydy:AgentWarrantsIssuedWithRegisteredDirectEquityOfferingMember 2017-06-01 2018-05-31 0001175680 cydy:BeforeInducementMember us-gaap:InvestorMember 2017-06-01 2018-05-31 0001175680 us-gaap:InvestorMember 2017-06-01 2018-05-31 0001175680 cydy:MeasurementInputProbabilityOfHolderRequestingCashPaymentMember 2017-06-01 2018-05-31 0001175680 cydy:MeasurementInputProbabilityOfFundamentalTransactionMember 2017-06-01 2018-05-31 0001175680 us-gaap:MeasurementInputRiskFreeInterestRateMember 2017-06-01 2018-05-31 0001175680 us-gaap:MeasurementInputExpectedTermMember 2017-06-01 2018-05-31 0001175680 us-gaap:MeasurementInputExercisePriceMember 2017-06-01 2018-05-31 0001175680 cydy:ShortTermConvertibleNotesMember 2017-06-01 2018-05-31 0001175680 cydy:ConversionOfPreferredStockToCommonStockMember 2017-06-01 2018-05-31 0001175680 2017-06-01 2018-05-31 0001175680 us-gaap:SeriesBPreferredStockMember 2009-06-01 2010-05-31 0001175680 2017-01-01 2017-12-31 0001175680 2018-01-01 2018-11-30 0001175680 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2018-11-09 2018-12-11 0001175680 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember cydy:PlacementAgentMember 2018-11-09 2018-12-11 0001175680 cydy:InvestorWarrantsMember cydy:ShortTermConvertibleNotesMember 2018-11-09 2018-11-30 0001175680 cydy:InceptionDateValueOfRedemptionProvisionMember 2018-06-01 2018-11-30 0001175680 cydy:ContractManufacturingCompaniesMember 2018-06-01 2018-11-30 0001175680 cydy:EmployeeSavingsPlanMember 2018-06-01 2018-11-30 0001175680 us-gaap:PrivatePlacementMember cydy:PlacementAgentMember 2018-06-01 2018-11-30 0001175680 us-gaap:PrivatePlacementMember 2018-06-01 2018-11-30 0001175680 us-gaap:SeriesBPreferredStockMember 2018-06-01 2018-11-30 0001175680 cydy:TwoThousandTwelveStockIncentivePlanMember 2018-06-01 2018-11-30 0001175680 cydy:DevelopmentMilestonePaymentsMember cydy:ScenarioThreeMember 2018-06-01 2018-11-30 0001175680 cydy:DevelopmentMilestonePaymentsMember 2018-06-01 2018-11-30 0001175680 cydy:MilestonePaymentsMember cydy:ScenarioTwoMember 2018-06-01 2018-11-30 0001175680 cydy:MilestonePaymentsMember cydy:ScenarioFourMember 2018-06-01 2018-11-30 0001175680 cydy:MeasurementInputProbabilityOfHolderRequestingCashPaymentMember 2018-06-01 2018-11-30 0001175680 cydy:MeasurementInputProbabilityOfFundamentalTransactionMember 2018-06-01 2018-11-30 0001175680 us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-06-01 2018-11-30 0001175680 us-gaap:MeasurementInputExpectedDividendRateMember 2018-06-01 2018-11-30 0001175680 us-gaap:MeasurementInputExpectedTermMember 2018-06-01 2018-11-30 0001175680 us-gaap:MeasurementInputExercisePriceMember 2018-06-01 2018-11-30 0001175680 us-gaap:PatentsMember 2018-06-01 2018-11-30 0001175680 cydy:ConvertibleNoteRedemptionProvisionDerivativeLiabilityMember 2018-06-01 2018-11-30 0001175680 cydy:RegisteredDirectEquityOfferingMember cydy:InvestorWarrantsIssuedWithRegisteredDirectEquityOfferingMember 2018-06-01 2018-11-30 0001175680 cydy:ShortTermConvertibleNotesMember 2018-06-01 2018-11-30 0001175680 cydy:NoteMember 2018-06-01 2018-11-30 0001175680 cydy:ConversionOfPreferredStockToCommonStockMember 2018-06-01 2018-11-30 0001175680 srt:MinimumMember cydy:DetachableCommonStockWarrantsMember cydy:ShortTermConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-06-01 2018-11-30 0001175680 srt:MaximumMember cydy:DetachableCommonStockWarrantsMember cydy:ShortTermConvertibleNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-06-01 2018-11-30 0001175680 cydy:DetachableCommonStockWarrantsMember cydy:ShortTermConvertibleNotesMember us-gaap:MeasurementInputExpectedTermMember 2018-06-01 2018-11-30 0001175680 srt:MinimumMember cydy:DetachableCommonStockWarrantsMember cydy:ShortTermConvertibleNotesMember us-gaap:MeasurementInputExercisePriceMember 2018-06-01 2018-11-30 0001175680 srt:MaximumMember cydy:DetachableCommonStockWarrantsMember cydy:ShortTermConvertibleNotesMember us-gaap:MeasurementInputExercisePriceMember 2018-06-01 2018-11-30 0001175680 cydy:DetachableCommonStockWarrantsMember cydy:ShortTermConvertibleNotesMember 2018-06-01 2018-11-30 0001175680 cydy:InvestorWarrantsMember 2018-06-01 2018-11-30 0001175680 cydy:EmployeeStockOptionOneMember cydy:TwoThousandTwelveStockIncentivePlanMember cydy:NonEmployeeDirectorsMember 2018-06-01 2018-11-30 0001175680 cydy:EmployeeStockOptionOneMember cydy:TwoThousandTwelveStockIncentivePlanMember cydy:RangeTwoMember us-gaap:DirectorMember 2018-06-01 2018-11-30 0001175680 cydy:EmployeeStockOptionOneMember cydy:TwoThousandTwelveStockIncentivePlanMember cydy:RangeOneMember us-gaap:DirectorMember 2018-06-01 2018-11-30 0001175680 cydy:EmployeeStockOptionOneMember cydy:TwoThousandTwelveStockIncentivePlanMember us-gaap:DirectorMember 2018-06-01 2018-11-30 0001175680 srt:MinimumMember cydy:EmployeeStockOptionOneMember cydy:TwoThousandTwelveStockIncentivePlanMember cydy:NonEmployeeDirectorsMember 2018-06-01 2018-11-30 0001175680 srt:MaximumMember cydy:EmployeeStockOptionOneMember cydy:TwoThousandTwelveStockIncentivePlanMember cydy:NonEmployeeDirectorsMember 2018-06-01 2018-11-30 0001175680 us-gaap:EmployeeStockOptionMember cydy:TwoThousandTwelveStockIncentivePlanMember cydy:ExecutiveManagementAndEmployeeMember 2018-06-01 2018-11-30 0001175680 us-gaap:EmployeeStockOptionMember cydy:TwoThousandTwelveStockIncentivePlanMember cydy:ExecutiveChairmanMember 2018-06-01 2018-11-30 0001175680 us-gaap:EmployeeStockOptionMember cydy:TwoThousandTwelveStockIncentivePlanMember cydy:ChiefMedicalOfficerMember 2018-06-01 2018-11-30 0001175680 us-gaap:EmployeeStockOptionMember cydy:TwoThousandTwelveStockIncentivePlanMember us-gaap:OfficerMember 2018-06-01 2018-11-30 0001175680 us-gaap:EmployeeStockOptionMember cydy:TwoThousandTwelveStockIncentivePlanMember us-gaap:DirectorMember 2018-06-01 2018-11-30 0001175680 cydy:ProstageneLlcMember cydy:DrPestellMember cydy:StockRestrictionAgreementMember 2018-06-01 2018-11-30 0001175680 cydy:ProstageneLlcMember 2018-06-01 2018-11-30 0001175680 2018-06-01 2018-11-30 0001175680 cydy:EmployeeSavingsPlanMember 2017-06-01 2017-11-30 0001175680 cydy:TwoThousandTwelveStockIncentivePlanMember 2017-06-01 2017-11-30 0001175680 us-gaap:PatentsMember 2017-06-01 2017-11-30 0001175680 cydy:ShortTermConvertibleNotesMember 2017-06-01 2017-11-30 0001175680 cydy:NoteMember 2017-06-01 2017-11-30 0001175680 cydy:DetachableCommonStockWarrantsMember cydy:ShortTermConvertibleNotesMember 2017-06-01 2017-11-30 0001175680 2017-06-01 2017-11-30 0001175680 cydy:MeasurementInputProbabilityOfHolderRequestingCashPaymentMember 2016-09-15 2016-09-15 0001175680 cydy:MeasurementInputProbabilityOfFundamentalTransactionMember 2016-09-15 2016-09-15 0001175680 us-gaap:MeasurementInputRiskFreeInterestRateMember 2016-09-15 2016-09-15 0001175680 us-gaap:MeasurementInputExpectedTermMember 2016-09-15 2016-09-15 0001175680 us-gaap:MeasurementInputExercisePriceMember 2016-09-15 2016-09-15 0001175680 cydy:NoteMember 2018-06-26 2018-06-26 0001175680 cydy:PlacementAgentMember 2018-06-15 2018-06-15 0001175680 cydy:SubscriptionAgreementMember 2018-06-15 2018-06-15 0001175680 cydy:ShortTermConvertibleNotesMember 2018-02-01 2018-02-01 0001175680 cydy:ShortTermConvertibleNotesMember cydy:PlacementAgentMember 2018-01-31 2018-01-31 0001175680 cydy:ShortTermConvertibleNotesMember 2018-01-31 2018-01-31 0001175680 cydy:DetachableCommonStockWarrantsMember cydy:ConvertibleNotesTwoThousandAndThirteenMember us-gaap:InvestorMember 2018-01-31 2018-01-31 0001175680 us-gaap:EmployeeStockOptionMember cydy:TwoThousandTwelveStockIncentivePlanMember us-gaap:ScenarioForecastMember us-gaap:OfficerMember 2019-04-08 2019-04-08 0001175680 cydy:ConvertibleNoteMember us-gaap:SubsequentEventMember 2018-12-27 2018-12-27 0001175680 us-gaap:SubsequentEventMember cydy:ChiefTechnologyOfficerMember 2018-12-22 2018-12-22 0001175680 us-gaap:SubsequentEventMember us-gaap:BoardOfDirectorsChairmanMember 2018-12-19 2018-12-19 0001175680 us-gaap:SubsequentEventMember us-gaap:BoardOfDirectorsChairmanMember 2018-12-10 2018-12-10 0001175680 cydy:ProstageneLlcMember cydy:DrRichardgPestellMember cydy:StockRestrictionAgreementMember 2018-11-16 2018-11-16 0001175680 cydy:ProstageneLlcMember 2018-11-16 2018-11-16 0001175680 us-gaap:MeasurementInputExpectedDividendRateMember 2018-11-15 2018-11-15 0001175680 us-gaap:MeasurementInputExpectedTermMember 2018-11-15 2018-11-15 0001175680 us-gaap:MeasurementInputExercisePriceMember 2018-11-15 2018-11-15 0001175680 cydy:ConvertibleNoteRedemptionProvisionDerivativeLiabilityMember 2018-11-15 2018-11-15 0001175680 cydy:NoteMember 2018-11-15 2018-11-15 0001175680 cydy:AnthonyCaraccioloMember us-gaap:PrivatePlacementMember 2017-11-08 2017-11-08 0001175680 cydy:PlacementAgentAgreementMember us-gaap:SubsequentEventMember 2019-01-08 2019-01-08 0001175680 cydy:ConvertibleNoteMember us-gaap:SubsequentEventMember 2019-01-08 2019-01-08 0001175680 cydy:ConvertibleNoteMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2019-01-08 2019-01-08 0001175680 cydy:ShortTermConvertibleNotesMember 2018-01-30 2018-01-30 0001175680 cydy:ShortTermConvertiblePromissoryNotesMember cydy:AlphaVentureCapitalPartnersLPMember 2017-07-28 2017-07-28 0001175680 cydy:ShortTermConvertiblePromissoryNotesMember cydy:JordanGNaydenovMember us-gaap:PrivatePlacementMember 2017-07-26 2017-07-26 0001175680 us-gaap:PatentsMember 2012-10-16 2012-10-16 0001175680 cydy:FiscalYearToDateMember 2018-05-31 0001175680 us-gaap:WarrantMember 2018-05-31 0001175680 us-gaap:TreasuryStockMember 2018-05-31 0001175680 us-gaap:RetainedEarningsMember 2018-05-31 0001175680 us-gaap:PreferredStockMember 2018-05-31 0001175680 us-gaap:CommonStockMember 2018-05-31 0001175680 us-gaap:AdditionalPaidInCapitalMember 2018-05-31 0001175680 us-gaap:SeriesBPreferredStockMember 2018-05-31 0001175680 cydy:BeforeInducementMember us-gaap:InvestorMember 2018-05-31 0001175680 us-gaap:InvestorMember 2018-05-31 0001175680 us-gaap:MeasurementInputExpectedDividendRateMember 2018-05-31 0001175680 us-gaap:MeasurementInputPriceVolatilityMember 2018-05-31 0001175680 us-gaap:EquitySecuritiesMember 2018-05-31 0001175680 us-gaap:FairValueInputsLevel2Member 2018-05-31 0001175680 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2018-05-31 0001175680 us-gaap:FairValueInputsLevel3Member 2018-05-31 0001175680 us-gaap:FairValueInputsLevel1Member 2018-05-31 0001175680 cydy:RegisteredDirectEquityOfferingMember cydy:InvestorWarrantsIssuedWithRegisteredDirectEquityOfferingMember 2018-05-31 0001175680 cydy:ShortTermConvertibleNotesMember 2018-05-31 0001175680 cydy:ConversionOfPreferredStockToCommonStockMember 2018-05-31 0001175680 cydy:DetachableCommonStockWarrantsMember cydy:ShortTermConvertibleNotesMember 2018-05-31 0001175680 2018-05-31 0001175680 cydy:FiscalYearToDateMember 2017-05-31 0001175680 us-gaap:RetainedEarningsMember 2017-05-31 0001175680 us-gaap:PreferredStockMember 2017-05-31 0001175680 us-gaap:CommonStockMember 2017-05-31 0001175680 us-gaap:AdditionalPaidInCapitalMember 2017-05-31 0001175680 2017-05-31 0001175680 us-gaap:MeasurementInputExpectedDividendRateMember 2016-09-15 0001175680 us-gaap:MeasurementInputPriceVolatilityMember 2016-09-15 0001175680 cydy:RegisteredDirectEquityOfferingMember cydy:InvestorWarrantsIssuedWithRegisteredDirectEquityOfferingMember 2016-09-15 0001175680 us-gaap:SeriesBPreferredStockMember 2010-05-31 0001175680 us-gaap:ScenarioForecastMember 2019-03-15 0001175680 cydy:FiscalYearToDateMember 2018-11-30 0001175680 cydy:ConsultantMember 2018-11-30 0001175680 cydy:ConvertibleNoteRedemptionProvisionMember 2018-11-30 0001175680 cydy:WarrantsIssuedMember us-gaap:PrivatePlacementMember 2018-11-30 0001175680 us-gaap:PrivatePlacementMember cydy:PlacementAgentMember 2018-11-30 0001175680 us-gaap:PrivatePlacementMember 2018-11-30 0001175680 us-gaap:WarrantMember 2018-11-30 0001175680 us-gaap:TreasuryStockMember 2018-11-30 0001175680 us-gaap:RetainedEarningsMember 2018-11-30 0001175680 us-gaap:PreferredStockMember 2018-11-30 0001175680 us-gaap:CommonStockMember 2018-11-30 0001175680 us-gaap:AdditionalPaidInCapitalMember 2018-11-30 0001175680 us-gaap:SeriesBPreferredStockMember 2018-11-30 0001175680 srt:MinimumMember 2018-11-30 0001175680 srt:MaximumMember 2018-11-30 0001175680 cydy:TwoThousandTwelveStockIncentivePlanMember 2018-11-30 0001175680 cydy:DevelopmentMilestonePaymentsMember cydy:ScenarioThreeMember 2018-11-30 0001175680 cydy:MilestonePaymentsMember cydy:ScenarioTwoMember 2018-11-30 0001175680 srt:MinimumMember cydy:TerminationTwoMember cydy:ProjectWorkOrderMember 2018-11-30 0001175680 srt:MaximumMember cydy:TerminationTwoMember cydy:ProjectWorkOrderMember 2018-11-30 0001175680 srt:MaximumMember cydy:TerminationOneMember cydy:ContractManufacturingCompaniesMember 2018-11-30 0001175680 srt:MaximumMember cydy:TerminationOneMember cydy:ProjectWorkOrderMember 2018-11-30 0001175680 us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-11-30 0001175680 us-gaap:MeasurementInputExpectedDividendRateMember 2018-11-30 0001175680 us-gaap:MeasurementInputPriceVolatilityMember 2018-11-30 0001175680 us-gaap:MeasurementInputDiscountRateMember 2018-11-30 0001175680 us-gaap:EquitySecuritiesMember 2018-11-30 0001175680 us-gaap:FairValueInputsLevel2Member 2018-11-30 0001175680 us-gaap:FairValueInputsLevel3Member cydy:ConvertibleNoteRedemptionProvisionMember 2018-11-30 0001175680 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2018-11-30 0001175680 us-gaap:FairValueInputsLevel3Member 2018-11-30 0001175680 us-gaap:FairValueInputsLevel1Member 2018-11-30 0001175680 cydy:ConvertibleNoteRedemptionProvisionDerivativeLiabilityMember 2018-11-30 0001175680 us-gaap:ShortTermDebtMember 2018-11-30 0001175680 us-gaap:LongTermDebtMember 2018-11-30 0001175680 us-gaap:CommonStockMember 2018-11-30 0001175680 cydy:RegisteredDirectEquityOfferingMember cydy:InvestorWarrantsIssuedWithRegisteredDirectEquityOfferingMember 2018-11-30 0001175680 cydy:ShortTermConvertibleNotesMember 2018-11-30 0001175680 cydy:NoteMember 2018-11-30 0001175680 cydy:ConversionOfPreferredStockToCommonStockMember 2018-11-30 0001175680 cydy:DetachableCommonStockWarrantsMember cydy:ShortTermConvertibleNotesMember us-gaap:MeasurementInputExpectedDividendRateMember 2018-11-30 0001175680 cydy:DetachableCommonStockWarrantsMember cydy:ShortTermConvertibleNotesMember us-gaap:MeasurementInputPriceVolatilityMember 2018-11-30 0001175680 cydy:DetachableCommonStockWarrantsMember cydy:ShortTermConvertibleNotesMember 2018-11-30 0001175680 cydy:InvestorWarrantsMember cydy:ShortTermConvertibleNotesMember 2018-11-30 0001175680 us-gaap:EmployeeStockOptionMember cydy:TwoThousandTwelveStockIncentivePlanMember 2018-11-30 0001175680 cydy:ProstageneLlcMember cydy:DrPestellMember cydy:StockRestrictionAgreementMember 2018-11-30 0001175680 us-gaap:InvestmentAdvisoryManagementAndAdministrativeServiceMember cydy:ProstageneLlcMember 2018-11-30 0001175680 cydy:ProstageneLlcMember 2018-11-30 0001175680 2018-11-30 0001175680 cydy:FiscalYearToDateMember 2018-08-31 0001175680 us-gaap:TreasuryStockMember 2018-08-31 0001175680 us-gaap:RetainedEarningsMember 2018-08-31 0001175680 us-gaap:PreferredStockMember 2018-08-31 0001175680 us-gaap:CommonStockMember 2018-08-31 0001175680 us-gaap:AdditionalPaidInCapitalMember 2018-08-31 0001175680 us-gaap:ShortTermDebtMember 2018-08-31 0001175680 us-gaap:LongTermDebtMember 2018-08-31 0001175680 cydy:RegisteredDirectEquityOfferingMember cydy:InvestorWarrantsIssuedWithRegisteredDirectEquityOfferingMember 2018-08-31 0001175680 2018-08-31 0001175680 cydy:ChiefScienceOfficerMember 2018-07-10 0001175680 us-gaap:DirectorMember 2018-07-10 0001175680 cydy:NoteMember 2018-06-26 0001175680 cydy:PlacementAgentMember 2018-06-15 0001175680 cydy:SubscriptionAgreementMember 2018-06-15 0001175680 cydy:SubscriptionAgreementMember 2018-06-15 0001175680 2018-06-07 0001175680 2018-03-15 0001175680 cydy:FiscalYearToDateMember 2018-02-28 0001175680 us-gaap:RetainedEarningsMember 2018-02-28 0001175680 us-gaap:PreferredStockMember 2018-02-28 0001175680 us-gaap:CommonStockMember 2018-02-28 0001175680 us-gaap:AdditionalPaidInCapitalMember 2018-02-28 0001175680 2018-02-28 0001175680 cydy:ShortTermConvertibleNotesMember 2018-01-31 0001175680 srt:MinimumMember cydy:DetachableCommonStockWarrantsMember cydy:ConvertibleNotesTwoThousandAndThirteenMember us-gaap:InvestorMember 2018-01-31 0001175680 srt:MaximumMember cydy:DetachableCommonStockWarrantsMember cydy:ConvertibleNotesTwoThousandAndThirteenMember us-gaap:InvestorMember 2018-01-31 0001175680 cydy:FiscalYearToDateMember 2017-11-30 0001175680 us-gaap:RetainedEarningsMember 2017-11-30 0001175680 us-gaap:PreferredStockMember 2017-11-30 0001175680 us-gaap:CommonStockMember 2017-11-30 0001175680 us-gaap:AdditionalPaidInCapitalMember 2017-11-30 0001175680 us-gaap:EquitySecuritiesMember 2017-11-30 0001175680 2017-11-30 0001175680 cydy:FiscalYearToDateMember 2017-08-31 0001175680 us-gaap:RetainedEarningsMember 2017-08-31 0001175680 us-gaap:PreferredStockMember 2017-08-31 0001175680 us-gaap:CommonStockMember 2017-08-31 0001175680 us-gaap:AdditionalPaidInCapitalMember 2017-08-31 0001175680 2017-08-31 0001175680 cydy:AfterAmendmentMember us-gaap:EmployeeStockOptionMember cydy:TwoThousandTwelveStockIncentivePlanMember 2016-03-31 0001175680 cydy:BeforeAmendmentMember us-gaap:EmployeeStockOptionMember cydy:TwoThousandTwelveStockIncentivePlanMember 2016-03-31 0001175680 cydy:AfterAmendmentMember us-gaap:EmployeeStockOptionMember cydy:TwoThousandTwelveStockIncentivePlanMember 2015-02-28 0001175680 cydy:BeforeAmendmentMember us-gaap:EmployeeStockOptionMember cydy:TwoThousandTwelveStockIncentivePlanMember 2015-02-28 0001175680 2018-12-31 0001175680 cydy:ConvertibleNoteMember us-gaap:SubsequentEventMember 2018-12-27 0001175680 us-gaap:SubsequentEventMember us-gaap:BoardOfDirectorsChairmanMember 2018-12-19 0001175680 cydy:WarrantsIssuedMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2018-12-11 0001175680 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2018-12-11 0001175680 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember cydy:PlacementAgentMember 2018-12-11 0001175680 cydy:ProstageneLlcMember cydy:DrRichardgPestellMember cydy:StockRestrictionAgreementMember 2018-11-16 0001175680 cydy:ProstageneLlcMember cydy:DrRichardgPestellMember 2018-11-16 0001175680 cydy:ProstageneLlcMember cydy:EscrowAccountDepositMember cydy:DrRichardgPestellMember 2018-11-16 0001175680 cydy:ProstageneLlcMember 2018-11-16 0001175680 us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-11-15 0001175680 us-gaap:MeasurementInputPriceVolatilityMember 2018-11-15 0001175680 us-gaap:MeasurementInputDiscountRateMember 2018-11-15 0001175680 cydy:ConvertibleNoteRedemptionProvisionDerivativeLiabilityMember 2018-11-15 0001175680 2018-11-15 0001175680 srt:MinimumMember 2018-11-08 0001175680 srt:MaximumMember 2018-11-08 0001175680 us-gaap:SubsequentEventMember 2019-01-08 0001175680 us-gaap:SubsequentEventMember cydy:MichaelKlumpMember 2019-01-08 0001175680 cydy:PlacementAgentAgreementMember us-gaap:SubsequentEventMember 2019-01-08 0001175680 cydy:ConvertibleNoteMember us-gaap:SubsequentEventMember 2019-01-08 0001175680 cydy:ConvertibleNoteMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2019-01-08 0001175680 cydy:AfterAmendmentMember us-gaap:EmployeeStockOptionMember cydy:TwoThousandTwelveStockIncentivePlanMember 2017-08-24 0001175680 cydy:BeforeAmendmentMember us-gaap:EmployeeStockOptionMember cydy:TwoThousandTwelveStockIncentivePlanMember 2017-08-24 0001175680 2017-08-24 0001175680 2017-08-23 0001175680 cydy:AlphaVentureCapitalPartnersLPMember 2017-07-28 0001175680 cydy:JordanGNaydenovMember us-gaap:PrivatePlacementMember 2017-07-26 0001175680 2010-04-30 shares iso4217:USD shares pure iso4217:USD iso4217:GBP cydy:Installment The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of November 30, 2018 and May 31, 2018.

EX-101.SCH 7 cydy-20181130.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity link:calculationLink link:presentationLink link:definitionLink 108 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Organization link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Convertible Instruments link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Derivative Liabilities link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Stock Options and Warrants link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Acquisition of Patents and Intangibles link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - License Agreements link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Private Securities Offerings link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Registered Direct Equity Offerings link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Employee Benefit Plan link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Convertible Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Derivative Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Stock Options and Warrants (Tables) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Acquisition of Patents and Intangibles (Tables) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Liabilities Measured At Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Liabilities Measured At Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Reconciliation of Liability Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3) (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Convertible Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Weighted Average Assumptions to Value Investor Warrants (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Activity Related to Notes (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Derivative Liability - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Summary of Fair Value Warrant Derivative Liability and Related Common Shares (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Assumptions used in Estimating Fair Value of Warrant Derivative Liability (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Summary of Fair Value of Convertible Note Redemption Provision Derivative Liability (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Assumptions used in Estimating Fair Value of Convertible Note Redemption Provision Derivative Liability (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Stock Options and Warrants - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Stock Options and Warrants (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Acquisition of patents and Intangibles - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Intangible Assets Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - License Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Private Securities Offerings - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Registered Direct Equity Offerings - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - Employee Benefit Plan - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 151 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 152 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 cydy-20181130_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 cydy-20181130_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 cydy-20181130_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Text Block] Recent Accounting Pronouncements Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable, Current Accounts payable Accrued interest to convertible note payable. Accrued Interest To Convertible Note Payable Accrued interest converted into note payable Accrued license fees current. Accrued License Fees Current Accrued license fee Accrued license fees Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Acquisition Fees Received Subject To Acquisition Fee Tail Agreement Acquisition Fees Received Subject To Acquisition Fee Tail Agreement Acquisition fees received subject to acquisition fee tail agreement Acquisition fees received subject to acquisition warrants exercisable Acquisition Fees Received Subject To Acquisition Warrants Exercisable Acquisition fees received subject to acquisition warrants exercisable Additional Paid in Capital Additional paid-in capital Additional Paid-in Capital [Member] Additional Paid-in Capital Adjustments to additional paid in capital debt discounts on convertible notes payable. Adjustments To Additional Paid In Capital Debt Discounts On Convertible Notes Payable Debt discount related to convertible notes payable Adjustments to additional paid in capital legal fees in connection with equity offering. Adjustments to additional paid in capital legal fees in connection with equity offering Legal fees in connection with equity offerings Adjustments to additional paid in capital offering cost related to direct offering. Adjustments to additional paid in capital offering cost related to direct offering Offering costs related to registered direct offering Adjustments to additional paid in capital offering cost related to equity offering. Adjustments To Additional Paid In Capital Offering Cost Related To Equity Offering Offering costs related to private equity offering Adjustments to additional paid in capital offering cost related to private offering. Adjustments to additional paid in capital offering cost related to private offering Offering costs related to private equity offering Adjustments to additional paid in capital offering cost related to warrant tender offer. Adjustments to additional paid in capital offering cost related to warrant tender offer Offering costs related to warrant tender offer Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation Adjustments to Additional Paid in Capital, Warrant Issued Interest expense related to warrant extension Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used by operating activities: Adjustment to additional paid in capital interest expense related to conversion of note payable. Adjustment to additional paid in capital interest expense related to conversion of note payable Interest expense related to conversion of notes payable Adjustment to additional paid in capital interest expense related to warrant tender offer. Adjustment to additional paid in capital interest expense related to warrant tender offer Interest expense related to warrant tender offer Adjustment to additional paid in capital stock issued for board compensation. Adjustment to additional paid in capital stock issued for board compensation Stock issued for board compensation After amendment. After Amendment [Member] After Amendment Agent warrants issued with registered direct equity offering. Agent Warrants Issued With Registered Direct Equity Offering [Member] Placement Agent Warrants Issued with Registered Direct Equity Offering Alpha Venture Capital Partners, LP [Member] Alpha Venture Capital Partners, LP [Member] Alpha Venture Capital Partners, L.P. Amendment Flag Amendment Flag Amortization of Debt Discount (Premium) Amortization of debt discount Amortization of discount on convertible notes Amortization of discount on convertible notes Amortization of Debt Issuance Costs Amortization of debt issuance costs Amortization of Intangible Assets Amortization expense related to acquired patents Anthony D Caracciolo. Anthony D Caracciolo [Member] Anthony D Caracciolo Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Common stock options and warrants to purchase Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Asset purchase agreement aggregate consideration paying period. Asset Purchase Agreement Aggregate Consideration Paying Period Asset Purchase Agreement Aggregate Consideration Paying Period Assets Total assets Assets [Abstract] Assets Assets, Current Total current assets Assets, Current [Abstract] Current assets: Assets, Fair Value Disclosure Assets fair value Award Type [Axis] Award Type [Axis] Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Before Amendment [Member] Before Amendment [Member] Before Amendment Before Inducement [Member] Before Inducement [Member] Before Inducement Board of Directors Chairman [Member] Chairman of the board Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Transaction Costs Acquisition Expenses Business Combination, Acquisition Related Costs Allocation of Acquisition Costs Business Combination, Consideration Transferred Total Cost of Acquisition Business Combination, Consideration Transferred, Equity Interests Issued and Issuable CytoDyn Inc. Equity Business Combination Disclosure [Text Block] Acquisition of Patents and Intangibles Business combination of deferred tax asset release. Business Combination Of Deferred Tax Asset Release Release of Deferred Tax Asset Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Intangible asset acquisition Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Other Business Combinations [Abstract] Business Combinations [Abstract] Cash and Cash Equivalents, at Carrying Value Cash, end of period Cash, beginning of period Cash Cash and Cash Equivalents, Policy [Policy Text Block] Cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net change in cash Cash, Uninsured Amount Balance in excess of federally insured limits Chief Medical Officer [Member] Chief Medical Officer [Member] Chief Medical Officer Chief science officer. Chief Science Officer [Member] Chief Science Officer Chief Technology Officer [Member] Chief Technology Officer [Member] Chief Technology Officer Class of Stock [Domain] Class of Stock [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Class of Warrant Covering Common Stock Shares Purchased, Percentage Class of Warrant Covering Common Stock Shares Purchased, Percentage Warrant covering common stock shares purchased, percentage Class of Warrant, Fair Value Assumption, Expected Dividend Yield Class of Warrant, Fair Value Assumption, Expected Dividend Yield Expected dividend yield Class of Warrant, Fair Value Assumption, Stock Volatility Class of Warrant, Fair Value Assumption, Stock Volatility Stock price volatility Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Class of Warrant or Right, Exercise Price of Warrants or Rights Class of warrants, exercise price Exercise price of warrants, per share Class of Warrant or Right, Expiration Date Class of Warrant or Right, Expiration Date Class of warrant or right expiration date Class of Warrant or Right, Fair Value Assumption, Expected Dividend Yield Class of Warrant or Right, Fair Value Assumption, Expected Dividend Yield Expected dividend yield Class of Warrant or Right, Fair Value Assumption, Stock Volatility Class of Warrant or Right, Fair Value Assumption, Stock Volatility Stock price volatility Class of Warrant or Right, Number of Securities Called by Warrants or Rights Common stock warrants to purchase shares Warrants to purchase common shares, shares Class of warrant or right term. Class of warrant or right Term Term of warrants Class Of Warrants Fair Value Assumptions Expected Term Class Of Warrants Fair Value Assumptions Expected Term Expected term Expected term (in years) Class Of Warrants Fair Value Assumptions Risk Free Interest Rate Class Of Warrants Fair Value Assumptions Risk Free Interest Rate Risk free rate Risk-free interest rate Class Of Warrants Fair Value Of Underlying Stock Per Share Class Of Warrants Fair Value Of Underlying Stock Per Share Fair value of underlying stock Grant-date fair value Collaborative Arrangement Disclosure [Text Block] License Agreements Commitments and Contingencies Commitments and Contingencies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and Contingencies [Line Items] Commitments and Contingencies [Table] Commitments and Contingencies [Table] Commitments and Contingencies [Table] Common Stock, Capital Shares Reserved for Future Issuance Common stock held for future issuance Restricted common stock, shares Common stock conversion closing bid price period. Common Stock Conversion Closing Bid Price Period Common stock conversion closing bid price period Common stock conversion price per share. Common Stock Conversion Price Per Share Common stock conversion price Common stock issuable upon conversion of convertible note ratio. Common Stock Issuable upon Conversion of Convertible Note Ratio Terms of conversion Common Stock Issued For Acquisitions Common Stock Issued For Acquisitions Common stock issued for acquisition Common Stock [Member] Common Stock Common Stock, Par or Stated Value Per Share Common stock per shares Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Issuance of common stock shares Common Stock issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock, $0.001 par value; 600,000,000 and 375,000,000 shares authorized, 290,808,960 and 216,881,790 issued and 290,649,949 and 216,722,779 outstanding at November 30, 2018 and May 31, 2018, respectively Compensation and Employee Benefit Plans [Text Block] Employee Benefit Plan Retirement Benefits [Abstract] Retirement Benefits [Abstract] Consecutive Trading Days Consecutive Trading Days Consecutive trading days Consolidation, Policy [Policy Text Block] Principles of Consolidation Constructive dividend to preferred stock holders. Constructive Dividend To Preferred Stock Holders Constructive dividend to Preferred stock holders Consultant. Consultant [Member] Consultant Contract manufacturing companies. Contract Manufacturing Companies [Member] Contract Manufacturing Companies Conversion factor percentage rate. Conversion Factor Percentage Rate Conversion Factor Conversion of Preferred Stock to Common Stock [Member] Conversion of Preferred Stock to Common Stock [Member] Conversion of Preferred Stock to Common Stock Stock Conversion Description [Axis] Stock Conversion Description [Axis] Conversion of Stock, Name [Domain] Conversion of Stock, Name [Domain] Convertible Notes Payable, Noncurrent Convertible note payable, net Convertible Note [Member] Convertible Note [Member] Convertible Note Convertible note redemption provision derivative liability. Convertible Note Redemption Provision Derivative Liability [Member] Convertible Note Redemption Provision Derivative Liability [Member] Convertible Note Redemption Provision. Convertible Note Redemption Provision [Member] Convertible Note Redemption Provision Convertible notes face amount. Convertible Notes Face Amount Convertible promissory note principle amount Convertible Notes Payable Outstanding balance of convertible note including accrued unpaid interest Registered direct equity offering Convertible Notes Payable, Current Convertible note payable, net Convertible Notes Two Thousand and Thirteen [Member] Convertible Notes Two Thousand and Thirteen [Member] 2013 Convertible Notes Convertible Preferred Stock, Shares Issued upon Conversion Number of common shares issued upon conversion of preferred stock Convertible promissory note maturity period. Convertible Promissory Note Maturity Period Convertible promissory note maturity period Convertible promissory note maximum redemption amount. Convertible Promissory Note Maximum Redemption Amount Convertible promissory note maximum redemption amount Convertible promissory note redemption description. Convertible Promissory Note Redemption Description Convertible promissory note redemption description Current Fiscal Year End Date Current Fiscal Year End Date Debt Conversion Accrued Interest Amount Debt Conversion Accrued Interest Amount Accrued but unpaid interest Debt Conversion, Converted Instrument, Amount Convertible note, redeemed amount Debt Conversion, Converted Instrument, Rate Purchased short term convertible promissory note interest Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Convertible Instruments Debt discount. Debt Discount [Policy Text Block] Debt Discount Debt Instrument Accrued Interest Debt Instrument Accrued Interest Debt Instrument, accrued interest Debt Instrument [Axis] Debt Instrument [Axis] Long-term Debt, Gross Face amount of convertible promissory note Long-term debt and capital lease obligations including current maturities Debt Instrument, Convertible, Conversion Price Conversion price Effective fixed conversion price for Common stock Debt Instrument Convertible Conversion Price Per Share Debt Instrument Convertible Conversion Price Per Share Conversion of stock Debt Instrument, Face Amount Convertible note, aggregate principal Debt Instrument, face amount Debt Instrument, Interest Rate, Stated Percentage Convertible notes, interest rate Debt stated percentage Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Maturity Date Convertible note maturity date Debt Instrument, maturity date Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt Instrument, Periodic Addition Payment Debt Instrument, Periodic Addition Payment Monthly redemption Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Unamortized Discount Debt discount Unamortized discount Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Debt discount associated with convertible notes payable Debt issuance costs. Debt Issuance Costs [Policy Text Block] Debt Issuance Cost Debt payment obligation against which common stock issued. Debt Payment Obligation Against which Common Stock Issued Payment obligation against which common stock issued Debt Related Commitment Fees and Debt Issuance Costs Amortization of debt issuance costs Amortization of debt issuance costs Deferred Charges, Policy [Policy Text Block] Offering Costs Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance Previously awarded stock options Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance Shares available for future issuance Deferred Debt Issuance Costs Deferred Debt Issuance Costs Direct costs associated with the convertible notes Deferred Income Tax Expense (Benefit) Deferred income tax benefit Deferred Income Tax Expense Benefit Deferred Offering Costs Deferred offering costs Defined Contribution Plan, Cost Qualified non-elective contribution expense Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Qualified non-elective contribution Defined Contribution Plan [Table] Defined Contribution Plan [Table] Depreciation, Depletion and Amortization, Nonproduction Amortization and depreciation Derivative Contract [Domain] Derivative Contract [Domain] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Text Block] Derivative Liabilities Derivative Liability Derivative liability Derivative Liability, Noncurrent Derivative liabilities Derivative [Line Items] Derivative [Line Items] Derivative [Table] Derivative [Table] Detachable Common Stock Warrants [Member] Detachable Common Stock Warrants [Member] Detachable Common Stock Warrants Development Milestone Payments [Member] Development Milestone Payments [Member] Development Milestone Payments Director [Member] Managing Director Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Dividends Payable Accrued dividend Document and Entity Information [Abstract] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Information [Table] Document Information [Table] Document Period End Date Document Period End Date Document Type Document Type Dr .Pestell [Member]. Dr .Pestell [Member] Dr .Pestell Dr RichardG Pestell [Member]. Dr RichardG Pestell [Member] Dr Richard G Pestell Earnings Per Share, Policy [Policy Text Block] Loss per Common Share Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Federal statutory income tax rate, percent Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Embedded Derivative, Fair Value of Embedded Derivative Liability Derivative Liability Embedded derivative liability Embedded derivative liability exercise price. Embedded Derivative Liability Exercise Price Embedded Derivative Liability, Exercise Price Embedded derivative liability expected dividend yield. Embedded Derivative Liability Expected Dividend Yield Embedded derivative liability, dividend yield Embedded derivative liability expected term. Embedded Derivative Liability Expected Term Embedded Derivative Liability Expected Term Embedded derivative liability, expected term Embedded Derivative Liability, Measurement Input Embedded Derivative Liability, Measurement Input Embedded derivative liability price per share. Embedded Derivative Liability Price Per Share Embedded derivative liability, price per share Employee-related Liabilities, Current Accrued liabilities and compensation Employee savings plan. Employee Savings Plan [Member] Employee Savings Plan Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Weighted average period over which unrecognized compensation expense is expected to be recognized Employee Stock Option [Member] Stock Options Employee Stock Option One [Member] Employee Stock Option One [Member] Employee Stock Option One Employment extension contract end Date Employment extension Contract end Date Extended service period Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding EX-101.PRE 11 cydy-20181130_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Nov. 30, 2018	Dec. 31, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Nov. 30, 2018
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Trading Symbol	CYDY
Entity Registrant Name	CYTODYN INC.
Entity Central Index Key	0001175680
Current Fiscal Year End Date	--05-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		292,923,481
Entity Emerging Growth Company	false
Entity Small Business	true

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets	Nov. 30, 2018 USD ($)	May 31, 2018 USD ($)
Current assets:
Cash	$ 772,361	$ 1,231,445
Prepaid expenses	200,890	227,173
Prepaid service fees	2,954,624	1,862,009
Total current assets	3,927,875	3,320,627
Furniture and equipment, net	10,127	11,228
Intangibles, net	16,452,951	1,567,143
Total assets	20,390,953	4,898,998
Current liabilities:
Accounts payable	18,852,414	15,841,859
Accrued liabilities and compensation	560,013	757,778
Accrued license fees	347,333	133,600
Accrued interest on convertible notes	23,001
Convertible note payable, net	4,200,000
Total current liabilities	23,982,761	16,733,237
Long-term liabilities:
Convertible note payable, net	1,396,974
Derivative liabilities	3,075,142	1,323,732
Total long-term liabilities	4,472,116	1,323,732
Total liabilities	28,454,877	18,056,969
Commitments and Contingencies
Stockholders' (Deficit) equity
Series B convertible preferred stock, $0.001 par value; 400,000 shares authorized, 92,100 shares issued and outstanding at November 30, 2018 and May 31, 2018, respectively	92	92
Common stock, $0.001 par value; 600,000,000 and 375,000,000 shares authorized, 290,808,960 and 216,881,790 issued and 290,649,949 and 216,722,779 outstanding at November 30, 2018 and May 31, 2018, respectively	290,810	216,881
Additional paid-in capital	193,503,678	159,764,611
Accumulated (deficit)	(201,858,345)	(173,139,396)
Less: treasury stock, at par (159,011 shares at $0.001)	(159)	(159)
Total stockholders' (deficit)	(8,063,924)	(13,157,971)
Total liabilities and stockholders' (deficit) equity	$ 20,390,953	$ 4,898,998

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Nov. 30, 2018	May 31, 2018
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	600,000,000	375,000,000
Common stock, shares issued	290,808,960	216,881,790
Common stock, shares outstanding	290,649,949	216,722,779
Treasury stock, shares	159,011	159,011
Treasury Stock
Common stock, par value	$ 0.001	$ 0.001
Series B Convertible Preferred Stock
Series B Convertible preferred stock, par value	$ 0.001	$ 0.001
Series B Convertible preferred stock, shares authorized	400,000	400,000
Series B Convertible preferred stock, shares issued	92,100	92,100
Series B Convertible preferred stock, shares outstanding	92,100	92,100

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
Consolidated Statements of Operations - USD ($)	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2018	Nov. 30, 2017
Operating expenses:
General and administrative	$ 2,663,745	$ 1,608,743	$ 4,594,804	$ 3,178,420
Research and development	12,869,244	9,077,172	24,337,910	17,225,348
Amortization and depreciation	154,801	89,136	243,772	178,282
Total operating expenses	15,687,790	10,775,051	29,176,486	20,582,050
Operating loss	(15,687,790)	(10,775,051)	(29,176,486)	(20,582,050)
Interest income	1,021	422	2,002	1,206
Change in fair value of derivative liabilities	281,055	829,600	(466,412)	466,934
Interest expense:
Amortization of discount on convertible notes	(52,954)	(728,843)	(117,534)	(1,172,995)
Amortization of debt issuance costs	(10,411)	(168,429)	(19,589)	(282,129)
Loss on extinguishment of convertible note	(1,519,603)		(1,519,603)
Inducement interest related to warrant exercise				(826,252)
Interest on convertible note payable	(143,617)	(105,384)	(248,247)	(180,673)
Total interest expense	(1,726,585)	(1,002,656)	(1,904,973)	(2,462,049)
Loss before income taxes	(17,132,299)	(10,947,685)	(31,545,869)	(22,575,959)
Income tax benefit	2,826,919		2,826,919
Net loss	$ (14,305,380)	$ (10,947,685)	$ (28,718,950)	$ (22,575,959)
Basic and diluted loss per share	$ (0.06)	$ (0.07)	$ (0.12)	$ (0.15)
Basic and diluted weighted average common shares outstanding	259,088,835	157,843,773	238,731,091	154,774,327

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Nov. 30, 2018	Nov. 30, 2017
Cash flows from operating activities:
Net loss	$ (28,718,950)	$ (22,575,959)
Adjustments to reconcile net loss to net cash used by operating activities:
Amortization and depreciation	243,772	178,282
Amortization of debt issuance costs	19,589	282,129
Amortization of discount on convertible notes	117,534	1,172,995
Inducement interest related to warrant exercise		826,252
Interest expense associated with derivative liabilities	0	0
Change in fair value of derivative liabilities	466,412	(466,934)
Stock-based compensation	1,510,486	529,617
Loss on extinguishment of convertible note	1,519,603
Deferred income tax benefit	(2,826,919)
Changes in current assets and liabilities:
(Increase) decrease in prepaid expenses	(1,807,629)	907,606
Increase in accounts payable and accrued expenses	3,283,113	6,256,192
Net cash used in operating activities	(26,192,989)	(12,889,820)
Cash flows from investing activities:
Furniture and equipment purchases	(2,262)
Net cash used in investing activities	(2,262)
Cash flows from financing activities:
Proceeds from sale of common stock and warrants	23,463,585	7,050,651
Proceeds from warrant exercises		1,647,500
Proceeds from convertible note payable	5,000,000	4,888,500
Payment of offering costs	(2,727,418)	(1,175,575)
Net cash provided by financing activities	25,736,167	12,411,076
Net change in cash	(459,084)	(478,744)
Cash, beginning of period	1,231,445	1,775,583
Cash, end of period	772,361	1,296,839
Non-cash investing and financing transactions:
Financing costs associated with placement agent warrants		70,383
Accrued interest converted into note payable	225,245
Debt discount associated with convertible notes payable	700,000	$ 1,574,628
Derivative liability associated a convertible note payable	1,284,998
ProstaGene, LLC
Non-cash investing and financing transactions:
Common stock issued for acquisition	$ 11,558,000

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Changes in Stockholders' (Deficit) Equity - USD ($)	Total	ProstaGene, LLC	Preferred Stock	Common Stock	Common Stock ProstaGene, LLC	Treasury Stock	Additional Paid-in Capital	Additional Paid-in Capital ProstaGene, LLC	Accumulated Deficit
Beginning balance (Fiscal Year To Date) at May. 31, 2017	$ (1,103,234)
Beginning balance at May. 31, 2017	(1,103,234)		$ 92	$ 149,468			$ 121,736,921		$ (122,989,715)
Beginning balance, shares at May. 31, 2017			92,100	149,468,244
Proceeds from warrant exercise \| Fiscal Year To Date	1,647,500
Proceeds from warrant exercise	1,647,500			$ 3,295			1,644,205
Proceeds from warrant exercise, shares				3,295,000
Offering costs related to registered direct offering, shares			0	0		0
Interest expense related to warrant extension \| Fiscal Year To Date	826,252
Interest expense related to warrant extension	826,252						826,252
Debt discount related to convertible notes payable \| Fiscal Year To Date	1,645,010
Debt discount related to convertible notes payable	1,645,010						1,645,010
Stock-based compensation \| Fiscal Year To Date	254,952
Stock-based compensation	254,952						254,952
Net loss \| Fiscal Year To Date	(11,628,273)
Net loss	(11,628,273)								(11,628,273)
Ending balance (Fiscal Year To Date) at Aug. 31, 2017	(8,357,793)
Ending balance at Aug. 31, 2017	(8,357,793)		$ 92	$ 152,763			126,107,340		(134,617,988)
Ending balance, shares at Aug. 31, 2017			92,100	152,763,244
Beginning balance (Fiscal Year To Date) at May. 31, 2017	(1,103,234)
Beginning balance at May. 31, 2017	(1,103,234)		$ 92	$ 149,468			121,736,921		(122,989,715)
Beginning balance, shares at May. 31, 2017			92,100	149,468,244
Net loss	(22,575,959)
Ending balance (Fiscal Year To Date) at Nov. 30, 2017	(12,790,510)
Ending balance at Nov. 30, 2017	(12,790,510)		$ 92	$ 165,135			132,609,936		(145,565,673)
Ending balance, shares at Nov. 30, 2017			92,100	165,135,155
Beginning balance (Fiscal Year To Date) at Aug. 31, 2017	(8,357,793)
Beginning balance at Aug. 31, 2017	(8,357,793)		$ 92	$ 152,763			126,107,340		(134,617,988)
Beginning balance, shares at Aug. 31, 2017			92,100	152,763,244
Proceeds from warrant exercise \| Fiscal Year To Date	1,647,500
Proceeds from private equity offering, value \| Fiscal Year To Date	3,325,397
Proceeds from private equity offering, value	3,325,397			$ 6,652			3,318,745
Offering costs related to private equity offering \| Fiscal Year To Date	(312,456)
Offering costs related to private equity offering	(312,456)						(312,456)
Proceeds from private equity offering, shares				6,651,800
Offering costs related to registered direct offering \| Fiscal Year To Date	(319,228)
Offering costs related to registered direct offering	(319,228)						(319,228)
Proceeds from registered direct offering, shares				5,720,111
Proceeds from registered direct offering \| Fiscal Year To Date	3,725,254
Proceeds from registered direct offering	3,725,254			$ 5,720			3,719,534
Offering costs related to registered direct offering, shares			0	0		0
Legal fees in connection with equity offerings \| Fiscal Year To Date	(178,664)
Legal fees in connection with equity offerings	(178,664)						(178,664)
Interest expense related to warrant extension \| Fiscal Year To Date	826,252
Debt discount related to convertible notes payable \| Fiscal Year To Date	1,645,010
Stock-based compensation \| Fiscal Year To Date	529,617
Stock-based compensation	274,665						274,665
Net loss \| Fiscal Year To Date	(22,575,958)
Net loss	(10,947,685)								(10,947,685)
Ending balance (Fiscal Year To Date) at Nov. 30, 2017	(12,790,510)
Ending balance at Nov. 30, 2017	(12,790,510)		$ 92	$ 165,135			132,609,936		(145,565,673)
Ending balance, shares at Nov. 30, 2017			92,100	165,135,155
Proceeds from warrant exercise \| Fiscal Year To Date	1,647,500
Proceeds from private equity offering, value \| Fiscal Year To Date	17,642,948
Proceeds from private equity offering, value	14,317,551			$ 28,635			14,288,916
Offering costs related to private equity offering \| Fiscal Year To Date	(1,729,242)
Offering costs related to private equity offering	(1,416,786)						(1,416,786)
Proceeds from private equity offering, shares				28,635,104
Offering costs related to registered direct offering \| Fiscal Year To Date	(650,849)
Offering costs related to registered direct offering	(331,621)						(331,621)
Proceeds from registered direct offering, shares				15,133,742
Proceeds from registered direct offering \| Fiscal Year To Date	11,291,419
Proceeds from registered direct offering	7,566,165			$ 15,134			7,551,031
Offering costs related to registered direct offering, shares			0	0		0
Interest expense related to warrant tender offer \| Fiscal Year To Date	2,352,045
Interest expense related to warrant tender offer	2,352,045						2,352,045
Legal fees in connection with equity offerings \| Fiscal Year To Date	(344,886)
Legal fees in connection with equity offerings	(166,222)						(166,222)
Stock issued for board compensation \| Fiscal Year To Date	260,190
Stock issued for board compensation	260,190						260,190
Interest expense related to warrant extension \| Fiscal Year To Date	826,252
Debt discount related to convertible notes payable \| Fiscal Year To Date	1,645,010
Stock-based compensation \| Fiscal Year To Date	1,096,226
Stock-based compensation	566,609						566,609
Net loss \| Fiscal Year To Date	(40,526,058)
Net loss	(17,950,100)								(17,950,100)
Ending balance (Fiscal Year To Date) at Feb. 28, 2018	(7,592,679)
Ending balance at Feb. 28, 2018	(7,592,679)		$ 92	$ 208,904			155,714,098		(163,515,773)
Ending balance, shares at Feb. 28, 2018			92,100	208,904,001
Proceeds from warrant exercise \| Fiscal Year To Date	3,161,131
Proceeds from warrant exercise	1,513,631			$ 3,027			1,510,604
Proceeds from warrant exercise, shares				3,027,263
Offering costs related to warrant tender offer \| Fiscal Year To Date	(73,234)
Offering costs related to warrant tender offer	(73,234)						(73,234)
Proceeds from private equity offering, value \| Fiscal Year To Date	17,642,948
Offering costs related to private equity offering \| Fiscal Year To Date	(1,729,242)
Offering costs related to registered direct offering \| Fiscal Year To Date	(857,149)
Offering costs related to registered direct offering	(206,300)						(206,300)
Interest expense related to conversion of notes payable \| Fiscal Year To Date	393,686
Interest expense related to conversion of notes payable	393,686						393,686
Proceeds from registered direct offering, shares				4,640,000
Proceeds from registered direct offering \| Fiscal Year To Date	13,611,419
Proceeds from registered direct offering	2,320,000			$ 4,640			2,315,360
Offering costs related to registered direct offering, shares			0	0		0
Stock issued for bonuses and tendered for income tax, shares				310,526		159,011
Interest expense related to warrant tender offer \| Fiscal Year To Date	2,352,045
Stock issued for bonuses and tendered for income tax, value \| Fiscal Year To Date	104,545
Stock issued for bonuses and tendered for income tax, value	104,545			$ 310		$ (159)	104,394
Legal fees in connection with equity offerings \| Fiscal Year To Date	(533,434)
Legal fees in connection with equity offerings	(188,548)						(188,548)
Stock issued for board compensation \| Fiscal Year To Date	260,190
Interest expense related to warrant extension \| Fiscal Year To Date	826,252
Debt discount related to convertible notes payable \| Fiscal Year To Date	1,645,010
Stock-based compensation \| Fiscal Year To Date	1,290,777
Stock-based compensation	194,551						194,551
Net loss \| Fiscal Year To Date	(50,149,681)
Net loss	(9,623,623)								(9,623,623)
Ending balance (Fiscal Year To Date) at May. 31, 2018	(13,157,971)
Ending balance at May. 31, 2018	(13,157,971)		$ 92	$ 216,881		$ (159)	159,764,611		(173,139,396)
Ending balance, shares at May. 31, 2018			92,100	216,881,790		159,011
Proceeds from private equity offering, value \| Fiscal Year To Date	7,514,300
Proceeds from private equity offering, value	7,514,300			$ 15,029			7,499,271
Proceeds from private equity offering, shares				15,028,600
Offering costs related to private equity offering \| Fiscal Year To Date	(882,716)
Offering costs related to private equity offering	(882,716)						(882,716)
Proceeds from registered direct offering, shares				1,970,000
Proceeds from registered direct offering \| Fiscal Year To Date	985,000
Proceeds from registered direct offering	985,000			$ 1,970			983,030
Offering costs related to registered direct offering \| Fiscal Year To Date	(75,151)
Offering costs related to registered direct offering	(75,151)						(75,151)
Offering costs related to registered direct offering, shares			0	0		0
Legal fees in connection with equity offerings \| Fiscal Year To Date	(50,544)
Legal fees in connection with equity offerings	(50,544)						(50,544)
Stock-based compensation \| Fiscal Year To Date	283,346
Stock-based compensation	283,346						283,346
Net loss \| Fiscal Year To Date	(14,413,569)
Net loss	(14,413,569)								(14,413,569)
Ending balance (Fiscal Year To Date) at Aug. 31, 2018	(19,797,305)
Ending balance at Aug. 31, 2018	(19,797,305)		$ 92	$ 233,880		$ (159)	167,521,847		(187,552,965)
Ending balance, shares at Aug. 31, 2018			92,100	233,880,390		159,011
Beginning balance (Fiscal Year To Date) at May. 31, 2018	(13,157,971)
Beginning balance at May. 31, 2018	(13,157,971)		$ 92	$ 216,881		$ (159)	159,764,611		(173,139,396)
Beginning balance, shares at May. 31, 2018			92,100	216,881,790		159,011
Acquisition		$ 11,558,000
Net loss	(28,718,950)
Ending balance (Fiscal Year To Date) at Nov. 30, 2018	(8,063,924)
Ending balance at Nov. 30, 2018	(8,063,924)		$ 92	$ 290,810		$ (159)	193,503,678		(201,858,345)
Ending balance, shares at Nov. 30, 2018			92,100	290,808,960		159,011
Beginning balance (Fiscal Year To Date) at Aug. 31, 2018	(19,797,305)
Beginning balance at Aug. 31, 2018	(19,797,305)		$ 92	$ 233,880		$ (159)	167,521,847		(187,552,965)
Beginning balance, shares at Aug. 31, 2018			92,100	233,880,390		159,011
Acquisition \| Fiscal Year To Date		11,558,000
Acquisition		$ 11,558,000			$ 18,658			$ 11,539,342
Acquisition, share					18,658,000
Issuance of stock payment shares \| Fiscal Year To Date	8,342
Issuance of stock payment shares	8,342			$ 8,342
Proceeds from private equity offering, value \| Fiscal Year To Date	22,478,585
Proceeds from private equity offering, value	14,964,285			$ 29,930			14,934,355
Issuance of stock payment shares, shares				8,342,000
Proceeds from private equity offering, shares				29,928,570
Offering costs related to private equity offering \| Fiscal Year To Date	(2,576,070)
Offering costs related to private equity offering	(1,693,354)						(1,693,354)
Proceeds from registered direct offering \| Fiscal Year To Date	985,000
Offering costs related to registered direct offering \| Fiscal Year To Date	(75,151)
Offering costs related to registered direct offering, shares			0	0		0
Legal fees in connection with equity offerings \| Fiscal Year To Date	(76,195)
Legal fees in connection with equity offerings	(25,652)						(25,652)
Stock-based compensation \| Fiscal Year To Date	1,510,486
Stock-based compensation	1,227,140						1,227,140
Net loss \| Fiscal Year To Date	(28,718,950)
Net loss	(14,305,380)								(14,305,380)
Ending balance (Fiscal Year To Date) at Nov. 30, 2018	(8,063,924)
Ending balance at Nov. 30, 2018	$ (8,063,924)		$ 92	$ 290,810		$ (159)	$ 193,503,678		$ (201,858,345)
Ending balance, shares at Nov. 30, 2018			92,100	290,808,960		159,011

XML 18 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Parenthetical) - $ / shares	3 Months Ended
	Nov. 30, 2018	Aug. 31, 2018	May 31, 2018	Feb. 28, 2018	Nov. 30, 2017	Aug. 31, 2017
Warrants granted per share			$ 0.50	$ 0.50	$ 0.50	$ 0.50
Proceeds from private equity offering, per share	$ 0.50	$ 0.50	0.50	0.50	0.50	0.50
Proceeds from registered direct offering, per share	0.50	0.50	0.50	0.50	0.50	0.50
Common Stock
Warrants granted per share			0.50			0.5
Proceeds from private equity offering, per share	$ 0.50	0.50	0.50	0.50	0.50	0.5
Proceeds from registered direct offering, per share		$ 0.50	$ 0.50	$ 0.50	$ 0.50	$ 0.5

XML 19 R8.htm IDEA: XBRL DOCUMENT

Organization

6 Months Ended

Nov. 30, 2018

Organization

Note 1 – Organization

XML 20 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Nov. 30, 2018

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

Principles of Consolidation

Reclassifications

Going Concern

The consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to obtain additional operating capital, complete development of its product candidates, obtain U.S. Food & Drug Administration (“FDA”) approval, outsource manufacturing of the product candidates, and ultimately achieve initial revenues and attain profitability. The Company is currently engaging in significant research and development activities related to these product candidates, and expects to incur significant research and development expenses in the future primarily related to its clinical trials. These research and development activities are subject to significant risks and uncertainties. The Company intends to finance its future development activities and its working capital needs largely from the sale of equity and debt securities, combined with additional funding from other traditional sources. There can be no assurance, however, that the Company will be successful in these endeavors.

Use of Estimates

Cash

Identified Intangible Assets

Research and Development

Pre-launch Inventory

Fair Value of Financial Instruments

Fair Value Hierarchy

The three levels of inputs that may be used to measure fair value are as follows:

Level 1. Quoted prices in active markets for identical assets or liabilities.

Liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of November 30, 2018 and May 31, 2018 is as follows:


	Fair Value Measurement at				Fair Value Measurement at
	November 30, 2018 (1)				May 31, 2018 (1)
	Using				Using
	Level 3		Total		Level 3		Total
Liabilities:
Derivative liability - warrants	$	1,789,066	$	1,789,066	$	1,323,732	$	1,323,732
Derivative liability - convertible note redemption provision		1,286,076		1,286,076		—		—

Total liabilities	$	3,075,142	$	3,075,142	$	1,323,732	$	1,323,732

(1)	The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of November 30, 2018 and May 31, 2018.


Investor warrants issued with registered direct equity offering	$	4,360,000
Placement agent warrants issued with registered direct equity offering		819,200
Fair value adjustments		(3,855,468	)

Balance at May 31, 2018		1,323,732
Inception date value of redemption provision		1,284,998
Fair value adjustments		466,412

Balance at November 30, 2018	$	3,075,142

Stock-Based Compensation

Common Stock

Preferred Stock

Treasury Stock

Debt Discount

Debt Issuance Cost

Offering Costs

Stock for Services

Loss per Common Share

Income Taxes

XML 21 R10.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

6 Months Ended

Nov. 30, 2018

Recent Accounting Pronouncements

Note 3 – Recent Accounting Pronouncements

XML 22 R11.htm IDEA: XBRL DOCUMENT

Convertible Instruments

6 Months Ended

Nov. 30, 2018

Convertible Instruments

Note 4 – Convertible Instruments

Series B Convertible Preferred Stock

During fiscal 2010, the Company issued 400,000 shares of Series B, $0.001 par value Convertible Preferred Stock (“Series B”) at $5.00 per share for cash proceeds totaling $2,009,000, of which 92,100 shares remain outstanding at November 30, 2018. Each share of the Series B is convertible into ten shares of the Company’s $0.001 par value common stock, including any accrued dividends, with an effective fixed conversion price of $0.50 per share. The holders of the Series B can only convert their shares to common shares provided the Company has sufficient authorized common shares at the time of conversion. Accordingly, the conversion option was contingent upon the Company increasing its authorized common shares, which occurred in April 2010, when the Company’s stockholders approved an increase in the authorized shares of common stock to 100,000,000. At the commitment date, which occurred upon such stockholder approval, the conversion option related to the Series B was beneficial. The intrinsic value of the conversion option at the commitment date resulted in a constructive dividend to the Series B holders of approximately $6,000,000. The constructive dividend increased and decreased additional paid-in capital by identical amounts. The Series B has liquidation preferences over the common shares at $5.00 per share plus any accrued dividends. Dividends are payable to the Series B holders when declared by the board of directors at the rate of $0.25 per share per annum. Such dividends are cumulative and accrue whether or not declared and whether or not there are any profits, surplus or other funds or assets of the Company legally available. The Series B holders have no voting rights. As of November 30, 2018 and May 31, 2018, the undeclared, accrued dividends were approximately $205,000 and $199,000, respectively, or 410,000 and 387,000 shares of common stock, respectively.

Short-term Convertible Notes


		2018
Expected dividend yield		0%
Stock price volatility		69.80%
Expected term		5 year
Risk-free interest rate		1.77-1.93%
Grant-date fair value		$0.30-$0.39

Activity related to the short-term Convertible Notes was as follows:


	November 30, 2018		May 31, 2018
Face amount of short-term Convertible Notes	$	—	$	6,038,500

Unamortized discount		—		—
Registered direct equity offering		—		(5,788,500	)
Note repayment		—		(250,000	)

Carrying value of short-term Convertible Notes	$	—	$	—

Long-term Convertible Note

Activity related to the Note was as follows:


	November 30, 2018
	Short term			Long term			Total			May 31, 2018
Face amount of convertible promissory note	$	—		$	—		$	—		$	—
June 26, 2018 convertible promissory note		2,100,000			3,600,000			5,700,000			—
Monthly redemption		700,000			(700,000	)		—			—
Unamortized discount at August 31, 2018		(344,614	)		(281,628	)		(626,242	)		—

Carrying value of convertible notes at August 31, 2018	$	2,455,386		$	2,618,372		$	5,073,758		$	—

Carrying value of convertible notes at November 30, 2018	$	4,200,000		$	1,396,974		$	5,596,974		$	—

XML 23 R12.htm IDEA: XBRL DOCUMENT

Derivative Liabilities

6 Months Ended

Nov. 30, 2018

Derivative Liabilities

Note 5 – Derivative Liabilities


	Shares Indexed		Derivative Liability
Inception date September 15, 2016		7,733,334	$	5,179,200
Balance May 31, 2018		7,733,334	$	1,323,732
Balance August 31, 2018		7,733,334	$	2,071,199
Balance November 30, 2018		7,733,334	$	1,789,066

The Company estimated the fair value of the warrant derivative liability as of inception date September 15, 2016, May 31, 2018 and November 30, 2018, using the following assumptions:


	September 15, 2016			May 31, 2018			November 30, 2018
Fair value of underlying stock	$	0.78		$	0.49		$	0.58
Risk free rate		1.20	%		2.63	%		2.83	%
Expected term (in years)		5			3.3			2.79
Stock price volatility		106	%		64	%		62	%
Expected dividend yield		—			—			—
Probability of Fundamental Transaction		50	%		50	%		95	%
Probability of holder requesting cash payment		50	%		50	%		50	%

The following table summarizes the fair value of the convertible note redemption provision derivative liability as of inception date November 15, 2018 and November 30, 2018:


	Net Proceeds		Derivative Liability
Inception date, November 15, 2018	$	5,000,000	$	1,284,998
Balance November 30, 2018	$	5,000,000	$	1,286,076

The Company estimated the fair value of the redemption provision using the following assumptions on the closing date of November 15, 2015 and November 30, 2018:


	November 15, 2018			November 30, 2018
Fair value of underlying stock	$	0.57		$	0.58
Risk free rate		2.78	%		2.78	%
Expected term (in years)		1.61			1.61
Stock price volatility		58.8	%		58.8	%
Expected dividend yield		—			—
Discount factor		85	%		85	%

XML 24 R13.htm IDEA: XBRL DOCUMENT

Stock Options and Warrants

6 Months Ended

Nov. 30, 2018

Stock Options and Warrants

Note 6 – Stock Options and Warrants

Stock Options

Warrants

The following table represents stock option and warrant activity as of and for the six months ended November 30, 2018:


	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Options and warrants outstanding - May 31, 2018		132,385,269		$	0.80		3.78	$	3,673

Granted		33,483,124			0.69		—		—
Exercised		—			—		—		—
Forfeited/expired/cancelled		(10,031,717	)		0.75		—		—

Options and warrants outstanding - November 30, 2018		155,836,676			0.78		3.97		769,360

Outstanding exercisable - November 30, 2018		150,960,607		$	0.78		3.80	$	565,356

XML 25 R14.htm IDEA: XBRL DOCUMENT

Acquisition of Patents and Intangibles

6 Months Ended

Nov. 30, 2018

Acquisition of Patents and Intangibles

Note 7 – Acquisition of Patents and Intangibles

A summary of the net purchase price and allocation to the acquired assets is as follows:


	ProstaGene, LLC
CytoDyn Inc. Equity	$	11,558,000
Acquisition Expenses		741,297
Release of Deferred Tax Asset		2,826,919

Total Cost of Acquisition	$	15,126,216

Intangible assets	$	15,126,216
Other		—

Allocation of Acquisition Costs	$	15,126,216

The following presents intangible assets activity:


	November 30, 2018			May 31, 2018
Gross carrying amounts	$	3,500,000		$	3,500,000
Intangible asset acquisition:
ProstaGene, LLC		15,126,216			—
Accumulated amortization		(2,209,254	)		(1,968,846	)

Total amortizable intangible assets, net		16,416,962			1,531,154
Patents currently not amortized		35,989			35,989

Carrying value of intangibles, net	$	16,452,951		$	1,567,143

XML 26 R15.htm IDEA: XBRL DOCUMENT

License Agreements

6 Months Ended

Nov. 30, 2018

License Agreements

Note 8 – License Agreements

XML 27 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Nov. 30, 2018

Commitments and Contingencies

Note 9 – Commitments and Contingencies

XML 28 R17.htm IDEA: XBRL DOCUMENT

Private Securities Offerings

6 Months Ended

Nov. 30, 2018

Private Securities Offerings

Note 10 – Private Securities Offerings

XML 29 R18.htm IDEA: XBRL DOCUMENT

Registered Direct Equity Offerings

6 Months Ended

Nov. 30, 2018

Registered Direct Equity Offerings

Note 11 – Registered Direct Equity Offerings

XML 30 R19.htm IDEA: XBRL DOCUMENT

Employee Benefit Plan

6 Months Ended

Nov. 30, 2018

Employee Benefit Plan

Note 12 – Employee Benefit Plan

XML 31 R20.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Nov. 30, 2018

Related Party Transactions

Note 13 – Related Party Transactions

XML 32 R21.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Nov. 30, 2018

Subsequent Events

Note 14 – Subsequent Events

XML 33 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Nov. 30, 2018

Basis of Presentation

Basis of Presentation

Principles of Consolidation

Principles of Consolidation

Reclassifications

Reclassifications

Going Concern

Going Concern

Use of Estimates

Use of Estimates

Cash

Cash

Identified Intangible Assets

Identified Intangible Assets

Research and Development

Research and Development

Pre-launch Inventory

Pre-launch Inventory

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Fair Value Hierarchy

The three levels of inputs that may be used to measure fair value are as follows:

Level 1. Quoted prices in active markets for identical assets or liabilities.

Liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of November 30, 2018 and May 31, 2018 is as follows:


	Fair Value Measurement at				Fair Value Measurement at
	November 30, 2018 (1)				May 31, 2018 (1)
	Using				Using
	Level 3		Total		Level 3		Total
Liabilities:
Derivative liability - warrants	$	1,789,066	$	1,789,066	$	1,323,732	$	1,323,732
Derivative liability - convertible note redemption provision		1,286,076		1,286,076		—		—

Total liabilities	$	3,075,142	$	3,075,142	$	1,323,732	$	1,323,732

(1)	The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of November 30, 2018 and May 31, 2018.


Investor warrants issued with registered direct equity offering	$	4,360,000
Placement agent warrants issued with registered direct equity offering		819,200
Fair value adjustments		(3,855,468	)

Balance at May 31, 2018		1,323,732
Inception date value of redemption provision		1,284,998
Fair value adjustments		466,412

Balance at November 30, 2018	$	3,075,142

Stock-Based Compensation

Stock-Based Compensation

Common Stock

Preferred Stock

Treasury Stock

Debt Discount

Debt Issuance Cost

Offering Costs

Offering Costs

Stock for Services

Stock for Services

Loss per Common Share

Loss per Common Share

Income Taxes

Income Taxes

XML 34 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Nov. 30, 2018

Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy

Liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of November 30, 2018 and May 31, 2018 is as follows:


	Fair Value Measurement at				Fair Value Measurement at
	November 30, 2018 (1)				May 31, 2018 (1)
	Using				Using
	Level 3		Total		Level 3		Total
Liabilities:
Derivative liability - warrants	$	1,789,066	$	1,789,066	$	1,323,732	$	1,323,732
Derivative liability - convertible note redemption provision		1,286,076		1,286,076		—		—

Total liabilities	$	3,075,142	$	3,075,142	$	1,323,732	$	1,323,732

(1)	The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of November 30, 2018 and May 31, 2018.

Reconciliation of Liability Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)

The following is a reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended November 30, 2018 and the year ended May 31, 2018:


Investor warrants issued with registered direct equity offering	$	4,360,000
Placement agent warrants issued with registered direct equity offering		819,200
Fair value adjustments		(3,855,468	)

Balance at May 31, 2018		1,323,732
Inception date value of redemption provision		1,284,998
Fair value adjustments		466,412

Balance at November 30, 2018	$	3,075,142

XML 35 R24.htm IDEA: XBRL DOCUMENT

Convertible Instruments (Tables)

6 Months Ended

Nov. 30, 2018

Activity Related to Notes

Activity related to the Note was as follows:


	November 30, 2018
	Short term			Long term			Total			May 31, 2018
Face amount of convertible promissory note	$	—		$	—		$	—		$	—
June 26, 2018 convertible promissory note		2,100,000			3,600,000			5,700,000			—
Monthly redemption		700,000			(700,000	)		—			—
Unamortized discount at August 31, 2018		(344,614	)		(281,628	)		(626,242	)		—

Carrying value of convertible notes at August 31, 2018	$	2,455,386		$	2,618,372		$	5,073,758		$	—

Carrying value of convertible notes at November 30, 2018	$	4,200,000		$	1,396,974		$	5,596,974		$	—

Convertible Note Redemption Provision Derivative Liability [Member]

Summary of Fair Value Valuation Technique

The Company estimated the fair value of the redemption provision using the following assumptions on the closing date of November 15, 2015 and November 30, 2018:


	November 15, 2018			November 30, 2018
Fair value of underlying stock	$	0.57		$	0.58
Risk free rate		2.78	%		2.78	%
Expected term (in years)		1.61			1.61
Stock price volatility		58.8	%		58.8	%
Expected dividend yield		—			—
Discount factor		85	%		85	%

Short-Term Convertible Notes

Activity Related to Notes

Activity related to the short-term Convertible Notes was as follows:


	November 30, 2018		May 31, 2018
Face amount of short-term Convertible Notes	$	—	$	6,038,500

Unamortized discount		—		—
Registered direct equity offering		—		(5,788,500	)
Note repayment		—		(250,000	)

Carrying value of short-term Convertible Notes	$	—	$	—

Investor Warrants

Summary of Fair Value Valuation Technique

The Company determined the fair value of the warrants at issuance using the Black-Scholes option pricing model utilizing certain weighted average assumptions, such as expected stock price volatility, expected term of the warrants, risk-free interest rates and expected dividend yield at the grant date.


		2018
Expected dividend yield		0%
Stock price volatility		69.80%
Expected term		5 year
Risk-free interest rate		1.77-1.93%
Grant-date fair value		$0.30-$0.39

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

Derivative Liabilities (Tables)

6 Months Ended

Nov. 30, 2018

Assumptions used in Estimating Fair Value of Warrant Derivative Liability

The Company estimated the fair value of the warrant derivative liability as of inception date September 15, 2016, May 31, 2018 and November 30, 2018, using the following assumptions:


	September 15, 2016			May 31, 2018			November 30, 2018
Fair value of underlying stock	$	0.78		$	0.49		$	0.58
Risk free rate		1.20	%		2.63	%		2.83	%
Expected term (in years)		5			3.3			2.79
Stock price volatility		106	%		64	%		62	%
Expected dividend yield		—			—			—
Probability of Fundamental Transaction		50	%		50	%		95	%
Probability of holder requesting cash payment		50	%		50	%		50	%

Convertible Note Redemption Provision Derivative Liability [Member]

Summary of Derivative Liabilities at Fair Value

The following table summarizes the fair value of the convertible note redemption provision derivative liability as of inception date November 15, 2018 and November 30, 2018:


	Net Proceeds		Derivative Liability
Inception date, November 15, 2018	$	5,000,000	$	1,284,998
Balance November 30, 2018	$	5,000,000	$	1,286,076

Registered Direct Equity Offering | Investor Warrants Issued with Registered Direct Equity Offering

Summary of Derivative Liabilities at Fair Value


	Shares Indexed		Derivative Liability
Inception date September 15, 2016		7,733,334	$	5,179,200
Balance May 31, 2018		7,733,334	$	1,323,732
Balance August 31, 2018		7,733,334	$	2,071,199
Balance November 30, 2018		7,733,334	$	1,789,066

XML 37 R26.htm IDEA: XBRL DOCUMENT

Stock Options and Warrants (Tables)

6 Months Ended

Nov. 30, 2018

Stock Option and Warrant Activity

The following table represents stock option and warrant activity as of and for the six months ended November 30, 2018:


	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Options and warrants outstanding - May 31, 2018		132,385,269		$	0.80		3.78	$	3,673

Granted		33,483,124			0.69		—		—
Exercised		—			—		—		—
Forfeited/expired/cancelled		(10,031,717	)		0.75		—		—

Options and warrants outstanding - November 30, 2018		155,836,676			0.78		3.97		769,360

Outstanding exercisable - November 30, 2018		150,960,607		$	0.78		3.80	$	565,356

XML 38 R27.htm IDEA: XBRL DOCUMENT

Acquisition of Patents and Intangibles (Tables)

6 Months Ended

Nov. 30, 2018

Summary of the Net Purchase Price and Allocation to the Acquired Assets

A summary of the net purchase price and allocation to the acquired assets is as follows:


	ProstaGene, LLC
CytoDyn Inc. Equity	$	11,558,000
Acquisition Expenses		741,297
Release of Deferred Tax Asset		2,826,919

Total Cost of Acquisition	$	15,126,216

Intangible assets	$	15,126,216
Other		—

Allocation of Acquisition Costs	$	15,126,216

Intangible Assets Activity

The following presents intangible assets activity:


	November 30, 2018			May 31, 2018
Gross carrying amounts	$	3,500,000		$	3,500,000
Intangible asset acquisition:
ProstaGene, LLC		15,126,216			—
Accumulated amortization		(2,209,254	)		(1,968,846	)

Total amortizable intangible assets, net		16,416,962			1,531,154
Patents currently not amortized		35,989			35,989

Carrying value of intangibles, net	$	16,452,951		$	1,567,143

XML 39 R28.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended						6 Months Ended		11 Months Ended	12 Months Ended
	Nov. 30, 2018	Aug. 31, 2018	May 31, 2018	Feb. 28, 2018	Nov. 30, 2017	Aug. 31, 2017	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2018	May 31, 2019	May 31, 2018	Dec. 31, 2017	Nov. 08, 2018	Jun. 07, 2018	Aug. 24, 2017	Aug. 23, 2017	Apr. 30, 2010
Summary Of Significant Accounting Policies [Line Items]
Net loss	$ (14,305,380)	$ (14,413,569)	$ (9,623,623)	$ (17,950,100)	$ (10,947,685)	$ (11,628,273)	$ (28,718,950)	$ (22,575,959)
Accumulated (deficit)	(201,858,345)		(173,139,396)				(201,858,345)		$ (201,858,345)		$ (173,139,396)
Balance in excess of federally insured limits	500,000		1,100,000				500,000		500,000		1,100,000
Impairment charges							0	0
Pre-launch inventory qualified for capitalization	$ 0		$ 0				$ 0		$ 0		$ 0
Estimated future unvested forfeitures							0.00%
Common stock, shares authorized	600,000,000		375,000,000				600,000,000		600,000,000		375,000,000			450,000,000	375,000,000	350,000,000	100,000,000
Treasury stock, par value			$ 0.001								$ 0.001
Treasury stock, shares											159,011
Debt discount		$ 626,242	$ 0								$ 0
Amortization of discount on convertible notes	$ 52,954				728,843		$ 117,534	1,172,995
Direct costs associated with the convertible notes							100,000				400,000
Amortization of debt issuance costs							$ 19,589	$ 282,129
Common stock options and warrants to purchase							155,836,676	87,551,801
Unrecognized benefits	0						$ 0		$ 0
Federal statutory income tax rate, percent									21.00%			35.00%
Effective income tax rate reconciliation, at blended income tax rate, percent									28.62%
Tax cuts and jobs act of 2017, incomplete accounting, change in tax rate, deferred tax liability, provisional income tax benefit											17,497,051
Provision for taxes on income	2,826,919						2,826,919				0
Deferred Income Tax Expense Benefit	2,826,919						(2,826,919)
Derivative liability	2,826,919						2,826,919		$ 2,826,919
Equity Securities
Summary Of Significant Accounting Policies [Line Items]
Deferred offering costs	2,700,000		3,500,000		$ 600,000		2,700,000	$ 600,000	2,700,000		3,500,000
Scenario, Forecast \| ProstaGene, LLC
Summary Of Significant Accounting Policies [Line Items]
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent										21.00%
Short-Term Convertible Notes
Summary Of Significant Accounting Policies [Line Items]
Debt discount	0		0				0		0		0
Amortization of debt issuance costs							20,000	300,000
Short-Term Convertible Notes \| Detachable Common Stock Warrants
Summary Of Significant Accounting Policies [Line Items]
Debt discount	$ 600,000		$ 1,500,000				600,000		$ 600,000		$ 1,500,000
Amortization of discount on convertible notes							$ 117,500	$ 1,200,000
Series B Convertible Preferred Stock
Summary Of Significant Accounting Policies [Line Items]
Preferred Stock Shares authorized to be issued	400,000		400,000				400,000		400,000		400,000
Common stock options and warrants to purchase	92,100		92,100				92,100		92,100		92,100
Common shares issued upon conversion of preferred stock							921,000
Maximum
Summary Of Significant Accounting Policies [Line Items]
Common stock, shares authorized													600,000,000
Preferred Stock Shares authorized to be issued	5,000,000						5,000,000		5,000,000
Minimum
Summary Of Significant Accounting Policies [Line Items]
Common stock, shares authorized													450,000,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Liabilities Measured At Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Detail) - USD ($)

Nov. 30, 2018

May 31, 2018

Liabilities:

Derivative liability

$ 2,826,919

Total liabilities

^[1]

3,075,142

$ 1,323,732

Convertible Note Redemption Provision

Liabilities:

Derivative liability

^[1]

1,286,076

Warrants

Liabilities:

Derivative liability

^[1]

1,789,066

1,323,732

Level 3

Liabilities:

Total liabilities

^[1]

3,075,142

1,323,732

Level 3 | Convertible Note Redemption Provision

Liabilities:

Derivative liability

^[1]

1,286,076

Level 3 | Warrants

Liabilities:

Derivative liability

^[1]

$ 1,789,066

$ 1,323,732

[1]	The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of November 30, 2018 and May 31, 2018.

XML 41 R30.htm IDEA: XBRL DOCUMENT

Liabilities Measured At Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Parenthetical) (Detail) - USD ($)

Nov. 30, 2018

May 31, 2018

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Liabilities fair value

^[1]

$ 3,075,142

$ 1,323,732

Level 1

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets fair value

Level 2

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Liabilities fair value

$ 0

[1]	The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of November 30, 2018 and May 31, 2018.

XML 42 R31.htm IDEA: XBRL DOCUMENT

Reconciliation of Liability Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3) (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Nov. 30, 2018	May 31, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value adjustments	$ 466,412	$ (3,855,468)
Ending Balance	3,075,142	1,323,732
Investor Warrants Issued with Registered Direct Equity Offering
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrants issued		4,360,000
Placement Agent Warrants Issued with Registered Direct Equity Offering
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrants issued		$ 819,200
Inception Date Value of Redemption Provision
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrants issued	$ 1,284,998

XML 43 R32.htm IDEA: XBRL DOCUMENT

Convertible Instruments - Additional Information (Detail)				1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Nov. 15, 2018 USD ($) $ / shares	Jun. 26, 2018 USD ($) $ / shares	Jan. 31, 2018 USD ($) $ / shares shares	Nov. 30, 2018 USD ($) $ / shares shares	Nov. 30, 2018 USD ($) $ / shares shares	Nov. 30, 2017 USD ($)	Nov. 30, 2018 USD ($) $ / shares shares	Nov. 30, 2017 USD ($)	May 31, 2018 USD ($) $ / shares shares	May 31, 2010 USD ($) $ / shares shares	Aug. 31, 2018 USD ($)	Jun. 07, 2018 shares	Aug. 24, 2017 shares	Aug. 23, 2017 shares	Apr. 30, 2010 shares
Class of Stock [Line Items]
Common stock, shares authorized \| shares				600,000,000	600,000,000		600,000,000		375,000,000			450,000,000	375,000,000	350,000,000	100,000,000
Common stock, par value \| $ / shares				$ 0.001	$ 0.001		$ 0.001		$ 0.001
Debt discount									$ 0		$ 626,242
Amortization of debt discount					$ 52,954	$ 728,843	$ 117,534	$ 1,172,995
Amortization of debt issuance costs					10,411	168,429	19,589	282,129
Proceeds from sale of common stock and warrant							23,463,585	7,050,651
Interest expense					143,617	$ 105,384	248,247	180,673
Extinguishment loss					(1,519,603)		(1,519,603)
Net carrying value of note				$ 5,596,974	5,596,974		5,596,974		0		$ 5,073,758
Conversion of Preferred Stock to Common Stock
Class of Stock [Line Items]
Undeclared dividend							205,000		199,000
Accrued dividend				410,000	410,000		410,000		$ 387,000
Short-Term Convertible Notes
Class of Stock [Line Items]
Conversion price \| $ / shares									$ 0.75
Convertible note, aggregate principal			$ 6,000,000						$ 4,890,000
Convertible note maturity date			Jan. 31, 2018						Jan. 31, 2018
Convertible notes, interest rate									7.00%
Common stock warrants to purchase shares \| shares			7,718,010
Exercise price of warrants, per share \| $ / shares			$ 0.75
Debt discount				0	0		0		$ 0
Payment obligation against which common stock issued			$ 5,788,500
Accrued but unpaid interest			$ 243,000
Number of shares to be sold \| shares			12,062,728
Sale of Stock, Price Per Share \| $ / shares			$ 0.50
Proceeds from sale of common stock and warrant			$ 6,000,000
Repayment of note			$ 259,000				0		250,000
Interest expense							0	75,000
Net carrying value of note				$ 0	$ 0		$ 0		0
Short-Term Convertible Notes \| Investor Warrants
Class of Stock [Line Items]
Common stock warrants to purchase shares \| shares				4,025,656	4,025,656		4,025,656
Exercise price of warrants, per share \| $ / shares				$ 1.00	$ 1.00		$ 1.00
Term of warrants				5 years
Short-Term Convertible Notes \| Detachable Common Stock Warrants
Class of Stock [Line Items]
Debt discount				$ 600,000	$ 600,000		$ 600,000		1,500,000
Amortization of debt discount							117,500	1,200,000
Unamortized issuance costs									$ 400,000
Amortization of debt issuance costs							0	300,000
Note
Class of Stock [Line Items]
Convertible notes, interest rate		10.00%
Debt discount				600,000	600,000		600,000
Amortization of debt discount							118,000	0
Unamortized issuance costs				100,000	100,000		100,000
Amortization of debt issuance costs							20,000	0
Interest expense							248,000	$ 0
Convertible promissory note maturity period		2 years
Convertible promissory note principle amount		$ 5,700,000
Proceeds from convertible promissory note		$ 5,000,000
Common stock conversion price \| $ / shares	$ 0.55	$ 0.55
Convertible promissory note maximum redemption amount	$ 350,000	$ 350,000
Convertible promissory note redemption description	Effective November 15, 2018, the Note was amended to allow the Investor to redeem the monthly redemption amount of $350,000 in cash or stock, at the lesser of (i) $0.55, or (ii) the lowest closing bid price of the Company’s common stock during the 20 days prior to the conversion, multiplied by a conversion factor of 85%.	The Investor may redeem any portion of the Note, at any time after six months from the issue date upon five trading days' notice, subject to a maximum monthly redemption amount of $350,000.
Consecutive trading days		5
Terms of conversion		1.5
Conversion Factor	85.00%
Common stock conversion closing bid price period	20 days
Extinguishment loss							1,500,000
Net carrying value of note				5,400,000	5,400,000		5,400,000
Fair value of Note				$ 6,900,000	$ 6,900,000		$ 6,900,000
Common Stock
Class of Stock [Line Items]
Number of common shares issued upon conversion of preferred stock \| shares				10	10		10
Conversion price \| $ / shares				$ 0.50	$ 0.50		$ 0.50
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Series B Convertible preferred stock, shares issued \| shares				92,100	92,100		92,100		92,100	400,000
Preferred Stock, Share issuance price \| $ / shares										$ 5.00
Cash proceeds										$ 2,009,000
Series B Convertible preferred stock, shares outstanding \| shares				92,100	92,100		92,100		92,100
Constructive dividend to Preferred stock holders							$ 6,000,000
Liquidation preference on common shares \| $ / shares				$ 5.00	$ 5.00		$ 5.00
Dividends are payable to preferred stock holders \| $ / shares							0.25
Convertible preferred stock, par value \| $ / shares				$ 0.001	$ 0.001		$ 0.001		$ 0.001	$ 0.001

XML 44 R33.htm IDEA: XBRL DOCUMENT

Weighted Average Assumptions to Value Investor Warrants (Detail) - $ / shares		6 Months Ended	12 Months Ended
	Sep. 15, 2016	Nov. 30, 2018	May 31, 2018
Expected Term (In Years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term	5 years	2 years 9 months 14 days	3 years 3 months 18 days
Risk free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-free interest rate	1.20%	2.83%	2.63%
Fair value of underlying stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Grant-date fair value	$ 0.78	$ 0.58	$ 0.49
Detachable Common Stock Warrants \| Short-Term Convertible Notes \| Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield		0.00%
Detachable Common Stock Warrants \| Short-Term Convertible Notes \| Stock price volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock price volatility		69.80%
Detachable Common Stock Warrants \| Short-Term Convertible Notes \| Expected Term (In Years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term		5 years
Detachable Common Stock Warrants \| Minimum \| Short-Term Convertible Notes \| Risk free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-free interest rate		1.77%
Detachable Common Stock Warrants \| Minimum \| Short-Term Convertible Notes \| Fair value of underlying stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Grant-date fair value		$ 0.30
Detachable Common Stock Warrants \| Maximum \| Short-Term Convertible Notes \| Risk free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-free interest rate		1.93%
Detachable Common Stock Warrants \| Maximum \| Short-Term Convertible Notes \| Fair value of underlying stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Grant-date fair value		$ 0.39

XML 45 R34.htm IDEA: XBRL DOCUMENT

Activity Related to Notes (Detail) - USD ($)		3 Months Ended	6 Months Ended	12 Months Ended
Activity Related to Notes (Detail) - USD ($)	Jan. 31, 2018	Aug. 31, 2018	Nov. 30, 2018	May 31, 2018
Debt Instrument [Line Items]
Face amount of convertible promissory note		$ 5,700,000		$ 0
Monthly redemption		0		0
Unamortized discount		(626,242)		0
Carrying value of convertible notes		5,073,758	$ 5,596,974	0
Short-Term Debt
Debt Instrument [Line Items]
Face amount of convertible promissory note		2,100,000
Monthly redemption		700,000
Unamortized discount		(344,614)
Carrying value of convertible notes		2,455,386	4,200,000
Long-Term Debt
Debt Instrument [Line Items]
Face amount of convertible promissory note		3,600,000
Monthly redemption		(700,000)
Unamortized discount		(281,628)
Carrying value of convertible notes		$ 2,618,372	1,396,974
Short-Term Convertible Notes
Debt Instrument [Line Items]
Face amount of convertible promissory note	$ 6,300,000		0	6,038,500
Unamortized discount			0	0
Registered direct equity offering			0	(5,788,500)
Note repayment	$ (259,000)		0	(250,000)
Carrying value of convertible notes			$ 0	$ 0

XML 46 R35.htm IDEA: XBRL DOCUMENT

Derivative Liability - Additional Information (Detail)		3 Months Ended		6 Months Ended
Derivative Liability - Additional Information (Detail)	Nov. 15, 2018 USD ($)	Nov. 30, 2018 USD ($)	Nov. 30, 2017 USD ($)	Nov. 30, 2018 USD ($)	Nov. 30, 2017 USD ($)
Derivative [Line Items]
Percentage Of Outstanding Common Stock To Be Acquired				50.00%
Change in fair value of derivative liability		$ 281,055	$ 829,600	$ (466,412)	$ 466,934
Embedded derivative liability	$ 1,280,000	$ 1,280,000		$ 1,280,000
Stock price volatility
Derivative [Line Items]
Embedded Derivative Liability, Measurement Input	0.588	0.588		0.588
Risk free rate
Derivative [Line Items]
Embedded Derivative Liability, Measurement Input	0.0278	0.0278		0.0278
Fair value of underlying stock
Derivative [Line Items]
Embedded Derivative Liability, Exercise Price				$ 2
Expected Term (In Years)
Derivative [Line Items]
Embedded Derivative Liability Expected Term	1 year 7 months 9 days			1 year 7 months 9 days

XML 47 R36.htm IDEA: XBRL DOCUMENT

Summary of Fair Value Warrant Derivative Liability and Related Common Shares (Detail) - USD ($)	Nov. 30, 2018	Aug. 31, 2018	May 31, 2018	Sep. 15, 2016
Derivative [Line Items]
Derivative liability	$ 2,826,919
Registered Direct Equity Offering \| Investor Warrants Issued with Registered Direct Equity Offering
Derivative [Line Items]
Shares indexed	7,733,334	7,733,334	7,733,334	7,733,334
Derivative liability	$ 1,789,066	$ 2,071,199	$ 1,323,732	$ 5,179,200

XML 48 R37.htm IDEA: XBRL DOCUMENT

Assumptions used in Estimating Fair Value of Warrant Derivative Liability (Detail) - $ / shares		6 Months Ended	12 Months Ended
	Sep. 15, 2016	Nov. 30, 2018	May 31, 2018
Fair value of underlying stock
Derivative [Line Items]
Fair value of underlying stock	$ 0.78	$ 0.58	$ 0.49
Risk free rate
Derivative [Line Items]
Risk free rate	1.20%	2.83%	2.63%
Expected Term (In Years)
Derivative [Line Items]
Expected term (in years)	5 years	2 years 9 months 14 days	3 years 3 months 18 days
Stock price volatility
Derivative [Line Items]
Stock price volatility	106.00%	62.00%	64.00%
Expected dividend yield
Derivative [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Probability of Fundamental Transaction
Derivative [Line Items]
Probability of Fundamental Transaction	50.00%	95.00%	50.00%
Probability of Holder Requesting Cash Payment
Derivative [Line Items]
Probability of holder requesting cash payment	50.00%	50.00%	50.00%

XML 49 R38.htm IDEA: XBRL DOCUMENT

Summary of Fair Value of Convertible Note Redemption Provision Derivative Liability (Detail) - USD ($)		6 Months Ended
	Nov. 15, 2018	Nov. 30, 2018	Nov. 30, 2017
Derivative [Line Items]
Net Proceeds		$ 5,000,000	$ 4,888,500
Derivative Liability	$ 1,280,000	1,280,000
Convertible Note Redemption Provision Derivative Liability [Member]
Derivative [Line Items]
Net Proceeds	5,000,000	5,000,000
Derivative Liability	$ 1,284,998	$ 1,286,076

XML 50 R39.htm IDEA: XBRL DOCUMENT

Assumptions used in Estimating Fair Value of Convertible Note Redemption Provision Derivative Liability (Detail)		6 Months Ended
	Nov. 15, 2018 $ / shares	Nov. 30, 2018 $ / shares
Fair value of underlying stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, price per share	$ 0.57	$ 0.58
Risk free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded Derivative Liability, Measurement Input	0.0278	0.0278
Expected Term (In Years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, expected term	1 year 7 months 9 days	1 year 7 months 9 days
Stock price volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded Derivative Liability, Measurement Input	0.588	0.588
Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, dividend yield	0.00%	0.00%
Discount factor
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded Derivative Liability, Measurement Input	0.85	0.85

XML 51 R40.htm IDEA: XBRL DOCUMENT

Stock Options and Warrants - Additional Information (Detail) - USD ($)		3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 08, 2019	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2018	Nov. 30, 2017	May 31, 2018	Jun. 15, 2018	Aug. 24, 2017	Mar. 31, 2016	Feb. 28, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock issued		290,808,960		290,808,960		216,881,790
Inducement interest related to warrant extensions					$ 826,252	$ 800,000
Compensation expense				$ 1,510,486	529,617
Placement Agent
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase common shares, shares							133,600
Term of warrants							5 years
Exercise price of warrants, per share							$ 0.55
Consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase common shares, shares		300,000		300,000
Term of warrants		5 years		5 years
Exercise price of warrants, per share		$ 0.56		$ 0.56
Warrants grant date fair value		$ 0.30		$ 0.30
Investor
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share						$ 0.50
Common Stock issued						3,295,000
Proceeds from Issuance of Common Stock						$ 1,600,000
Before Inducement \| Investor
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants, per share						$ 1.00
Class of warrant or right expiration date						Jun. 30, 2017
Private Equity Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase common shares, shares		22,478,585		22,478,585
Term of warrants		5 years		5 years
Exercise price of warrants, per share		$ 0.75		$ 0.75
Proceeds from Issuance of Common Stock				$ 19,900,000
Private Equity Offering \| Placement Agent
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase common shares, shares		4,245,117		4,245,117
Term of warrants		5 years		5 years
Exercise price of warrants, per share		$ 0.50		$ 0.50
Subscription Agreements
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase common shares, shares							1,970,000
Term of warrants							5 years
Exercise price of warrants, per share							$ 0.75
2012 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense		$ 1,200,000	$ 1,500,000	$ 275,000	530,000
Grant date fair value of options and warrants		485,000	$ 1,200,000	127,000	$ 574,000
Unrecognized compensation expense		$ 5,700,000		$ 5,700,000
Weighted average period over which unrecognized compensation expense is expected to be recognized				2 years 8 months 8 days
2012 Equity Incentive Plan \| Employee Stock Option One \| Managing Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				1 year
Stock options, term				10 years
2012 Equity Incentive Plan \| Employee Stock Option One \| Managing Director \| Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, Shares				680,822
Stock option granted, exerices price				$ 0.49
2012 Equity Incentive Plan \| Employee Stock Option One \| Managing Director \| Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, Shares				80,822
Stock option granted, exerices price				$ 0.47
2012 Equity Incentive Plan \| Employee Stock Option One \| Non Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, Shares				80,822
Stock option granted, exerices price				$ 0.30
Stock options grant date fair value				$ 0.31
2012 Equity Incentive Plan \| Employee Stock Option One \| Non Employee Directors [Member] \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual increase stock option granted, shares				75,000
2012 Equity Incentive Plan \| Employee Stock Option One \| Non Employee Directors [Member] \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual increase stock option granted, shares				100,000
2012 Equity Incentive Plan \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future stock-based grants		553,048		553,048
2012 Equity Incentive Plan \| Stock Options \| Before Amendment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future issuance								7,000,000	5,000,000	3,000,000
2012 Equity Incentive Plan \| Stock Options \| After Amendment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future issuance								15,000,000	7,000,000	5,000,000
2012 Equity Incentive Plan \| Stock Options \| Managing Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, Shares				500,000
Stock option granted, exerices price				$ 0.565
Stock options, term				10 years
Stock options grant date fair value				$ 0.30
2012 Equity Incentive Plan \| Stock Options \| Executive Management and Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, Shares				875,000
Vesting period				3 years
Stock options, term				10 years
Stock options grant date fair value				$ 0.31
Stock options granted, exercise price, lower range limit				$ 0.49
2012 Equity Incentive Plan \| Stock Options \| Executive Chairman
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, Shares				950,000
Stock option granted, exerices price				$ 0.49
Vesting period				24 months
Stock options, term				10 years
Stock options grant date fair value				$ 0.41
2012 Equity Incentive Plan \| Stock Options \| Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, Shares				1,000,000
Stock option granted, exerices price				$ 0.565
Stock options, term				10 years
Stock options grant date fair value				$ 0.30
Stock option award vesting percentage				50.00%
2012 Equity Incentive Plan \| Stock Options \| Officer \| Scenario, Forecast
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting percentage	50.00%
2012 Equity Incentive Plan \| Stock Options \| Chief Medical Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option granted, Shares				350,000
Stock option granted, exerices price				$ 0.551
Vesting period				3 years
Stock options, term				10 years
Stock options grant date fair value				$ 0.30

XML 52 R41.htm IDEA: XBRL DOCUMENT

Stock Options and Warrants (Detail) - USD ($)	6 Months Ended	12 Months Ended
Stock Options and Warrants (Detail) - USD ($)	Nov. 30, 2018	May 31, 2018
Stock option and warrant activity
Options and warrants outstanding, Number of Shares	132,385,269
Granted, Number of Shares	33,483,124
Exercised, Number of Shares	0
Forfeited/expired/cancelled, Number of Shares	(10,031,717)
Options and warrants outstanding, Number of Shares	155,836,676	132,385,269
Outstanding exercisable, Number of Shares	150,960,607
Options and warrants outstanding, Weighted Average Exercise Price	$ 0.80
Granted, Weighted Average Exercise Price	0.69
Exercised, Weighted Average Exercise Price	0
Forfeited/expired/cancelled, Weighted Average Exercise Price	0.75
Options and warrants outstanding, Weighted Average Exercise Price	0.78	$ 0.80
Outstanding exercisable, Weighted Average Exercise Price	$ 0.78
Options and warrants outstanding, Weighted Average Remaining Contractual Life in Years	3 years 11 months 19 days	3 years 9 months 10 days
Outstanding exercisable, Weighted Average Remaining Contractual Life in Years	3 years 9 months 18 days
Options and warrants outstanding, Aggregate Intrinsic Value	$ 769,360	$ 3,673
Outstanding exercisable, Aggregate Intrinsic Value	$ 565,356

XML 53 R42.htm IDEA: XBRL DOCUMENT

Acquisition of patents and Intangibles - Additional Information (Detail) - USD ($)		3 Months Ended		6 Months Ended
	Oct. 16, 2012	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2018	Nov. 30, 2017	May 31, 2018
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible asset acquired gross		$ 3,500,000		$ 3,500,000
Issuance of common stock shares		290,808,960		290,808,960		216,881,790
Common stock per shares		$ 0.001		$ 0.001		$ 0.001
Estimated aggregate future amortization expense in next twelve months		$ 1,600,000		$ 1,600,000
Estimated aggregate future amortization expense in year two		1,600,000		1,600,000
Estimated aggregate future amortization expense in year three		1,600,000		1,600,000
Estimated aggregate future amortization expense in year four		1,600,000		1,600,000
Estimated aggregate future amortization expense in year five		1,600,000		1,600,000
ProstaGene, LLC
Acquired Finite-Lived Intangible Assets [Line Items]
Acquisition of ProstaGene LLC, value		$ 11,558,000		$ 11,558,000
Issuance of common stock shares		20,278,000		20,278,000
Common stock per shares		$ 0.57		$ 0.57
ProstaGene, LLC \| Dr .Pestell \| Stock Restriction Agreement
Acquired Finite-Lived Intangible Assets [Line Items]
Restricted common stock, shares		8,342,000		8,342,000
Common stock shares restriction period				3 years
Stock repurchase price, per share				$ 0.001
Investment Advisory, Management and Administrative Service [Member] \| ProstaGene, LLC
Acquired Finite-Lived Intangible Assets [Line Items]
Investment earned shares		1,620,000		1,620,000
Patents
Acquired Finite-Lived Intangible Assets [Line Items]
Asset purchase, cash paid	$ 3,500,000
Estimated useful life of acquired asset	10 years
Amortization expense related to acquired patents		$ 152,900	$ 87,500	$ 240,400	$ 175,000

XML 54 R43.htm IDEA: XBRL DOCUMENT

Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail) - ProstaGene, LLC - USD ($)	Nov. 16, 2018	Nov. 30, 2018
Business Acquisition, Contingent Consideration [Line Items]
CytoDyn Inc. Equity	$ 11,558,000
Acquisition Expenses	741,297
Release of Deferred Tax Asset	2,826,919
Total Cost of Acquisition	15,126,216
Intangible assets	15,126,216	$ 15,126,216
Other	0
Allocation of Acquisition Costs	$ 15,126,216

XML 55 R44.htm IDEA: XBRL DOCUMENT

Intangible Assets Activity (Detail) - USD ($)	Nov. 30, 2018	Nov. 16, 2018	May 31, 2018
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	$ 3,500,000		$ 3,500,000
Accumulated amortization	(2,209,254)		(1,968,846)
Total amortizable intangible assets, net	16,416,962		1,531,154
Patents currently not amortized	35,989		35,989
Carrying value of intangibles, net	16,452,951		$ 1,567,143
ProstaGene, LLC
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible asset acquisition	$ 15,126,216	$ 15,126,216

XML 56 R45.htm IDEA: XBRL DOCUMENT

License Agreements - Additional Information (Detail)	Mar. 15, 2019 USD ($)	Mar. 15, 2019 GBP (£)	Nov. 30, 2018 USD ($)	May 31, 2018 USD ($)	Mar. 15, 2018 USD ($)	Mar. 15, 2018 GBP (£)
Licenses Agreements [Line Items]
Accrued license fee			$ 347,333	$ 133,600	$ 400,000	£ 300,000
Scenario, Forecast
Licenses Agreements [Line Items]
Accrued license fee	$ 400,000	£ 300,000
Minimum
Licenses Agreements [Line Items]
Royalty on every net sales			0.75%
Maximum
Licenses Agreements [Line Items]
Royalty on every net sales			2.00%

XML 57 R46.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Nov. 30, 2018	May 31, 2016
Commitments and Contingencies [Line Items]
Asset Purchase Agreement Aggregate Consideration Paying Period	10 years
Payment to acquire other assets		$ 1,500,000
Minimum
Commitments and Contingencies [Line Items]
Royalty on every net sales	0.75%
Maximum
Commitments and Contingencies [Line Items]
Royalty on every net sales	2.00%
Development Milestone Payments
Commitments and Contingencies [Line Items]
Asset Purchase Agreement Aggregate Consideration Paying Period	10 years
Minimum annual license maintenance fees	$ 150,000
Project Work Order \| Termination of Any One Clinical Trial \| Maximum
Commitments and Contingencies [Line Items]
Financial penalties	200,000
Project Work Order \| Termination of All Clinical Trials \| Minimum
Commitments and Contingencies [Line Items]
Financial penalties	500,000
Project Work Order \| Termination of All Clinical Trials \| Maximum
Commitments and Contingencies [Line Items]
Financial penalties	1,100,000
Contract Manufacturing Companies
Commitments and Contingencies [Line Items]
Execution fees for process validation and manufacturing activities	2,100,000
Contract Manufacturing Companies \| Termination of Any One Clinical Trial \| Maximum
Commitments and Contingencies [Line Items]
Financial penalties	300,000
Biologic License Application with the FDA or Non-U.S. Equivalent Regulatory Body \| Milestone Payments
Commitments and Contingencies [Line Items]
Potential future milestone and royalties payments	500,000
First U.S. New Drug Application Approval by the FDA or Other Non-U.S. Approval \| Milestone Payments
Commitments and Contingencies [Line Items]
Potential future milestone and royalties payments	$ 5,000,000
Royalty on every net sales	5.00%
FDA Approval or Approval by Another Non-U.S. Equivalent Regulatory Body \| Development Milestone Payments
Commitments and Contingencies [Line Items]
Potential future milestone and royalties payments	$ 500,000
Royalty on every net sales	3.50%

XML 58 R47.htm IDEA: XBRL DOCUMENT

Private Securities Offerings - Additional Information (Detail) - USD ($)		6 Months Ended
	Jun. 15, 2018	Nov. 30, 2018	May 31, 2018
Equity and Equity Units Offering Disclosure [Line Items]
Common stock, par value		$ 0.001	$ 0.001
Placement Agent
Equity and Equity Units Offering Disclosure [Line Items]
Exercise price of warrants, per share	$ 0.55
Warrants to purchase common shares, shares	133,600
Percentage of shares, issued as warrants	8.00%
Term of warrants	5 years
Private Equity Offering
Equity and Equity Units Offering Disclosure [Line Items]
Exercise price of warrants, per share		$ 0.75
Warrant covering common stock shares purchased, percentage		50.00%
Common stock sold at private equity offering		44,957,170
Common stock, par value		$ 0.001
Proceeds from private equity offering		$ 22,500,000
Term of warrants		5 years
Warrants to purchase common shares, shares		22,478,585
Proceeds from issuance of common shares		$ 19,900,000
Term of warrants		5 years
Private Equity Offering \| Placement Agent
Equity and Equity Units Offering Disclosure [Line Items]
Exercise price of warrants, per share		$ 0.50
Warrants to purchase common shares, shares		4,245,117
Percentage of shares, issued as warrants		10.00%
Term of warrants		5 years
Payment of one time non-accountable fees		$ 25,000
Private Equity Offering \| Warrants
Equity and Equity Units Offering Disclosure [Line Items]
Exercise price of warrants, per share		$ 0.75
Warrants to purchase common shares, shares		22,478,585

XML 59 R48.htm IDEA: XBRL DOCUMENT

Registered Direct Equity Offerings - Additional Information (Detail) - USD ($)					6 Months Ended		12 Months Ended
	Jun. 15, 2018	Feb. 01, 2018	Jan. 31, 2018	Jan. 30, 2018	Nov. 30, 2018	Nov. 30, 2017	May 31, 2018	Aug. 31, 2018
Stockholders Equity Note [Line Items]
Gross proceeds from issuance of common stock					$ 23,463,585	$ 7,050,651
Long-term debt and capital lease obligations including current maturities							$ 0	$ 5,700,000
Investor
Stockholders Equity Note [Line Items]
Class of warrants, exercise price							$ 0.50
Proceeds from issuance of common shares							$ 1,600,000
Short-Term Convertible Notes
Stockholders Equity Note [Line Items]
Number of shares to be sold			12,062,728
Warrants to purchase common shares, shares			7,718,010
Purchase price, per share			$ 0.50
Gross proceeds from issuance of common stock			$ 6,000,000
Debt Instrument, maturity date			Jan. 31, 2018				Jan. 31, 2018
Debt Instrument, face amount			$ 6,000,000				$ 4,890,000
Debt Instrument, accrued interest			300,000
Long-term debt and capital lease obligations including current maturities			6,300,000		0		6,038,500
Stock repurchased during period, value			$ 259,000		$ 0		$ 250,000
Term of warrants			5 years
Class of warrants, exercise price			$ 0.75
Percentage of warrants coverage		100.00%	50.00%
Conversion of stock				$ 0.75
Reinvestment of the principal amount per share			$ 0.50
2013 Convertible Notes \| Investor \| Detachable Common Stock Warrants
Stockholders Equity Note [Line Items]
Inducement interest related to convertible notes			$ 2,400,000
2013 Convertible Notes \| Investor \| Detachable Common Stock Warrants \| Minimum
Stockholders Equity Note [Line Items]
Class of warrants, exercise price			$ 0.75
2013 Convertible Notes \| Investor \| Detachable Common Stock Warrants \| Maximum
Stockholders Equity Note [Line Items]
Class of warrants, exercise price			$ 1.00
Placement Agent
Stockholders Equity Note [Line Items]
Warrants to purchase common shares, shares	133,600
Term of warrants	5 years
Class of warrants, exercise price	$ 0.55
Percentage of shares, issued as warrants	8.00%
Placement Agent \| Short-Term Convertible Notes
Stockholders Equity Note [Line Items]
Cash commission paid			$ 164,425
Subscription Agreements
Stockholders Equity Note [Line Items]
Warrants to purchase common shares, shares	1,970,000
Purchase price, per share	$ 0.50
Term of warrants	5 years
Class of warrants, exercise price	$ 0.75
Number of shares to be sold	1,970,000
Proceeds from issuance of common shares	$ 900,000

XML 60 R49.htm IDEA: XBRL DOCUMENT

Employee Benefit Plan - Additional Information (Detail) - Employee Savings Plan - USD ($)	3 Months Ended		6 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2018	Nov. 30, 2017
Defined Contribution Plan Disclosure [Line Items]
Qualified non-elective contribution			3.00%
Qualified non-elective contribution expense	$ 15,200	$ 10,800	$ 31,000	$ 21,500

XML 61 R50.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail) - USD ($)					6 Months Ended
	Nov. 16, 2018	Nov. 08, 2017	Jul. 28, 2017	Jul. 26, 2017	Nov. 30, 2018	Jul. 10, 2018	May 31, 2018
Related Party Transaction [Line Items]
Common stock, outstanding					290,649,949		216,722,779
Private Equity Offering
Related Party Transaction [Line Items]
Proceeds from private equity offering					$ 22,500,000
Warrants to purchase common shares, shares					22,478,585
Exercise price of warrants, per share					$ 0.75
Chief Science Officer
Related Party Transaction [Line Items]
Stock options vested						500,000
Managing Director
Related Party Transaction [Line Items]
Stock options vested						100,000
Dr Richard G Pestell \| ProstaGene, LLC
Related Party Transaction [Line Items]
Percentage of outstanding equity interest	77.20%
Common stock held for future issuance	8,611,427
Common stock, outstanding	13,258,000
Dr Richard G Pestell \| ProstaGene, LLC \| Stock Restriction Agreement
Related Party Transaction [Line Items]
Common stock held for future issuance	8,342,000
Common stock shares restriction period	3 years
Dr Richard G Pestell \| ProstaGene, LLC \| Escrow Account Deposit
Related Party Transaction [Line Items]
Common stock held for future issuance	4,171,013
Common stock, outstanding	5,400,000
Jordan G. Naydenov \| Private Equity Offering
Related Party Transaction [Line Items]
Warrants to purchase common shares, shares				66,666
Exercise price of warrants, per share				$ 1.00
Jordan G. Naydenov \| Short Term Convertible Promissory Notes \| Private Equity Offering
Related Party Transaction [Line Items]
Purchased short term convertible promissory note interest				7.00%
Proceeds from private equity offering				$ 100,000
Alpha Venture Capital Partners, L.P.
Related Party Transaction [Line Items]
Warrants to purchase common shares, shares			33,333
Exercise price of warrants, per share			$ 1.00
Alpha Venture Capital Partners, L.P. \| Short Term Convertible Promissory Notes
Related Party Transaction [Line Items]
Purchased short term convertible promissory note interest			7.00%
Proceeds from private equity offering			$ 50,000
Anthony D Caracciolo \| Private Equity Offering
Related Party Transaction [Line Items]
Stock and warrants issued during period value common stock and warrants		$ 100,000

XML 62 R51.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail)						1 Months Ended	6 Months Ended
Subsequent Events - Additional Information (Detail)	Jan. 08, 2019 USD ($) $ / shares shares	Dec. 27, 2018 USD ($) shares	Dec. 22, 2018 USD ($) Installment shares	Dec. 19, 2018 USD ($) shares	Dec. 10, 2018 USD ($)	Dec. 11, 2018 USD ($) $ / shares shares	Nov. 30, 2018 USD ($) $ / shares shares	Jun. 15, 2018 $ / shares shares	May 31, 2018 $ / shares
Subsequent Event [Line Items]
Common stock, par value \| $ / shares							$ 0.001		$ 0.001
Placement Agent
Subsequent Event [Line Items]
Exercise price of warrants, per share \| $ / shares								$ 0.55
Term of warrants								5 years
Warrants to purchase common shares, shares								133,600
Private Equity Offering
Subsequent Event [Line Items]
Exercise price of warrants, per share \| $ / shares							$ 0.75
Warrant covering common stock shares purchased, percentage							50.00%
Common stock sold at private equity offering							44,957,170
Common stock, par value \| $ / shares							$ 0.001
Proceeds from private equity offering \| $							$ 22,500,000
Term of warrants							5 years
Warrants to purchase common shares, shares							22,478,585
Private Equity Offering \| Warrants
Subsequent Event [Line Items]
Exercise price of warrants, per share \| $ / shares							$ 0.75
Warrants to purchase common shares, shares							22,478,585
Private Equity Offering \| Placement Agent
Subsequent Event [Line Items]
Exercise price of warrants, per share \| $ / shares							$ 0.50
Term of warrants							5 years
Warrants to purchase common shares, shares							4,245,117
Subsequent Event
Subsequent Event [Line Items]
Convertible promissory note principle amount \| $	$ 3,100,000
Subsequent Event \| Convertible Note
Subsequent Event [Line Items]
Common stock sold at private equity offering	6,200,000
Convertible note, redeemed amount \| $		$ 100,000
Common stock issuance for redemption of covertible note		255,532
Outstanding balance of convertible note including accrued unpaid interest \| $		$ 5,900,000
Debt stated percentage	10.00%
Effective fixed conversion price for Common stock \| $ / shares	$ 0.50
Subsequent Event \| Placement Agent Agreement
Subsequent Event [Line Items]
Exercise price of warrants, per share \| $ / shares	$ 0.50
Acquisition fees received subject to acquisition warrants exercisable	620,000
Acquisition fees received subject to acquisition fee tail agreement \| $	$ 372,000
Tail fee period	5 years
Subsequent Event \| Chairman of the board
Subsequent Event [Line Items]
Annual base salary \| $				$ 5,000	$ 16,667
Extended service period				Apr. 16, 2019
Extension in expiration terms				10 years
Previously awarded stock options				150,000
Subsequent Event \| Chief Technology Officer
Subsequent Event [Line Items]
Annual base salary \| $			$ 335,000
Annual target bonus as percentage of base salary			50.00%
Initial signing bonus amount \| $			$ 100,000
Number of equal installment for signing bonus \| Installment			2
Initial signing bonus, installment amount \| $			$ 50,000
Frequency of installsment period			6 months
Stock options granted			400,000
Stock options vesting			3 years
Subsequent Event \| Michael A. Klump [Member]
Subsequent Event [Line Items]
Convertible promissory note principle amount \| $	$ 500,000
Subsequent Event \| Private Equity Offering
Subsequent Event [Line Items]
Exercise price of warrants, per share \| $ / shares						$ 0.50
Warrant covering common stock shares purchased, percentage						50.00%
Common stock sold at private equity offering						2,018,000
Common stock, par value \| $ / shares						$ 0.001
Proceeds from private equity offering \| $						$ 1,000,000
Term of warrants						5 years
Subsequent Event \| Private Equity Offering \| Convertible Note
Subsequent Event [Line Items]
Exercise price of warrants, per share \| $ / shares	$ 0.30
Term of warrants	5 years
Warrants to purchase common shares, shares	3,100,000
Warrants exercisable	50.00%
Subsequent Event \| Private Equity Offering \| Warrants
Subsequent Event [Line Items]
Exercise price of warrants, per share \| $ / shares						$ 0.75
Warrants to purchase common shares, shares						1,009,000
Subsequent Event \| Private Equity Offering \| Placement Agent
Subsequent Event [Line Items]
Exercise price of warrants, per share \| $ / shares						$ 0.50
Term of warrants						5 years
Warrants to purchase common shares, shares						201,800
Aggregate cash fee \| $						$ 100,000

EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ø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
(+[AI_;(+#Q?5+7>K!Y3:82U" M7+:DRUF_O@PR'&9GPQ-04_D/_B9QR)U3PY_JFA>&W0>4-^+<;A*L?,QP9 M+G:W2J)@R7$$WGE> T63)24ELZZ\TN!942TB<59_A[0Q'GVGG/3,V6QY+XL[ M0ENGFT1EFYJ-)G;ODPW-Q]*7T=J8C'ZS1ZG,$)%1VHK!2WU)GY!/RJ[C*B$8XOE=@%0U M7L/Q6*C*2XMO?*>!8RDH\KXO_;^'I33_'TOY_SR6,E%[HP,0>^?V]_B[Q#2B M[V\ H'[+$#8'^XJ\ZT<"U[(4<,T<#5Q+WE#S!.!:E@*NF2=Z"!/NE_\/7/MO M!J[I.)-*1^F5,!> M\$/J@.61[+G]RXN(#?^\]F$)%ZR TQ7X@Q=,IV=G^71TEKW(GH_GHWPZGN-? MI[" ,?!H/_!ED'V9=*6GQG\&JSP#\CZ=3^GO4U!X3F?(\"= 4T#2D[G:NR,_ MDB+1,U=EDF3)^30_GYW19R;V[_8S^XB8Z.NCW^HK=Y>4Y/2<_=_?TT3^SQYE M3#'\7YQ!0W6K*M F.R]FOSVL?F@W0)7__ =R#S6?RS_\BY:&'@64]E*F^(#Q MB$$O'33VNT[V1/'W2GI%3Y+.COD/X8-!OOJ;8(*J,"-[,)YEP\%DQG_,S<>J M1:Q"6;)Z/Q[,YMEW\H=Y'8#ZGH/R1U7\7F2CP71$_Y/2H5W(8C:9#W <_L./ M0PY+D"'98U6NEM$-LF%-*=Z3S2?<%I=4CJ:K[4TQC8YAO [ MT\_O]C*UO4,K#I:!0G<6<'E#X2)W9#\K-#H!R8S>UNIZY M+3C@$:(*G&OZP;F=^>9]J%NN2U>F+X:%,.FB[T1F/1&ESLV>QD-#@__<[\B#,X(>:D#H4*W9[@_\_C@'3$LO>9OQ>*(^XD M75TJR.!1A6FX0DE)L?"[,_4X+\FHO"3)ZPWTPFLLM*EY]S0/[=XD)\^SA*30 MM6M^,.' =LBG\OS9G/XX.^]A_:/!>$BL?WI*?\Q/]TF 278Z.$4Y<=Y'>:/A M%,:9GN'_QD\0 O;/*TIG=[CO-["H0B+2JCE]-L%)T__.05!TWQ(0F.I00)4R M;#Z\?YG^MT>EZ*'KP+H\F@95[S:RT%KZC@U7)HA1J62FWU>03J%+D&JD9?30 M)HB]^$(&,'L]H^Y/X.)D@OM+G6*"X73#XV]D,C&7L+L\FP&C&)K@][X 3ZD>]G6T? M[1HT^NDQD,0H'YV?[R&D<'3KGDL#)CZH *JCE3YII5_1;V16Q=SO'.++#GH8 M!Z';3B<:'\*U5>?P]A+:>+U\ F@%;JWSJ?_5ZCCN+QG;*N %^ O3^;G^:C\1D\-#V/&/MK*=O=S_KM MGV\XR:)_IB)GCM#4GG;&)*1=\&IL)W7JN!W)3!P3B2NB6>YQT&K]L7&Q:%]XBZ,' M$R>(W=^C/=%=L*/CU+OE]DF5]=6P2+!$05: O)B04VP$UV:>S\^F8)CR<=F' MV9W=62^5B\8N>F?PWSGHFD QL,31Y,S8*^3[;E"/>F=HGT[R\_FY_)$P@OVW MY"O/Z#N3<7X^&9%TF4QG^>CL]!LB@R<*J:);\V;/7V'3]=4+>.+GZU?9\V?1 MC1^-J#8"B(+7* JB7X_W_EJ10L*,@SLHOYS%75T_#[*AI-MT?_GGW1I^.4O_ M$B3[P.6!I7]YVO/+33.P5#SLV^T/AW?[W]]A[?FWH+NTD0?1:A1'E8F,[G%4 M:&Y/42U7JBK#YDF,/,D]F8)[L6Q.UD0%9]<*,F.A,%$A+X%48)W5'>VX2O)HR'81 M3$+WS?$HM7.GD]1/7SL80F?T3BR04@@MGN+HB1#>(CI"Q%)94,I_("BE6)!( M8X0R#4X%LU7=S5SJ5A*8QWTVB;MZS#4N0L]5=CJF;FN&"CZK)!\WOQB3E7S2 M@]BL1,]>IL=/1=&C8V"EX=KAT'N_&\*U(WX"QX#X9^K[42X*T!7^EG7D6S\) MJ#5]+"BT$9+ I3N#6%%I5<#BPB*PUD MK6774C1KJ_^_=1)%Z.BGEU7^H[*XM?^5MT\D<-ZU\_RCU_%!RD#[-P#!SD M.!C1?CC(WY,6K@K4'^]+JJWXX@C:\,/D]F;C I)S#&;%+IIUTYGF/KU%#^JW M-.%JIRJ1O0_\C\!IGKB5A_?O)?=BB3_:X<-[=S0-W8A8/OL!1&T\& #[)A>D M8P0]W+>W<]HW?=0[_5ZA)'.1F&-83!].Y:"]DS0WK%]9:.19]KU(FJ3]8;$@ MAY\NUL[.B9].OT/SL6SI*]Z9]="Y9FY'#JM>&1[Y"EE9G<_LM>'V#&,MN7V/ MG.Y]1%MUZ4LFUWZ7 1A^#,/_P#RF'1GE9[AO1]1P5Y_%^SK<'F;GW3D2-L(]E"O$&D'&IP^?I M>>\;1+W,B=A)[O&.P)7?( W9*VZPJ3FDN]&$+ M#!"^.)]\%]>UT3N$=?5EBRC=75+-7#",I8/JOE[<;I$S^FBJ:]S%58S+X[%]- #_\8)B<<8I-2G,R+@\77.9'ZA4:J.E/GY;SSN;ZQ MND6=1/ XQGT$:R+LD;#$;YJJCF+WJ[5D=4EZG 5= :5>=39/JJ'%;@4P#I=2 MUXA>X7J)Z\XI[5OQ*_FLI"07C[;+9/< 90Y/X.R=C3E.;?_N9^ $1O]-0L]^O-/H]UCOBQ:R31BKC/-NSS*QV1N[7'TL651C(?&P/V_O9@^DG* M;/6))_%6)]*[?A?W\)XO[3O/*U^=X,-MIK%^ 75_JK.7'C87V?IIL]P%?4-, M< H''(D$T(Z7:!P^Z>'4[N:Q3O'$]YVKB?PO3WHYY.81?^$$XYE5+\Z3VD4Z MR6]?8@BI3)9)Z I;QW *>;!B8'0BHO;[)*\=*J[(SU)\[(^.@S,L@JNDJSB">E*O M>@S (]*:GD9RO\,R]RZNGU2#$-D>BM['V'+O:^#7G_AVN<_J.?#N =T[3%-- MJ\S)Q()OP'I2J$Q EQ%=?LY&$BZH 8NUO=1Y^*A(M (;L;7'4S=V,LY&MO!W[HJX#!V) ]_3)T3;DP*Z1KK_PK=FBI@ MVNO:LNG,TKV)*F1S$&]W:$Q,T?!\L],7JL]S-+\U->_DB40W-R%Q#47:Y+&E9+P:Z38^U5'P&389\0H@$EU0% MW='J+LGPCO\N_%ODT87MDO*4J=B S3=-X(+"A[W??])8!QG=DT8#K4.BB.]] M3U*4-)8:^ES[1]PMRUZ\5I-3H!@$/'$"2HWYG69_>8_Y-+%4'9^)O/FF[WS@ MQAQ[.2KW4%0EOL4Y]'M\&'\391E\T\"7]U5YF[TOJT,.I2MW M7SB4@)MG/O*;EG _6JH[]*!+*C[\Z)ZLXL,O]R0 '_'BP;V(8I/[?6UN:Y[X MGMJI)[ZY=^.>.%;O/CYUG*=OZT?77@ELK6TC;07?8?^82@),/1PR&XU<]#/M MGSR-HJEI3,3QR_^&V9X?"-4>WCM7+ 3T,&*PHKOJ5(G_>LY>H1.\ONF)_G] M&SPH'Q;; :;OHJLCJJKHDN#?P&9ORY-WU)0W3L[>Y]!(YT?RQ[1^A6#DC=_&UL& M7SW4/1CDO]=@M_4N$HU?/190R@%B]JF#F#F8I^V2;O[\W[)733:XP@3?USQ;+&_B/TOR\\5QD;S MKHYZL7R ^P>?9I>LM++15LN!-$SU$3@<+"C7!WC>IIP[7"W"+BFWX84JAFDX M:MFUY>UNY?J/N3M/+" :/T5)RJ/IWMZDY_<[U?C0W+)+=P<"&].TD_DE9OEA MRKPB_9Q$%H@$/(U+Z4]P./DJ40=DW_VRE4#B2["G($CWX=ZJ((=X?"Q4L3)( M--_]!4+V?*13$^0(,96\&EWKFQY=7V&1B-#W]X]X'^S +P3/[!I/5M7IY M^^Z7S=-8R:[87YL_6&7GEO>[3;X%N<)RCHLX(]D?;DT;* :TI*Z&W",02B@=#M?ZV; M7[,/S9+<%I^H4JMG9NM'\CA>KN ;"P((8'?L7O #^KL7ZSK\W-Y- M>]I-/QU,4A <#HGZPB@N+/I-?%5N&=E'-=9DWLI<'D(]AF/VK M7JH2_H']R9NW&9(&I3>M@;:D\ _'/Y+LO2]2WI?G>+" P#>1$V%1ACVX7 ;M M#M._O/8-WUL[)4(\[:,Z5I0W!_<\A8<@G"SA\"CQ&V^ U.[*Q.IPB;2M:@XI MVK!-Q$SQ]0YXHNT&7"*KK#^5-CKO8RWU#@8ZWY\B'3U]ZV'1!Y\M1!GMRQ3N M>AF6-K>0G1)]OI2 H3C?)K&$Q$4?#?>DTMJ4LR0=?"PK[W 0H]QEGEMH>.\^ M RF?[D\X?GH1IP.0J8, \=]C3OV:V.\U>EIEZ19!V9]S$-N@+>>Y Q,@MU?* M[6,CZE*EC(-QQ_ \'ZLO/A.CE#=[$>NWU Z!]+SJAI5'>N5(F?H75U@014&Y MDF3DA1HOUAT2E^"(J1+[TK>4(]$A58B1ZDT.TU6)PH>HX(3;<9%WZ,#=T#2()73?:QPOJ4R^S' MS/N6#SA50W:JQ',#V*QV6YKC_38$>A%I/OS%:G-?9+_ GN*978KJ@]=C#1(3MFUP%26X'_/.\8N.1E]O M[VLP<5_!R& 8+]!Z/7YCKKM%>%PV>*!NB'NRKW)/PEWO&IB^_OQU?D?2>RWN M^\@:3U2]=SP+W(O[GAP'3Z)Z5JQ69%[VO_1_2[N:EHAA(/I7\@-$W8O@1?"P M7L2;X%G="(6Z5=.*!7^\>9-N.FDFZ13OZ:1-TLE\O3>[:ZWXW>4*-@MCMO%> M)?7N&TBR*EB$Y5;5'5:-=P<@^MHLLLFIXUK1R!?X(6M3!A*EP*-A#Y5Y$A4> MG2:H<49Z03Y4(CM+EK"K9&J%*:$8F0=U\A<6!$/2.Y*O =Y?>Z@X^3-/RUOS M0PG3!=<,/BKYW!J_@+#^2Z.T>!OQM!"%"?T5;JD,@;.,L$%15;&*BW\+]8,, M%)%YCO%L86T?,0)#"[EAX1A.Y7RQ'6KGK]U >P"\ MXZ;TL/P2A)A!$R:"$V28F?T)-!+XOB,R 7>BQ/WQW72#:\=0%1AY*[I"*:RT M ##RB+(!@=6Q9.=-:]"#0[SWRW0/.'I&WMZK0JV*6+:Z M;DQ+1D&^B0\P%VUK;L_-?3N\?U2Z4>:*0&F*J)]4*/PI\" ##$ #0 M 'AL+W-T>6QEW 0WKTY[]H/G>,-1E[C M4Q+C:/@.!W\N>A2&VX6MLR-^\D3QQ[0[TL,MTN5PHU1%=@)'3V-Z!*DC?+I# M^ J6P+8L4=OWX#*=/5YNV"ZX.U>C<%?P9G0W/-I1V,\?6ZJJ'0^5-!I8V:#< MXI-Q*D6STX^Q-YB\A -:$A;C"\+H5%$;E1).V=J;G&SV[56;& JC)2A-9VW+=T6R6UCI:CNMTN0X"%&%M M:+/W]WF6_S/Q\>COD=U7I0N\7[/ZTHCV+-0#R),^0 [W'_+X;/\9[6FU!Y"G M?8#LPW*/^O"9-/>!'D .7A@R*(^]K;/UQLFZMJ)I09FFHL1=T"0!SV.O-C'^ M8F]4;.-\VQRPC;PF4P:;^B8V@9043%_;$ITSQDW[RH)'PWK4;2T1XZ;]&1): M<'>Q#)J_+2:_ %!+ P04 " SA"E.4L!T)JH$ !N(@ #P 'AL+W=O MCEG*9?/K8WVNI1^&& MLJRT7$G8Z7;<6Z3FU["^MNBV7]31) M$[+AVMB5:]N?V7+)6_[$*K]E&O7XM]+\24E+Q:K42@A_E3O@+X(6S/.>.Z8M M+P 6M5^0S%526C/@N-P%@A@!F)P,D;Y8T M@,P1R/R(D"L'X2XP1&W(S9;I +) ((N305Y0TP20$P1RA^7:-6U+=4[UTTK7DL.EU$(C[.R5!V$ MQP#R P+Y(2[D+2M9 "5K B*4\+WT+SF,VF,L;(^C#\$'IT%H%:1BK/87A#$[ M1:T262MSIOD#=;D!N>+4JYBS 1VFE#2R4U96E?<0F?T!K^=O5&MZT'^83]+( M0IF5WSMHU.UWTV4)&"[ .-1+R)%"3,PH:62E7,%ITC RJS5C_QN F$;2Z!YI M6V[;YUZ#^>(F,Y/EP3C$-))&]LC23Q)(9UC9:3]#R,UF U-'U@-&S")I9(W< MLIH;R.C!='.N84% %C T(97=DX:8F%K2R&Y9M%NA=HR1STRR#;=D*0;90HHI M)8WN%.%3A275T'%?(=(8ZE=6@QP;TTD662>K;FW8]\Z9;_%P,(\S3"199)&@ M.<,@U8B):26+OTYY+6L@;V!]+09Q,<.TDD76RNO90T_Y1XB) M.2:+[)A?IQ$>-<3$+)-%M@R:2PRG$"::++)H\"E4A)B8:++(H@D'Y#^,FLZ9 M<6;)%\HUN0LSLPQ33A99.2CFX*7GF'?RR-Z!U9:"E$QPV@_/'GSGL$-,S$)Y M_"K9JW'S+9E5%0\7A3EFH3RRA;XQ7CF:W_&)ZM"3+18%GUQ M Z'=O>$^+[**7"OK(OR<#18W.6:A_/@6VO5O?%A3R3$+Y;$M]!(W?\8@T;'> M1&0>8F(6RF-;*!B*G8&7SB59&,M=,5S6),3$+)0?ST)!;[K"G@\!(29FH3RR MA=#>'(9WS$)Y9 LA&9*;2&%='+-0$7OU@R1R$)%"3,Q"160+'21RVV$B%RXR M"LQ"Q?'60K9AY!J:67:Z;*AA9#FH&!28A8K(%G)U-%E[I<-LAMY&V)B%BI.6'&#?@TQ,0L5IRRZ#<)[@5FH.$71 M[65XAIB8A8J3E=\.+33!+#0Y=@UN,-'#L3G!+#3Q%AKU_V^HX,5(5EU#$P;V MEU242TWS_LF[0LZIR[FQ#2JHZ'*EVT76R&7S9M?ZCR M\+7?AJY:O53;&'0^7X1^/*.XNQW/G#VLET7_L)9B]ESUVYB717C?A[>V?TEU MC#F%XT4NA@7#7SZZ^)_U[6:S6\7[=O5ZB$W^I>)[01%^#]+I(*4'V720T8-\ M.LCI0>5T4$D/6DP'+>A!E]-!E_2@J^F@*WK0]730-3U(YD#&.3\)8 M>H9G;?2PS==;@=[*UUN!WLK76X'>RM=;@=[*UUN!WLK76X'>RM=;@=[*U]N MWL;7VX#>QM?;@-YVAK,2=%C"U]N WL;7VX#>QM?;@-[&U]N WL;7VX#>QM?; M@-[&U]N!WL[7VX'>SM?;@=[.U]N!WGZ&LVYTV,W7VX'>SM?;@=[.U]N!WL[7 MVX'>SM?;@=[.U[L$>I=\O4N@=\G7NQSIG>JJC^NGW.^:;3IUR8_A?]:,X$[Y M8Q]/GW&<^N?^D=)YV!+#\?/DM^4X]2LB_'@]?O<)4$L#!!0 ( #.$*4X5 M2%_JR@$ !$? 3 6T-O;G1E;G1?5'EP97-=+GAM;,W9RV[",! %T%]! MV5;$^ %]"-BTW;9([0^XR4 BDMBR#86_KQ.@4BLJ40'2W1"2<69N@G4VC-^W MEGQO4U>-GR1%"/:!,9\55&N?&DM-K,R-JW6(IV[!K,Z6>D%,# 8CEIDF4!/Z MH>V13,=/-->K*O0>=]?;UI-$6UN5F0ZE:=BZR7\U[>\;IHZJ;HTO2NMOXH*D M][R)77R\-DEBU2?LA F_;VS/XWVO:W*NS.E?TH*M<H* MNT]^UL##;LB,H[YUL>I">>3Q8J19K'K6+KSD(U*[=7+*3QH>6U_OA_TT;ME] M/_;"OXN>=8?SWOKE<@B0'!(DAP+),03),0+)<0N2XPXDQSU(#CY "8(B*D &PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( #.$*4[M="(D@ ( .$( M 8 " ?<( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ ,X0I3O(IN&E] M @ *@D !@ ( !] \ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ,X0I3B?*-Z 9#P H6( !@ M ( !(AP 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ ,X0I3L0%B5^G 0 D0, !@ ( !&3 'AL+W=O M&UL M4$L! A0#% @ ,X0I3JJOLE.H 0 D0, !D ( !U3, M 'AL+W=O&PO=V]R:W-H965TSPJ0$ )$# 9 M " 9,W !X;"]W;W)K&UL4$L! A0#% @ M,X0I3J8I;OZG 0 D0, !D ( !&PO=V]R:W-H965T&UL4$L! A0#% @ ,X0I3EE(,C6G 0 D0, !D M ( !KD0 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ ,X0I3GCP.EFU 0 ]@, !D ( !5$L 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ,X0I M3H5V.\&L 0 D0, !D ( !<5$ 'AL+W=O&PO=V]R:W-H965T?08 /\E 9 " 495 !X;"]W;W)K M&UL4$L! A0#% @ ,X0I3M.+/%+, @ :PL M !D ( !^EL 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ,X0I3D>Q>;/.!P ^F$'^H" !T#0 &0 @ $9; >&PO=V]R:W-H965T M&UL4$L! A0# M% @ ,X0I3D<'&]ZL @ O0H !D ( !NW( 'AL+W=O M M!@ &0 @ &>=0 >&PO=V]R:W-H965T&UL4$L! A0#% @ ,X0I3JQ1 M>PX6 @ 8@8 !D ( !\7H 'AL+W=O&PO=V]R:W-H965TI_ !X;"]W;W)K&UL4$L! A0#% @ ,X0I3CCM;X?H @ (@L !D M ( !S8< 'AL+W=OC7D# #[$ &0 @ 'LB@ >&PO M=V]R:W-H965T&UL4$L! A0#% @ ,X0I3IHU=%I> @ BP< !D ( ! M[) 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ ,X0I3J?+,W&PO=V]R:W-H965T&UL4$L! A0#% @ ,X0I3KM809?T M P [Q, !D ( !!:0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ,X0I3E+ =":J! M;B( \ ( !IB8! 'AL+W=O7!E&UL4$L%!@ 0 \ #P 5A ) O 0 $! end XML 64 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 312 325 1 true 88 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.cytodyn.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Consolidated Balance Sheets Sheet http://www.cytodyn.com/taxonomy/role/StatementOfFinancialPositionClassified Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.cytodyn.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Consolidated Statements of Operations Sheet http://www.cytodyn.com/taxonomy/role/StatementOfIncomeAlternative Consolidated Statements of Operations Statements 4 false false R5.htm 106 - Statement - Consolidated Statements of Cash Flows Sheet http://www.cytodyn.com/taxonomy/role/StatementOfCashFlowsIndirect Consolidated Statements of Cash Flows Statements 5 false false R6.htm 107 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity Sheet http://www.cytodyn.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Consolidated Statements of Changes in Stockholders' (Deficit) Equity Statements 6 false false R7.htm 108 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Parenthetical) Sheet http://www.cytodyn.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical Consolidated Statements of Changes in Stockholders' (Deficit) Equity (Parenthetical) Statements 7 false false R8.htm 109 - Disclosure - Organization Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Organization Notes 8 false false R9.htm 110 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies Notes 9 false false R10.htm 111 - Disclosure - Recent Accounting Pronouncements Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsAccountingChangesAndErrorCorrectionsTextBlock Recent Accounting Pronouncements Notes 10 false false R11.htm 112 - Disclosure - Convertible Instruments Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Convertible Instruments Notes 11 false false R12.htm 113 - Disclosure - Derivative Liabilities Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock Derivative Liabilities Notes 12 false false R13.htm 114 - Disclosure - Stock Options and Warrants Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stock Options and Warrants Notes 13 false false R14.htm 115 - Disclosure - Acquisition of Patents and Intangibles Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock Acquisition of Patents and Intangibles Notes 14 false false R15.htm 116 - Disclosure - License Agreements Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock License Agreements Notes 15 false false R16.htm 117 - Disclosure - Commitments and Contingencies Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies Notes 16 false false R17.htm 118 - Disclosure - Private Securities Offerings Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsPrivateEquityOfferingsDisclosureTextBlock Private Securities Offerings Notes 17 false false R18.htm 119 - Disclosure - Registered Direct Equity Offerings Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsRegisteredDirectEquityOfferingTextBlock Registered Direct Equity Offerings Notes 18 false false R19.htm 120 - Disclosure - Employee Benefit Plan Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock Employee Benefit Plan Notes 19 false false R20.htm 121 - Disclosure - Related Party Transactions Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions Notes 20 false false R21.htm 122 - Disclosure - Subsequent Events Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events Notes 21 false false R22.htm 123 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 22 false false R23.htm 124 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Summary of Significant Accounting Policies (Tables) Tables http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock 23 false false R24.htm 125 - Disclosure - Convertible Instruments (Tables) Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables Convertible Instruments (Tables) Tables http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock 24 false false R25.htm 126 - Disclosure - Derivative Liabilities (Tables) Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables Derivative Liabilities (Tables) Tables http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock 25 false false R26.htm 127 - Disclosure - Stock Options and Warrants (Tables) Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Stock Options and Warrants (Tables) Tables http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock 26 false false R27.htm 128 - Disclosure - Acquisition of Patents and Intangibles (Tables) Sheet http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables Acquisition of Patents and Intangibles (Tables) Tables http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock 27 false false R28.htm 129 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) Details 28 false false R29.htm 130 - Disclosure - Liabilities Measured At Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureLiabilitiesMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchy Liabilities Measured At Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Detail) Details 29 false false R30.htm 131 - Disclosure - Liabilities Measured At Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Parenthetical) (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureLiabilitiesMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParenthetical Liabilities Measured At Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Parenthetical) (Detail) Details 30 false false R31.htm 132 - Disclosure - Reconciliation of Liability Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3) (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureReconciliationOfLiabilityMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsLevel3 Reconciliation of Liability Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3) (Detail) Details 31 false false R32.htm 133 - Disclosure - Convertible Instruments - Additional Information (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureConvertibleInstrumentsAdditionalInformation Convertible Instruments - Additional Information (Detail) Details 32 false false R33.htm 134 - Disclosure - Weighted Average Assumptions to Value Investor Warrants (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureWeightedAverageAssumptionsToValueInvestorWarrants Weighted Average Assumptions to Value Investor Warrants (Detail) Details 33 false false R34.htm 135 - Disclosure - Activity Related to Notes (Detail) Notes http://www.cytodyn.com/taxonomy/role/DisclosureActivityRelatedToNotes Activity Related to Notes (Detail) Details 34 false false R35.htm 136 - Disclosure - Derivative Liability - Additional Information (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureDerivativeLiabilityAdditionalInformation Derivative Liability - Additional Information (Detail) Details 35 false false R36.htm 137 - Disclosure - Summary of Fair Value Warrant Derivative Liability and Related Common Shares (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureSummaryOfFairValueWarrantDerivativeLiabilityAndRelatedCommonShares Summary of Fair Value Warrant Derivative Liability and Related Common Shares (Detail) Details 36 false false R37.htm 138 - Disclosure - Assumptions used in Estimating Fair Value of Warrant Derivative Liability (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureAssumptionsUsedInEstimatingFairValueOfWarrantDerivativeLiability Assumptions used in Estimating Fair Value of Warrant Derivative Liability (Detail) Details 37 false false R38.htm 139 - Disclosure - Summary of Fair Value of Convertible Note Redemption Provision Derivative Liability (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureSummaryOfFairValueOfConvertibleNoteRedemptionProvisionDerivativeLiability Summary of Fair Value of Convertible Note Redemption Provision Derivative Liability (Detail) Details 38 false false R39.htm 140 - Disclosure - Assumptions used in Estimating Fair Value of Convertible Note Redemption Provision Derivative Liability (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureAssumptionsUsedInEstimatingFairValueOfConvertibleNoteRedemptionProvisionDerivativeLiability Assumptions used in Estimating Fair Value of Convertible Note Redemption Provision Derivative Liability (Detail) Details 39 false false R40.htm 141 - Disclosure - Stock Options and Warrants - Additional Information (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureStockOptionsAndWarrantsAdditionalInformation Stock Options and Warrants - Additional Information (Detail) Details 40 false false R41.htm 142 - Disclosure - Stock Options and Warrants (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureStockOptionsAndWarrants Stock Options and Warrants (Detail) Details http://www.cytodyn.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables 41 false false R42.htm 143 - Disclosure - Acquisition of patents and Intangibles - Additional Information (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureAcquisitionOfPatentsAndIntangiblesAdditionalInformation Acquisition of patents and Intangibles - Additional Information (Detail) Details 42 false false R43.htm 144 - Disclosure - Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureSummaryOfTheNetPurchasePriceAndAllocationToTheAcquiredAssets Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail) Details 43 false false R44.htm 145 - Disclosure - Intangible Assets Activity (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureIntangibleAssetsActivity Intangible Assets Activity (Detail) Details 44 false false R45.htm 146 - Disclosure - License Agreements - Additional Information (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformation License Agreements - Additional Information (Detail) Details 45 false false R46.htm 147 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) Details 46 false false R47.htm 148 - Disclosure - Private Securities Offerings - Additional Information (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosurePrivateSecuritiesOfferingsAdditionalInformation Private Securities Offerings - Additional Information (Detail) Details 47 false false R48.htm 149 - Disclosure - Registered Direct Equity Offerings - Additional Information (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureRegisteredDirectEquityOfferingsAdditionalInformation Registered Direct Equity Offerings - Additional Information (Detail) Details 48 false false R49.htm 150 - Disclosure - Employee Benefit Plan - Additional Information (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation Employee Benefit Plan - Additional Information (Detail) Details 49 false false R50.htm 151 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) Details 50 false false R51.htm 152 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.cytodyn.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation Subsequent Events - Additional Information (Detail) Details 51 false false All Reports Book All Reports cydy-20181130.xml cydy-20181130.xsd cydy-20181130_cal.xml cydy-20181130_def.xml cydy-20181130_lab.xml cydy-20181130_pre.xml http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 69 0001193125-19-005378-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-19-005378-xbrl.zip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end

Large Accelerated Filer

Accelerated Filer

Non-accelerated Filer

Smaller Reporting Company

Emerging Growth Company